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Zusammenfassung 
I 
Zusammenfassung 
Noch heute zählt die Impfung zur wichtigsten Influenzaprävention. 
Influenzaimpfstoffe werden in embryonierten Hühnereiern oder in tierischer  
Zellkultur hergestellt. Klare Vorteile der zellkulturbasierten Produktion sind die 
Unabhängigkeit von Eilieferanten, das Ausschließen möglicher anaphylaktischer 
Reaktionen auf Eiproteine sowie die Möglichkeit, die Produktion schneller an den 
aktuellen Bedarf anzupassen. In allen Prozessen stellt das Glykoprotein 
Hämagglutinin (HA) das Hauptantigen dar. HA ist in der viralen Hülle hoch 
abundant und löst aufgrund seiner hohen Immunogenität schützende 
Immunantworten aus. Viele Eigenschaften eines Glykoproteins, wie z. B. 
Immunogenität, Antigenität, Rezeptorbindungsspezifitäten und Stabilität, können 
jedoch von dessen Glykosylierung entscheidend beeinflusst werden. Ein 
grundsätzliches Verständnis der Einflussgrößen verschiedener zellkulturbasierter 
Kultivierungsbedingungen auf die N-Glykosylierung ist daher essentiell zur 
Verbesserung des Prozessdesigns z. B. zur Auswahl der Zelle. 
Der Einfluss der Kultivierungsbedingungen auf das HA N-Glykosylierungsmuster 
des Influenzavirus A (IVA) wird in dieser Studie mittels kapillarer 
Gelelektrophorese mit Laser-induzierter Fluoreszenzdetektion- (CGE-LIF-) 
basierter Glykoanalytik untersucht. In den resultierenden, gut reproduzierbaren 
Fingerabdrücken repräsentiert jeder Peak mindestens eine bestimmte N-
Glykanstruktur. Auf genomischer Ebene erlaubt die Methode der 
Pyrosequenzierung darüber hinaus die Charakterisierung der viralen 
Quasispecies. Im Rahmen von in vitro und in vivo Mausstudien wird 
abschließend in einem transgenen HA-spezifischem T cell Rezeptor (TCR-HA) 
Modell sowie im BALB/c wildtyp (wt) Modell der Einfluß verschiedener 
Glykovarianten auf die Immunogenität verschiedener Viruspräperationen 
adressiert. 
Diese Studie zeigt, dass vor allem die Wahl des Produktionssystems (MDCK, 
Vero, AGE1.CR.pIX, Cap, MDCK.SUS1, MDCK.SUS2, MDCK.SUS3 Zellinien 
und embryonierte Hühnereier) und des Virusstammes (IVA PR/8/34, H1N1; 
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California/07/2009-Reassortant, H1N1pandemic; IVA Uruguay/716/2007-
Reassortant, H3N2, IVA Victoria/210/2009-Reassortant, H3N2) das N-
Glykosylierungsmuster des HA entscheidend beeinflussen und sowohl das 
Vorkommen als auch die relativen Häufigkeiten verschiedener N-
Glykanstrukturen bestimmen. Bemerkenswert ist, dass eine Adaptation von 
adhärent wachsenden Madin Darby canine kidney (MDCK) Produktionszellen an 
serumfreies Zellwachstum nur relative Häufigkeiten HA-assoziierter N-Glykane 
beeinflusst, während eine Adaptation an Suspensionswachstum in serumfreiem 
Medium das N-Glykosylierungsmuster grundlegend verändert. Im Allgemeinen ist 
zur Prozessoptimierung, oft eine Adaptation des Saatviruses an die 
Produktionszelle notwendig, um optimale Virusausbeuten zu erzielen. Diese 
Arbeit zeigt, dass der Adaptationsstatus des Viruses lediglich die relative 
Häufigkeit HA-assoziierter Glykane beeinflusst. Die Steigerung der Ausbeute ist 
auf erworbene Mutationen während der Adaptation vor allem im HA, aber auch 
im viralen Nukleoprotein (NP), in der Neuraminidase (NA) und im nicht-
strukturellen Protein 1 (NS1) zurückzuführen. Darüber hinaus wird gezeigt, dass 
der Lieferant/Ursprung des zur Virusproduktion verwendeten Saatviruses, die 
Viruspassage, die Kultivierungsgefäße und –medien, sowie der Erntezeitpunkt 
nur einen geringen Einfluss auf relative Häufigkeiten der HA-assoziierten N-
Glykane ausüben. Die Relevanz solcher Glykoanalyse für die Qualitätssicherung 
in der Impfstoffproduktion wird in einem transgenen TCR-HA Mausmodell, sowie 
in einem BALB/c wt Modell hervorgehoben. Ein Vergleich von MDCK- und Vero-
spezifisch glykosylierten Viruspräperationen des IVA PR/8/34 (H1N1) zeigt einen 
signifikanten Einfluss der N-Glykosylierung auf die Immunogenität in vitro und in 
vivo. Außerdem deuten die Daten auf eine ausgeprägtere Unterstützung der 
humoralen Immunantwort durch die MDCK Zell-spezifische Glykosylierung, 
sowie auf eine stärkere Förderung der zellulären Immunantwort durch die Vero 
Zell-spezifische Glykosylierung hin. 
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Abstract 
Vaccination and hygiene measures still represent the best strategies to prevent 
influenza virus infection. Manufactures produce influenza vaccines in different 
host systems, i.e. either in fertilized chicken eggs or in different mammalian cell 
lines. Advantages of cell culture-based virus production include independence 
from egg supply, prevention of anaphylactic reactions caused by egg proteins as 
well as the ability to rapidly scale-up and -down to better match vaccine demand. 
In all processes, the viral glycoprotein hemagglutinin (HA) is purified as the major 
vaccine antigen. HA is highly abundant in the envelope of influenza viruses, and 
able to induce strong and protective immune responses. Quality characteristics 
of glycoproteins, such as immunogenicity, antigenicity, protein stability and 
receptor-binding specificity can strongly depend on the glycan composition with 
respect to N-glycan structures attached as well as their relative abundances. A 
fundamental understanding of the impact of cultivation conditions is necessary to 
support process design, e.g. regarding the choice of host system, in cell culture-
derived influenza vaccine production. 
In this study the impact of cultivation conditions on the HA N-glycosylation 
pattern of influenza A virus (IVA) is investigated by capillary gel electrophoresis 
with laser-induced fluorescence detection- (CGE-LIF-) based glycoanalysis. As a 
result, well reproducible N-glycan fingerprints are obtained, in which one peak 
corresponds to at least one distinct N-glycan structure. Furthermore, for 
characterization of the viral quasispecies, next-generation pyrosequencing is 
applied. Finally, the importance of N-glycosylation on immunogenicity of virus 
preparations is addressed in vitro as well as in vivo using transgenic HA-specific 
T cell receptor (TCR-HA) and wild type (wt) BALB/c mouse models. 
The results demonstrate that peak presence as well as peak abundance mainly 
depend on the host system (MDCK, Vero, AGE1.CR.pIX, Cap, MDCK.SUS1, 
MDCK.SUS2, MDCK.SUS3 cell lines and embryonated hens’ eggs) and the virus 
strain (IVA PR/8/34, H1N1; California/07/2009-reassortant, H1N1pandemic; IVA 
Uruguay/716/2007-reassortant, H3N2, IVA Victoria/210/2009-reassortant, H3N2) 
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chosen. Interestingly, the adaptation of adherently growing Madin Darby canine 
kidney (MDCK) cells to serum-free cell growth only slightly affects relative 
abundances of HA-associated N-glycan structures. In contrast, the adaptation to 
suspension growth in serum-free medium alters HA N-glycan fingerprints 
drastically with respect to relative abundances as well as N-glycan structure 
presence. In particular, the total number of different N-glycan structures is 
reduced, and the N-glycans show a tendency towards smaller structures. In 
general, for process optimization, the adaptation of virus seed is often necessary 
for sufficient virus yields. This work demonstrates that the adaptation status of 
the virus hardly affects the HA N-glycosylation fingerprint, only showing changes 
in relative N-glycan structure abundances. However, after virus adaptation, 
acquired mutations, in particular within the HA, allowed increased virus 
replication and hence improved final virus titers. Additional mutations are 
detected within the viral nucleoprotein (NP), the neuraminidase (NA) and the 
non-structural protein 1 (NS1). Changes in process conditions, including virus 
passages, virus suppliers/origin, virus production media, virus production vessels 
as well as time points of harvest only affect relative abundances of HA-
associated N-glycans. Finally, the relevance of glycoanalysis for quality control 
and assessment for vaccine production is highlighted in transgenic TCR-HA as 
well as wt BALB/c mouse models. A comparison of MDCK and Vero cell-specific 
glycosylated virus preparations demonstrates that N-glycosylation has a marked 
impact on immunogenicity in vitro as well as in vivo. Furthermore, results suggest 
that MDCK cell-specific glycosylation more promotes the humoral immune 
response whereas Vero cell-specific N-glycosylation seems to more promote the 
cellular immune response. 
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Abbreviations, indices and symbols 
2-AA  2-amino-antranillic acid 
AA  amino acid 
Ab  antibody 
2-AB  2-aminobenzamide  
ADCC  antibody dependent cell-mediated cytotoxicity 
Ag  antigen 
AGE1.CR.pIX 
immortalized and modified designer cell line from ProBioGen AG, 
Berlin, Germany; originating from Muscovy Duck 
ANTS  8-aminonaphthalene-1,3,6-trisulfonic 
APC  antigen presenting cell 
APTS  8-aminopyrene-1,3,6-trisulfonic acid 
Asn  asparagine 
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BCR  B cell receptor 
bp  base pairs 
°C  degree Celsius 
Cap immortalized designer cell line from Cevec Pharmaceuticals GmbH, 
Cologne, Germany; originating from primary human amniocytes 
CD  cluster of differentiation 
cDNA  coding DNA 
CE  capillary electrophoresis 
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cRNA  complementary RNA 
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Da  dalton 
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ΙΔRPHΙ absolute value of ΔRPH 
DC  dendritic cell 
DC-SIGN DC-specific intercellular adhesion molecule-3-grabbing non-integrin 
DNA  deoxyribonucleic acid 
dNTP  deoxinucleoside triphosphate 
ddNTP dideoxinucleoside triphosphate 
DMSO dimethylsulfoxid 
DO  dissolved oxygen 
Dol  dolichol 
dpi  days post immunization 
dsRNA double-stranded RNA 
e.g.  for example (exempli gratia) 
elF4G1 eukaryotic initiation factor 4 G1 
ELISA  enzyme-linked immunosorbent assay 
ELISPOT enzyme-linked immunosorbent spot assay 
EMA  European medicines agency 
emPCR emulsion PCR 
EndoH endonuclease H 
ER  endoplasmatic reticulum 
et al.  and others (et alii) 
FACE  fluorescence-assisted carbohydrate electrophoresis 
FDA  U.S. food and drug administration 
FLI  Friedrich-Loeffler-Institut, Greifswald – Insel Riems, Germany 
g  gravity constant (earth: g = 9.81 m/s2) 
GDP  guanine diphosphate 
Glc  glucose 
GlcNAc N-acetylglucosamine 
GMP  good manufacturing practice 
h  hour 
HA  hemagglutinin 
HAI  hemagglutination inhibition 
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HCD  high confidence difference 
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HPLC  high-performance liquid chromatography 
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H2OMQ  ultrapure water (Millipore) 
i.e.  that is (id est) 
IFN  interferon 
IL  interleukin 
i.p.  intraperitoneal 
i.v.  intravenous 
IVA  influenza A virus 
IVA-California 
IVA reassortant California/07/2009 (H1N1pandemic) 
IVA-PR8 IVA Puerto Rico/8/34 (H1N1) 
IVA-Uruguay IVA reassortant Uruguay/716/2007 (H3N2) x IVA-PR8/34 (H1N1) 
IVA-Victoria IVA reassortant Victoria/210/2009 (H3N2) x IVA-PR8/34 (H1N1) 
kDa  kilodalton 
L  liter 
LAIV  live attenuated influenza virus 
LIF  laser-induced fluorescence 
LOD  limit of detection 
M1  matrix protein 1 
M2  matrix protein 2 (also termed proton channel protein M2) 
mAb  monoclonal antibody 
Man  mannose 
MDCK Madin Darby canine kidney 
MHC  major histocompatibility complex 
min  minute 
Abbreviations, indices and symbols 
VIII 
MGL  macrophage galactose-type lectin 
MMR  macrophage mannose receptor 
µL  microliter 
mL  milliliter 
moi  multiplicity of infection 
MPI-KG Max Planck Institute for Colloids and Interfaces, Potsdam – Golm, 
Germany 
mRNA messenger RNA 
MS  mass spectrometry 
MTU  migration time units 
MTU’  normalized migration time units (equivalent of bp) 
MW  molecular weight 
NA  neuraminidase 
NaBH3CN sodium cyanoborohydride 
NEP  nuclear export protein (also termed NS 2) 
NIBSC National Institute for Biological Standards and Control 
NIBSC-strain IVA-PR8 purchased from NIBSC 
NP  nucleoprotein 
NS1  non-structural protein 1 
NS2  non-structural protein 2 (aslo termed NEP) 
OST  oligosaccharyltransferase 
P  phosphate 
PA  polymerase acidic protein 
PAD  pulsed amperometric detection 
PAGE  polyacrylamide gel electrophoresis 
PAS  periodic acid -Schiff 
PB1 polymerase basic protein 1 (also termed RNA-directed RNA 
polymerase catalytic subunit) 
PB1-F2 protein PB1-F2 
PB2  polymerase basic protein 2 
PCR  polymerase chain reaction 
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PP  pyrophosphate 
RFU  relative fluorescence units 
RIG-I  retinoic inducible gene I 
RKI  Robert Koch Institute 
RKI-strain IVA-PR8 obtained from RKI 
RNA  ribonucleic acid 
RNP  ribonucleoprotein complex 
RP  reverse phase 
RPH  relative peak height 
rpm  rounds per minute 
RT  room temperature 
RT-PCR reverse transcriptase PCR 
s  second 
SEC  size exclusion chromatography 
SEM  standard error of mean 
Ser  serine 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
SOP  standard operating procedure 
SP-D  surfactant protein D 
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1 Introduction and motivation of work 
Many biopharmaceuticals such as monoclonal antibodies (mAbs), growth factors, 
protein hormones, therapeutic enzymes and coagulation factors are 
glycoproteins. Since it is known that glycosylation impacts essential 
characteristics such as stability, activity as well as immunogenicity of these 
proteins, regulatory agencies like the U.S. Food And Drug Administration (FDA) 
and European medicines agency (EMA) demand N-glycosylation profiles for 
quality control and drug release. Interestingly, however, such regulations are still 
absent for vaccines, where glycoproteins are often the main antigens. In contrast 
to other biopharmaceuticals, there is only little known so far about the impact of 
variations in cultivation condition on the N-glycosylation of vaccine components. 
Accordingly, little is known about the impact of differential glycosylation on 
vaccine efficacy and safety (e.g. [1-3]). 
So far, our understanding of conditions affecting protein glycosylation, limits our 
ability to control final product glycosylation. In general, direct cultivation factors 
such as the production system, the medium composition, the pH as well as 
indirect factors such as the availability of sugar-nucleotides within the cell, the 
residence time of the N-glycan in the Golgi, the host cell’s glycosylation 
machinery and the three-dimensional protein structure have been described to 
markedly impact glycosylation site occupancy and/or types of glycan structures 
attached. 
 
The aim of this work was to investigate the impact of various process conditions 
on the hemagglutinin (HA) N-glycosylation pattern of influenza virus A (IVA) and 
determine possible consequences on characteristics of virus preparations for 
vaccine production. Therefore, high-performance capillary gel electrophoresis 
with laser-induced fluorescence detection- (CGE-LIF)-based glycoanalysis is 
applied for the comparison of HA-associated glycan pools. Different upstream 
processing steps for IVA production are investigated: seed virus (with respect to 
passages, strains, suppliers and adaptation status), host cell (with respect to cell 
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line and adaptation status), cultivation scale and vessel (with respect to T-flask, 
roller bottle and stirred tank reactor, STR, cultivations in varying volumes) and 
virus production medium (with respect to composition and trypsin activity). The 
main focus is laid on MDCK cell-derived IVA PR/8/34 (H1N1, in the following 
termed as IVA-PR8) preparations. However, for multiple cultivation conditions 
such as virus adaptation status, production vessels, etc. other production 
systems (Vero, AGE1.CR.pIX, MDCK.SUS2 cell lines; embryonated hens’ eggs) 
or virus strains (IVA reassortant California/07/2009-like, H1N1pandemic; IVA 
reassortant Uruguay/716/2007-like, H3N2; IVA reassortant Victoria/210/2009-
like, H3N2) complement and confirm the trend of MDCK cell-derived IVA-PR8 
data. 
For seed virus adaptation, factors are addressed, leading to higher virus titers in 
shorter time frames. Therefore, CGE-LIF-based glycoanalysis characterizes HA 
N-glycosylation and next-generation pyrosequencing confirms stable potential 
N-glycosylation sites during virus adaptation and allows the characterization of 
quasispecies composition. Pyrosequencing is performed in cooperation with Dr. 
D. Höper from the Friedrich-Loeffler-Institut (FLI, Greifswald - Insel Riems, 
Germany). Altogether, these data contribute to a better understanding of the 
common requirement for virus seed adaptation to production cell lines. 
Finally, the impact of N-glycosylation on immunogenicity is addressed, which 
is of particular relevance for influenza vaccine potency and efficiency. This is 
done in cooperation with Dr. B. Lepenies and J. Hütter from the Max Planck 
Institute for Colloids and Interfaces (MPI-KG, Potsdam-Golm, Germany). 
Therefore, differentially glycosylated virus preparations are characterized in a 
variety of in vitro and in vivo immunogenicity assays (e.g. whole spleen cell 
assays, adaptive T cell transfer, etc.) using a transgenic mouse model 
expressing a HA111-119-specific T-cell receptor (TCR-HA) presented by class II 
major histocompatibility complex (MHCII) molecules or a BALB/c wt model, 
respectively. 
Finally, potential ‘rescue mutations’, allowing increased virus yields after virus 
adaptation, are identified. Moreover, no-, low- and high- impact process 
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conditions that contribute to HA N-glycosylation are identified. Such information is 
of high value since it not only allows estimating consequences of production 
process modifications but also allows evaluating process failures. 
Immunogenicity studies allow for identification of possible consequences of 
altered N-glycosylation with respect to T cell activation, proliferation and induction 
of HA-specific antibody (Ab) levels. Finally, the importance of N-glycosylation 
assessment for influenza virus preparations is affirmed and favorable 
characteristics of IVA-PR8 glycovariants are identified. 
 
Many aspects of this thesis have been published as first/shared-first [1, 4-7] or 
co-author [8, 9]. Within this work quotations of these publications will not be 
indicated specifically. Whenever parts of phrases, phrases, parts of paragraphs 
or paragraphs are used, the reference will only be given after the phrase or 
paragraph by the reference number [reference]. Throughout this work, text from 
first/shared-first or co-author articles/book chapters is generally only quoted, if it 
was primarily written by myself for the publication. A detailed overview of 
publications is given in section 13, including a statement on authorship. 
Since J. Hütter (shared-first co-author of [1]) may use parts of the published work 
for her dissertation, too, it will additionally be indicated in the beginning of a 
section, if text, analogous text content, structure, figures, figure legends or parts 
of figure legends were taken from the paper published together with J. Hütter, D. 
Höper, P.H. Seeberger, E. Rapp and B. Lepenies, January 2013 in J. Immunol. 
[1]. 
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2 Theory and background 
2.1 Influenza virus 
Influenza virus belongs to the family of Orthomyxoviridae. The virions are 
pleomorphic, i.e. they vary in size and shape between spherical and filamentous 
appearances of 80 nm to 120 nm in diameter [10]. Influenza is an enveloped, 
negative-sense (complementary to mRNA) RNA virus with a segmented genome, 
coding for up to 14 viral proteins. The genome of all influenza viruses encodes for 
the following seven proteins: the polymerase acidic protein (PA), the polymerase 
basic protein 1 (PB1) and the polymerase basic protein 2 (PB2), nucleoprotein 
(NP), matrix protein M1, and the non-structural proteins NS1 and NS2. PA, PB1 
and PB2 represent the three subunits of the RNA-dependent RNA polymerase. 
The polymerase complex together with NP is associated with the viral RNA, 
forming a ribonucleotideprotein complex (RNP) for each segment (figure 1). The 
antigenic specificity of NP determines the type (A, B or C) of the influenza virus 
[11]. The matrix protein M1 is a structural protein. NS1 was described to inhibit 
mRNA transport from the nucleus and to act as an interferon (IFN) antagonist 
inhibiting antiviral host responses. In contrast, NS2 carries out functions during 
nuclear export (hence NS2 is also referred to as nuclear export protein, NEP). 
Besides these seven proteins, the eight segments of the genome of influenza A 
and B viruses (figure 1) additionally encode two glycoproteins the hemagglutinin 
(HA) and the neuramidase (NA), which are integrated into the viral lipid 
envelope. HA mediates host cell binding and following membrane fusion, 
whereas NA finally liberates virus progeny from the host cell. Influenza A viruses 
also encode for the ion channel protein M2. It is located within the viral envelope 
and is described to be activated by low pH of the endosomes, allowing protons 
enter the virions’ core. In particular, it is highly specific for H+ ions [12]. Moreover, 
non-essential proteins derived from alternative splicing or reading frames have 
been described, recently. These include: PB1-F2, N40, PA-X and M42 [13-15]. 
Influenza A viruses are further categorized into different subtypes based on the 
antigenic specificity of their surface antigens HA and NA. Strain designations of 
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influenza viruses contain the type, the host of origin (only if non-human), 
geographical origin, strain number, year of isolation and for influenza A viruses 
the antigenic description of the HA and NA proteins (i.e the subtype) in 
parenthesis, e.g. influenza A virus/duck/USSR/695/1976 (H2N3) [11]. Up to date, 
17 different HA and ten different NA subtypes are described, although not all 
possible combinations of both proteins occur [16]. 
 
figure 1: Influenza A virus. 
(A) The genome consists of 8 segments, coding for up to 14 proteins. (B) Alternative reading 
frames (segments 2, due to alternative initiations; segment 3, due to ribosomal frameshifts; 
attached boxes) and splice variants (segments 7 and 8; free boxes) allow one sequence segment 
to code for different proteins. Modified and reprinted with permission [17]. 
2.2 Influenza – a threatening human pathogen 
So far, only influenza virus B and two IVA subtypes, i.e. H1N1 and H3N2, have 
been described to generally circulate in humans. An infection may cause severe 
illness, potentially leading to death. Once in a while pandemic outbreaks claim 
plenty of victims. Beside the pandemic threads, seasonal epidemics periodically 
demand profound economic losses, numerous hospitalizations and deaths each 
year. Up to date, hygiene and vaccination represent the best measures to 
prevent infection and resulting possible health complications. The periodical 
reoccurrence of pandemic and epidemic influenza outbreaks and hence the need 
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for seasonal vaccine reformulation is mainly attributed to the virus’ ability to 
rapidly adapt to new environments. 
2.3 Virus adaptation 
On the one hand, new influenza variants can originate from the virus’ ability to 
newly reassort (genetic shift) [4, 18]. On the other hand, the high error rate of the 
viral polymerase raises constantly new virus variants [19], which only differ in 
single or few amino acid positions, resulting in variations of the virus genome. 
Further, natural selection leads to the adaptation of a given virus as an 
evolutionary response to ‘new-host-pressure’ [18]. The frequency of a virus 
variant in a population largely depends on its ability to survive and reproduce – 
i.e. its fitness [20]. However, if coupled to high fitness genotypes, low fitness virus 
variants can be maintained at higher levels than expected [4, 21]. 
Virus adaptation is one of the most important processes in virus evolution, and a 
crucial factor to be taken into account for seasonal and pandemic vaccine 
production. Escape from immune pressure, balancing host cell receptor binding 
avidity of infecting virus with the release of progeny virus as well as adjustment to 
altered endosomal pH-values or to different, specific sialic acid containing host 
cell receptors have been described as driving forces for adaptation processes in 
virus evolution [22-25]. On the one hand, adaptation allows the virus to cross 
species boarders, evade immune or therapeutic pressures and optimize its 
replication in a given host system [26]. On the other hand, it challenges 
manufacturers to adapt emerging strains to existing egg-based or cell-culture-
based system processes to obtain maximum yields for formulation of potent 
vaccines [4, 22, 27]. 
2.4 Quasispecies 
In general, due to the viral polymerase’s error-prone nature, influenza replication  
and hence also adaptation processes, result in the co-existence of related virus 
subpopulations on the genomic and hence often on the proteomic level. Such a 
population of related, though differing virus variants is referred to as a 
quasispecies [28-30]. The consensus sequence of such a quasispecies 
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represents the most frequent information for each position. Often, no single virus 
of a vius population carries the consensus sequence, because no mutation is 
present at a sufficient high level. 
During most infections, i.e. during cell culture-based virus production as well as 
during illness, more than one virus particle is involved. Furthermore, each 
infected cell produces plenty of slightly differeing progeny viruses. Altogether, this 
suggests that hardly one seed virus stock matches the other. Moreover, it implies 
that a virus strain obtained from one supplier most likely not matches with the 
same virus strain obtained from another supplier. Hence, varying virus production 
yields during vaccine production processes and differing courses of disease 
during illness may result from such differing viral quasispecies compositions. 
Only recently, new deep sequencing methods, e.g. next generation 
pyrosequencing, allow the detection of different variants within such a 
quasispecies. 
2.5 Glycovariants 
The variation on the genomic level is further increased by the complexity of 
protein N-glycosylation of the two viral surface proteins hemagglutinin (HA) and 
neuramidase (NA). Glycoproteins can be considered as a collection of different 
glycoforms or glycosylation variants [4, 31]. They vary in glycosylation site 
occupancy (macroheterogeneity) and in structure and composition of sugar 
residues (microheterogeneity) attached to the protein backbone [4]. 
2.6 Influenza virus replication 
The glycoprotein HA plays a key role in virus replication and therefore is often 
affected during adaptation processes, resulting in altered amino acid sequences 
and/or altered HA N-glycosylation. However, other viral proteins also contribute 
to virus replication and may also be affected during virus adaptation. In order to 
help interpreting virus genome sequencing data presented in the result section, a 
short overview of the IVA replication cycle will be given in the following. 
The replication cycle of influenza A viruses comprises virus adsorption, entry, 
uncoating, mRNA synthesis (transcription) and replication of viral RNA, 
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synthesis of viral proteins (translation), virus assembly, budding and final 
release of virus progeny [32, 33]. 
2.6.1 Adsorption, entry and uncoating 
In the first step the virus binds to the host cell, which is mediated by interactions 
of the receptor binding domain on the distal tip of the viral HA molecule with sialic 
acid residues of host cell receptors (figure 2). Here, different HA subtypes (H1-
17) have different specificities for sialic acid bond to galactose by either α2,3 or 
α2,6 linkage. A change of this specificity, e.g. due to substituted amino acid 
residues within the receptor binding pocket, can allow to cross species borders. 
In cells of birds intestines for instance α2,3 linkages are predominant, whereas in 
cells of human trachea mainly α2,6 linkages are expressed. In contrast, cells in 
pigs trachea contain both α2,3 and α2,6 sialic acid linkages. This co-expression 
of α2,3 and α2,6 linkages makes them susceptible for avian and human influenza 
strains and turns them into a mixing vessel facilitating genetic/antigenic drift (via  
 
figure 2: Schematic influenza A virus replication cycle. 
The model was simplified by displaying only one vRNP within the virus particle, instead of eight 
and by omitting nonstructural proteins. Transport processes are indicated by dashed arrows, 
whereas synthesis and protein binding are indicated by solid arrows. The virus replication cycle 
comprises (1) virus adsorption, (2) entry by endocytosis, (3) uncoating, (4) nuclear import, (5) 
transcription and (6) replication of viral RNA (cRNA synthesis), (7) translation of viral proteins, (8) 
encapsidation of cRNA with newly synthesized NP and polymerase proteins, (9) replication of 
viral RNA (vRNA synthesis), (10) encapsidation of vRNA with newly synthesized NP and 
polymerase proteins, (11) M1 and NEP binding mediate (12) nuclear export, (13) virus assembly, 
budding and final release [33]. Modified and reprinted with permission. Copyright 2012, American 
Society for Microbiology. 
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mutation) and shift (reassortment). Furthermore, tissue tropism is determined by 
a cleavage site within the HA molecule. The HA molecule, as it is synthesized, is 
referred to as HA0 (molecular weight, MW, approximately 70 kDa). HA0 must be 
cleaved e.g. by host proteases into a HA1 (MW approximately 50 kDa) and a HA2 
(MW approximately 20 kDa) subunit to activate virus infectivity [34, 35]. In 
natively folded, cleaved HA molecules the HA1 and HA2 subunits are linked with 
a single disulfide bond and are considered to be in a metastable state. Adsorbed 
influenza virus is internalized within vesicles by receptor-mediated endocytosis. 
These vesicles begin to fuse with endosomes [12]. On the one hand increasingly 
acidic pH values activate the M2 ion channel [36] and permit the H+ ion flow into 
the virion, destabilizing protein-protein interactions and RNP - M1 interactions 
[12, 37, 38]. On the other hand the low-pH induces a conformational change of 
the cleaved, metastable HA molecule - especially the HA2 subunit refolds – 
leading to fusion of viral and cellular membrane [12] and thus allowing the viral 
RNA to enter the host cell’s cytoplasm. 
2.6.2 Transcription and replication of the virus genome 
Nuclear localization signals within viral proteins trigger specific interactions with 
nuclear transport complexes (so called importins) that interact with nuclear pore 
complexes of the host cell, thus allowing the transport of viral RNPs into the 
cellular nucleus ([39], figure 2). The synthesis of viral mRNA is dependent on the 
cellular RNA polymerase II. The PB2 subunit of the heterotrimeric viral 
polymerase recognizes and binds the 5’ cap of cellular mRNA transcripts of the 
polymerase II [40-42]. In a next step, the endonuclease active part of the PA 
subunit cleaves off the capped RNA fragments from the transcripts. This 
procedure is also known as cap-snatching [42-44]. The fragments of 10 to 13 
nucleotides serve as primers for the viral polymerase and are required for the 
initiation of viral mRNA synthesis [12]. PB1 binds the vRNA, which serves as 
template. A conserved domain within the PB1 subunit catalyzes the elongation of 
the mRNA [42, 45, 46] until a stretch of 4 to 7 uridine residues is reached, where 
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transcription is terminated and polyadenylation occurs. Consequently, viral and 
host cell mRNAs are structurally indistinguishable. 
In contrast to viral mRNA synthesis, the replication of the full-length RNA 
variants, the template cRNA and the vRNA, do not require any primers and are 
not terminated at the poly A site (reviewed in [12]). 
2.6.3 Translation 
PB1, PB2, PA, NP, M1 and NS2 proteins are essential for the nuclear export of 
the vRNA (figure 2). These proteins are translated from the viral mRNA in the 
cytoplasm and are, as described before, actively transported (with the exception 
of NS2, which is supposed to be small enough for diffusion through pores) into 
the cellular nucleus. Here, vRNA, PA, PB1, PB2 and NP assemble to form new 
RNPs. M1 is proposed to bind the RNP complex and NS2 in turn is proposed to 
bind M1. NS2 also interacts with exportin1 (also known as chromosome region 
maintenance protein 1, CRM1), which in turn binds a small GTPase called Ran, 
which again needs to be associated with GTP before the whole RNP-M1-NS2-
CRM1-RanGTP-complex can leave the nucleus (reviewed in [39]). Additionally, 
also NS1 carries nuclear localization signals and is transported into the host’s 
nucleus, where it does not interact with the RNP-export complex but antagonizes 
the cellular immune response [39, 47].  
The viral membrane proteins HA, NA and M2 are synthesized on membrane-
bound ribosomes and are flipped upon a signal sequence across the membrane 
into the endoplasmatic reticulum (ER, figure 2). The glycoproteins HA and NA are 
furthermore modified by N-linked glycosylation in the ER and the Golgi whereas 
HA and M2 are additionally palmitoylated in the Golgi [12]. 
2.6.4 Assembly, budding and release 
After completion of processing during the transport from the ER through the cis-, 
mid- to trans-Golgi, HA, NA and M2 are transported by separate transport 
vesicles to the plasma membrane domains ([48], figure 2). In polarized epithelial 
cells, such as MDCK or primary bronchial and lung epithelial cells, influenza 
viruses assemble at the apical surface of the cells [49], in so-called lipid rafts 
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(cholesterol- and sphingolipid-enriched regions within the plasma membrane). 
HA and NA both possess their own signal(s) for apical transport and lipid raft 
association [49]. Also M2, M1 and vRNPs assemble at the budding site, though 
there is still some discourse about the exact mechanisms (reviewed in [49, 50]). 
Also, the exact processes involved in budding as well as final scission of the new 
progeny viruses from the cellular membrane are still discussed (reviewed in [49, 
50]). Finally NA prevents virus progeny to aggregate to itself or the cell surface 
by removing sialic acid residues thus allowing the spread of virus progeny to 
other cells [12, 51]. 
2.6.5 Role of non-structural proteins 
So far, it is unknown how the multiple functions of NS1 contribute to the IVA 
phenotype (e.g. reviewed in [52]). One function of NS1 is cleavage and 
polyadenylation specificity factor- (CPSF-) binding, hence suppressing cellular 
gene expression. A second function suppresses the export of cellular mRNAs 
into the cytoplasm, impairing cellular protein synthesis and thereby suppressing 
the host’s IFN response. A third function is dsRNA- and tripartite motif-containing 
protein25- (TRIM25-) binding, which prevent retinoic acid inducible gene I (RIG-I) 
mediated IFN-induction. The forth function is the activation of the 
phosphatinositol 3-kinase/Akt pathway suppressing apoptosis in infected cells. 
The interaction of NS1 with eukaryotic initiation factor 4 G1 (elF4G1) represents 
a fifth function, stimulating the translation of viral transcripts. 
2.7 Anti-influenza drugs and influenza vaccines 
All food and drug administration (FDA) approved pharmaceutical substances to 
treat influenza infections interfere with the virus replication cycle: Zanamivir 
(Relenza) and oseltamivir phosphate (Tamiflu) are NA inhibitors, whereas 
amantadine (Symmetrel) and rimantadine (Flumadine) block the M2 ion channels 
[53]. However, due to the virus’ ability to rapidly adapt to environmental 
pressures, developing drug resistances may cause therapy failing. Therefore, 
prevention of infection in the first place is highly recommended. In this regard, 
hygiene and vaccination represent the best measures. Though, also for 
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vaccination, the virus’ ability to rapidly adapt to changing environments makes 
seasonal reformulations of influenza vaccines necessary. In general, the annual 
production circles start with the definition of virus strains recommended for the 
next season’s vaccine formulation by the World Health Organization (WHO). 
Often the recommendation matches the circulating strains, however some risks 
remain that wrong virus strains are selected. For virus seed preparation multiple 
virus variant selection steps are required: In order to minimize the risk of 
contamination with other human pathogens, clinical specimens of the strains 
recommended by the WHO are usually blind-passaged in embryonated chicken 
eggs by WHO Collaborating Centers. In general, human isolates replicate poorly 
in eggs. The manufacturers then usually select variants that replicate well to be 
reassorted to high-yield laboratory viruses to generate virus seeds used in 
production. Due to possible antigenic drift during each of these steps antigen 
identity testing and sequence analyses are required [4, 54, 55]. 
Currently, most commercially available influenza vaccines are inactivated 
vaccines produced in egg/cell culture. These are classified into whole virus, split 
(by detergent disrupted virus particles) or subunit (purified HA and NA) vaccines. 
Seasonal vaccine production requires approximately six month from the definition 
of WHO to commercialization [54]. Principally, seasonal vaccine formulations are 
trivalent, i.e. they comprise two IVA strains and one influenza virus B strain. In 
contrast, the production of a pandemic vaccine, which is usually monovalent, only 
comprising the pandemic strain, takes about five months [56].  
In some places such as the United States, alternatively to inactivated vaccines 
cold-adapted, live attenuated influenza whole virus (LAIV) vaccines are available 
[57, 58]. These are usually administered as nasal spray. 
In addition, other vaccine platforms using recombinant proteins/peptides, DNA, 
virus-like particles-, virosomes or vector-based vaccines have recently been 
described [59]. However, most liscensed vaccines, so far, are not from those 
other platforms. 
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2.8 Cell culture-based inactivated influenza vaccines 
So far, most influenza vaccines are still produced in embryonated hen’s eggs, 
though an increasing number of cell culture-based processes are being 
established (see section 2.8.1). Advantages of such cell culture-based processes 
include independence from egg supply, skills and equipment is transferable to 
production of other cell culture-derived vaccines such as rabies, enormous 
reduction of infectious solid waste (approx. 80 % of mass of eggs), possible rapid 
process adjustment to better match supply with vaccine demand e.g. during 
pandemics and finally cell culture-derived vaccines bear no risk of anaphylactic 
reactions caused by egg proteins [6, 60]. 
2.8.1 Host cells used in production 
So far, few cell culture-based processes using MDCK cells have been licensed 
(e.g. Novartis Behring for Optaflu® and Celtura). MDCK cells have been 
comprehensively characterized since their establishment in 1958 by Madin and 
Darby [6]: absence of contaminating viruses, resistance to prion infections and 
ideal properties for influenza virus replication have been demonstrated [61]. 
Suspension as well as adherently growing cell clones are being used [6, 62]. As 
an alternative, other cell lines such as Vero (Baxter International Inc. for 
Celvapan®, PreFluCel®, Vepacel®; [61, 63-66]), AGE1.CR [67], AGE1.CR.pIX 
[7, 67], PER.C6 [61, 68, 69], EBx [61], Eb14® [62], PBS-1 [70] or SJPL cells [61, 
62, 71] have been described for influenza virus production [6]. Here, the 
importance of host choice shall be emphazised, since the selected production 
cell line not only affects virus propagation dynamics and hence harvest time 
points and virus yields but most likely also the N-glycosylation pattern of HA [6, 
72, 73]. However, for virus seed preparation in all egg- and cell culture-based 
processes, multiple virus adaptation steps are usually required to achieve optimal 
yields. 
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2.8.2 Preparation of virus working seeds 
In general, human IVA isolates replicate poorly in eggs. Nevertheless, in order to 
minimize the risk of contamination with adventitious agents, clinical specimens of 
the strains recommended by the WHO for the next season’s vaccine formulation 
are usually blind-passaged in embryonated chicken eggs by WHO Collaborating 
Centers. Usually, the manufacturers select virus variants that replicate well in the 
particular final production host system, e.g. egg, MDCK cells, Vero cells, etc. and 
reassort these to even higher yielding laboratory viruses to generate virus seeds 
used in production (figure 3, [4, 54, 55]). 
Alternatively, propagation of human influenza virus isolates in mammalian cells 
would circumvent the passaging in embryonated hen’s eggs and thus prevent the 
selection of mutations in the HA, causing altered antigenic properties [74, 75]. 
One option for cell culture-derived virus production is the use of comprehensively 
characterized MDCK cells. However, here the reduction of contaminating 
pathogens due to broad species border may be smaller. The use of avian cell 
lines such as AGE1.CR, AGE1.CR.pIX [76] and EB66 [77] for isolation and 
production would probably combine the reduction of adventitious agents with the 
advantages of cell culture technologies, eliminating the need for additional 
adaptation steps [6, 7]. 
2.8.3  Vaccine production process 
While virus seeds for production are generated, production cells are expanded to 
desired quantities (figure 3): in lab and pilot scale sufficient virus is produced 
under good manufacturing practice (GMP) conditions for phase I and II clinical 
trials to demonstrate the product’s immunogenicity and safety; in industrial scale 
for final commercial vaccine production [60]. After cell expansion (cell growth 
phase), cells are infected with virus seed (virus production phase). 24 hours post 
infection (hpi) to 96 hpi the virus is harvested. During following downstream 
processing the harvest is inactivated (e.g. by formaldehyde or β-propiolactone), 
virus is concentrated, purified (e.g. using diafiltration or centrifugation) and 
contaminating host cell DNA may be degraded, e.g. by benzonase treatment or 
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removed by ion-exchange chromatography. For split and subunit vaccines the 
virus is again diluted. Added detergents such as Triton X-100, sodium lauryl 
sulphate or Tween 80 basically extract proteins from the viral envelope. 
Purification may be performed by e.g. sucrose gradient or diafiltration and the 
dilution in the formulation buffer result in final vaccines. Sometimes, adjuvants, 
stabilizers and/or preservatives are added [60, 78]. The final inactivated, cell-
culture-derived vaccine for human use must not contain more than 10 ng DNA 
per dose [79]. Furthermore, each dose should contain at least 15 µg HA per 
strain and the HA - total protein content ratio should be within the limits approved 
by national regulatory authorities [79]. However, total protein content including 
HA should not exceed 100 µg per strain, i.e. 300 µg per dose of a trivalent 
vaccine. For subunit vaccines the total protein content is even limited to a 
maximum of 40 µg per strain [79]. Additionally to HA, vaccines usually contain 
the lower abundant viral glycoprotein NA, which represents the second important 
antigen in influenza vaccines. 
 
figure 3: Cell culture-based influenza vaccine production process. 
(A) The generation of the production virus seed: The WHO defines the strains for the next year’s 
influenza vaccine. Human isolates of these recommended strains are blind-passaged in 
embryonated chicken eggs by WHO Collaborating Centers and are distributed to vaccine 
manufacturers. Here, well replicating variants are selected for the specific production system. 
These are reassorted with a high yield laboratory strain such as IVA PR/8/34 (H1N1) to high yield 
production strains, carrying the recommended HA and NA antigens. (B) Upstream processing: 
cell expansion from the cell bank to lab or industrial scale for final vaccine production. (C) 
Downstream processing and final fill and finish make the commercial product. 
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Altogether, the ready to administer vaccine has passed through a multitude of 
production steps. Hence, various up- and downstream process conditions such 
as production cells, production scales, media, production temperatures, harvest 
time points, etc. may vary between different established processes (reviewed in 
[62]). However, all processes have the vaccine’s major antigen in common - the 
HA, which is able to induce strong and protective immune responses. Here, 
questions arise concerning the impact of cultivation conditions such as virus 
adaptation, media, production scales, etc. on the N-glycosylation of HA and its 
impact on virus immunogenicity and hence on vaccine quality and savety. 
Glycoanalysis of NA is beyond the scope of this work and furthermore, due to 
lower abundance in the virus particle, bigger sample volumes would be required. 
2.9 N-glycoproteins and their synthesis 
Many antigenic proteins used for vaccination are N-glycoproteins. These 
glycoproteins such as HA from IVA (figure 4) often play key roles in virus 
replication, e.g. by enabling the attachment to and the infection of host cells. 
Glycoproteins can be considered as a collection of different glycoforms or 
glycosylation variants [31], varying in microheterogeneity as well 
macroheterogeneity [4]. With respect to the HA of IVA, depending on various 
factors such as protein conformation and host, various N-glycan structures of the 
high mannose, the hybrid and the complex type have been detected attached to 
the HA protein [73, 80, 81]. In general, differences in N-glycosylation may impact 
proteins’ characteristics such as Ab dependent cell-mediated cytotoxicity (ADCC, 
[82]), specific activity [83], antigenicity [83-85], binding avidity [86], specificity 
[87], immunogenicity and virulence [88]. For IVA in particular, N-glycosylation of 
HA was described to impact on protein folding, receptor binding activity, -avidity 
and –specificity, evasion of host immunity, protein cleavability as well as the 
recognition by the host’s innate immunity e.g. via calcium-dependent (C-type) 
lectins (summarized in [88]). 
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figure 4: Three-dimensional, spherical structure of trimeric, N-glycosylated IVA-PR8 HA. 
Attached N-glycans are couloured in red. (A) Side and (B) top view. The PDB entry 1RU7 and 
Pymol (v0.99, DeLano Scientific LLC, California, USA) software were used for structure display. 
N-glycan modeling was performed with GlyProt [89]. 
 
Viruses use the host cells for protein synthesis as well as the host cells’ 
glycosylation machinery for modifying their glycoproteins. The process of protein 
N-glycosylation takes place in different cell compartments: Briefly, in the 
cytoplasm of eukaryotes monosaccharyl-transferases stepwise attach seven 
monosaccharides (a to g, figure 5) from nucleotide sugar donors (UDP- 
acetylglucosamines, UDP-GlcNAc; GDP-Mannose, GDP-Man) to an ER 
membrane-bound lipid carrier (dolichol-pyrophosphate): two GlcNAc followed by 
five Man residues forming two branches (reviewed in [90]). Subsequently, the 
sugar moiety is flipped into the lumen of the ER by a still controversially 
discussed mechanism (reviewed in [91]). In the ER, additional four Man residues 
(h to k, figure 5) and three Glc residues (l to n, figure 5) are attached by different 
glycosyltransferases from dolichylphosphate-linked monosaccharides (Dol-P-
Man, Dol-P-Glc), finally forming the tri-antennary tetradecasaccharide 
(Glc3Man9GlcNAc2) core N-glycan structure [92]. The last glucose residue (n, 
figure 5) is required for recognition by the oligosaccharyltransferase (OST) 
complex [93], which transfers the core N-glycan structure co-translationally from 
the membrane-bound dolichol-pyrophosphate to the side chain nitrogen of the 
Asn of the N-glycosylation motif Asn-X-Ser/Thr of a growing polypeptide chain. In 
this motif, X represents any amino acid but proline. Proline is suggested to 
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impede the formation of a required loop, bringing the hydroxyl groups of Ser/Thr 
into closer contact with Asn. This close contact increases the nucleophilicity of 
Asn [94, 95], allowing the covalent attachment by a N-glycosidic bond of the 
sugar core N-glycan structure to the protein backbone. Gavel et al. estimated, 
that 90 % of such potential N-glycosylation sites are actually glycosylated [96], 
which leads to differing glycosylation site occupancy – so-called 
macroheterogeneity of glycoproteins. In mammalian cells two OST complexes 
are expressed, varying in substrate selectivity [97]: one uses complete whereas 
the second may also use incomplete oligosaccharide core structures and has a 
higher maximal reaction velocity. As soon as the oligosaccharide is attached to 
the protein-backbone a glucosidase (type I) detaches the last Glc residue (n, 
figure 5), and a further glucosidase (type II) removes the second Glc residue (m, 
figure 5). The monoglucosylated core structure is bound by calnexin and/or 
calreticulin, which support proper protein folding. The removal of the remaining 
Glc residue (l, figure 5) by glucosidase II allows properly folded proteins to leave 
the ER and enter the Golgi complex. Incorrectly folded proteins are either 
modified with a new Glc residue allowing the binding to calnexin and/or 
calreticulin again or ER-associated degradation is initiated (reviewed in [98]). 
Mannose residues are trimmed off (f, g, i, k, figure 5) by different mannosidases 
and a GlcNAc residue is added to mannose residue d (figure 5). After removal of 
mannose residues (h, j, figure 5) further sugars such as GlcNAc, galactose, sialic 
acid and fucose residues are added in the Golgi complex by a variety of different 
glycosyltransferases [99]. The Microheterogeneity of glycoproteins describes the 
resulting variance of attached glycans with respect to their sugar residue 
composition. Depending on the extent and the types of modification within the 
Golgi complex, final N-glycans are divided into three classes: high mannose, 
hybrid and complex N-glycan structures. But even complex IVA-derived 
glycoproteins, e.g. HA molecules, lack sialic acid residues, which is probably 
attributed to the neuramidase activity [73, 100, 101]. 
2 Theory and background 
19 
 
figure 5: Scheme of N-linked precursor oligosaccharide. 
In the cytoplasm, monosaccharyltransferases stepwise attach monosaccharides (a-g; ■,N-
acetylglucosamines, GlcNAc; ●, mannose, Man) to ER membrane-bound dolichol-pyrophosphate. 
Subsequently the sugar moiety is flipped into the lumen of the ER. Different glycosyltransferases 
stepwise add additional four Man and three glucose (●, Glc) residues (h-n). The 
oligosaccharyltransferase (OST) complex transfers this precursor N-glycan structure to the 
nitrogen side chain of an asparagine of the N-glycosylation motif. Glucosidase I removes the last 
(n) and glucosidase II removes the second Glc residue (m). The first Glc residue (l) now allows 
binding to calnexin and/or calreticulin, supporting proper protein folding. Glucosidase II then also 
removes the first Glc residue (l), allowing the properly folded protein to leave the ER. 
 
At first sight, this highly conserved biosynthetic pathway appears rather 
energetically unfavorable. Why should a core oligosaccharide be build up and 
straight after its translocation to a polypeptide chain be trimmed down again, just 
to re-synthesize it once again with different sugars? The answer is that the 
different stages of N-glycosylation serve important functions, such as proper 
protein folding and quality control in the ER, intracellular transport and targeting 
in the ER as well as in the Golgi complex and finally various different functions 
specific for the mature glycoprotein [90]. 
What does all this mean for the HA of the IVA-PR8 used throughout this study? 
Each HA monomer of the RKI-strain carries seven potential N-glycosylation sites, 
five within the HA1 (AA positions 27, 28, 40, 286, 304) and two within the HA2 
chain (AA positions 498, 557). However, an analysis of the HA AA sequence by 
NetNGlyc 1.0 [102] predicts no N-glycosylation on residue 27 due to a low N-
glycosylation potential of 0.4 [103]. Since naturally HA occurs as a trimeric 
structure, this makes 18 potentially N-glycosylated sites for each HA trimer 
(figure 6). Taking micro- and macroheterogeneity into account makes numerous 
different isoforms of one and the same HA protein possible. 
The N-glycans attached are likely to determine protein characteristics of HA: e.g. 
it was decribed that HA with terminal mannose induces lower hemagglutination 
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inhibition (HAI) than HA with complex structures or single GlcNAc residues [2, 3]. 
Furthermore, Wang et al. showed that HA carrying single GlcNAc residues 
induced Abs with higher binding affinity and neutralization activity than fully 
glycosylated HA [104]. Interestingly and somewhat contradictory, Lin et al. 
reported that high mannose glycan structures lead to higher levels of HA-specific 
Ab titers due to different antigen presentation efficiencies [2]. However, not only 
the type of attached glycans but also the numbers and/or positions of potential 
HA N-glycosylation sites may significantly impact immunogenicity as well as 
antigenicity. Sun et al. demonstrated that the introduction of HA N-glycosylation 
sites attenuated highly virulent viruses, whereas the removal of sites resulted in 
increased virulence of lower virulent strains [88]. Furthermore, other factors such 
as the presence of a HA polybasic cleavage site may contribute to the virus’ 
pathogenicity.[105]. 
 
figure 6: Three-dimensional cartoon structure of trimeric IVA-PR8 HA. 
HA1 chains are coloured in green, pink and brown, whereas HA2 chains are coloured in yellow, 
cyan and grey. Potentially N-glycosylated asparagine residues are highlighted as red spheres. 
The PDB entry 1RU7 and Pymol (v0.99, DeLano Scientific LLC, California, USA) software were 
used for structure display. 
2.10 Analytics 
2.10.1 N-glycan analysis 
N-glycosylation modifications are as complex and diverse as the methods 
available for their characterization. Therefore, a complete overview and detailed 
description of methods goes far beyond the scope of this work. However, a 
sketch of available methods for glycoanalysis is given in the following: 
So far, no single method is able to provide all structural and site-specific 
information for the complete characterization of a glycoprotein, i.e. sugar residue 
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sequence assigned to a specific N-glycosylation site. All glycosylated molecules 
can be detected by the periodic acid-Schiff (PAS) reaction [106], by which sugars 
are oxidized and subsequently react with the Schiff reagent to a pink color. 
Alternatively, glycan structures whether attached to or released from proteins can 
be detected by specific lectins or antibodies (Ab). Due to the availability of a 
broad range of different specific lectins and Ab some structural information can 
be gained by evaluating glycan’s binding characteristics [107]. In microarray 
approaches this principle of lectin or Ab-based N-glycan detection was 
transferred to high-throughput applications [108]. Furthermore, different 
glycoforms of a protein, varying in molecular weight and/or isoelectric point, can 
be visualized by one- or two-dimensional gel electrophoresis. 
The N-glycans may be released from the protein backbone either chemically by 
ozonolysis (e.g. hydrazinolysis) or enzymatically by specific enzymes, e.g. the 
peptide: N-glycosidase F (PNGaseF, [109], cleaves Asn-GlcNAc linkage of 
almost all N-glycans) or endoglycosidase H (EndoH, cleaves GlcNAc-GlcNAc 
linkage in core of high mannose and some hybrid N-glycans). In contrast to all 
other available enzymes, PNGaseF removes almost all types of N-glycans and 
the cleavage between Asn-GlcNAc retains the complete glycan structure. Other 
enzymes are favoured for structure characterization whereas PNGaseF 
predominantly serves unspecific N-glycan removal. However, factors such as 
accessibility of the N-glycan and the glycan structure itself (e.g. α1-3 core 
fucosylation) may inhibit PNGaseF digestion. 
Unlabeled mono- and oligosaccharides may be detected by pulsed amperometric 
detection (PAD, reviewed in [110]) or mass spectrometry (reviewed in [111]). 
Otherwise, glycans can be radio-labeled or fluorescence-labeled for detection 
[109]. The most common approach is fluorescence-labeling by reductive 
amination commonly using sodium cyanoborohydride (NaBH3CN, [112-114]) or 
more recently the non-toxic reducing agent 2-picoline borane [115]. Depending 
on the label requirements diverse labels are available such as 2-amino-antranillic 
acid (2-AA), 2-aminobenzamide (2-AB), 8-aminonaphthalene-1,3,6-trisulfonic 
acid (ANTS) and 8-aminopyrene-1,3,6-trisulfonic acid (APTS, reviewed in [111]). 
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After labeling, the N-glycans may be separated in an electric field for instance by 
gel electrophoresis (fluorescence-assisted carbohydrate electrophoresis, FACE, 
[116], kit commercially available from www.prozyme.de), capillary electrophoresis 
(CE, [117], charge-based separation) or capillary gel electrophoresis (CGE, [112, 
113], size-based and charge-based separation, separation of α- and β-isomers 
possible). An alternative is the chromatographic separation. Here, multiple 
methods have been described including capillary electrochromatography ([118, 
119], charged-based separation with chromatographic interaction for increased 
selectivity), gas-liquid chromatography (determination of monosaccharide linkage 
and position in complex N-glycans, [120]), or most commonly by adsorption using 
high-performance liquid chromatography (HPLC, [121]). Most widely applied is 
the HPLC in hydrophilic interaction chromatography mode (HILIC, reviewed in 
[122]). For this, a database was established by Rudd et al., allowing 2-AB labeled 
N-glycan structure assignment [123]. Other modes that have been applied for N-
glycan characterization include anion-exchange HPLC [124], high-performance 
(or high pH) anion exchange chromatography (HPAEC), porous graphitized 
carbon (PGC) HPLC and reversed phase (RP) HPLC (reviewed in [111, 125]). 
Furthermore, mixed modes such as HILIC in combination with anion exchange 
separations have been published [126]. 
HPLC-based techniques may be combined with mass spectrometry (MS) 
detection for on-line or off-line N-glycan structure elucidation. However, the great 
advantage of the CGE-LIF-based separation technique is its suitability for high-
throughput applications using multiplex DNA sequencers (e.g. ABI PRISM 3100-
Avant Genetic Analyzer from Applied Biosystems, Foster City, California, USA). 
However, the identification of the detected N-glycan structures is elaborate if no 
detailed database for structure identification is available and requires sequential 
exoglycosidase digestions as well as sample reanalysis. Since such a detailed 
and comprehensive database for N-glycan structure identification is currently 
being established in our group, glycoprofiling within this study was performed by 
CGE-LIF-based glycoanalysis. 
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2.10.2 CGE-LIF-based glycoanalysis 
As already addressed in the previous section, CGE-LIF-based glycoanalysis is 
used in this work to investigate the impact of different process conditions on the 
HA N-glycosylation. The following terms will be used frequently within this study: 
The N-glycosylation pattern of a glycoprotein includes information regarding 
the structures and abundances of attached sugars and if available information 
regarding the location of modification. As described earlier, glycoproteins are 
collections of different glycoforms/glycovariants, which vary in attached 
oligosaccharide structures (microheterogeneity) as well as in potential 
glycosylation site (Asn – X – Ser/Thr) occupancy (macroheterogeneity). Due to 
this heterogeneity and due to limitations of the available glycoanalysis methods, 
the N-glycosylation pattern of a glycoprotein can only be approximated by 
profiling the N-glycosylation of a glycoprotein pool (figure 7A). Specific 
enzymes such as PNGaseF allow release of the N-glycan pool of such a 
glycoprotein pool (set of different glycoforms of a protein, figure 7B). CGE-LIF-
based glycoprofiling of a labeled N-glycan pool results in electropherograms, 
where relative fluorescence units (RFU) are plotted over datapoints. These N-
glycosylation electropherograms show high batch-to-batch as well as day-to-day 
variations regarding the x-axis (figure 7C) due to minimal changes in buffer 
concentration, temperature, etc.. However, normalization of raw data to an 
internal DNA basepair (bp) standard results in N-glycosylation fingerprints 
(figure 7D), also referred to as N-glycan fingerprints, of a glycoprotein pool 
(patented strategy, [127, 128]). In such fingerprints RFU are plotted over 
normalized migration time units (MTU’, figure 7D), which are equivalent to bp. 
In electropherograms as well as in fingerprints one peak corresponds to at least 
one distinct N-glycan structure. Also relative quantification of detected N-glycan 
peaks is possible. Therefore, the y-axis is normalized by calculating the total 
peak height (TPH, summed peak height of all specific peaks) and setting it to 
100 %. Consequently the relative peak height (RPH) in % of each single peak 
corresponds to its relative N-glycan structure abundance (figure 7E). By  
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figure 7: Relevant terms and data processing steps for CGE-LIF-based N-glycoanalysis. 
(A) Glycoproteins can be considered as a collection of different glycoforms varying in attached 
sugars (microheterogeneity) as well as glycosylation site occupancy (macroheterogeneity). The 
N-glycosylation pattern of a glycoprotein can only be approximated. (B) Depending on their 
composition, N-glycans are classified into high mannose (hm), hybrid (h) and complex (c) 
structures. (C) CGE-LIF-based glyco-profiling results in electropherograms, where relative 
fluorescence units (RFU) are plotted over datapoints. Datapoints vary dramatically from run to 
run. (D) Data processing and normalization to an internal standard result in reproducible N-
glycosylation/N-glycan fingerprints of a given glycoprotein pool, in which RFU are plotted over 
migration times (tmig) in normalized migration time units (MTU’). In electropherograms as well as 
in fingerprints one peak corresponds to at least one distinct N-glycan structure. Furthermore, 
large glycan structures have high migration times unless they are sialated (not in case of IVA 
HA). Every sialiation introduces charges reducing the migration time. (E) Relative quantification of 
detected N-glycan structures. Total peak height (TPH, sum height of all specific peaks) is set to 
100 %. Consequently, relative peak heights (RPH) in % of the different peaks correspond to 
relative N-glycan structure abundances. Peaks < 5 % represent low abundant, whereas peaks 
> 5 % represent high abundant N-glycan structures. 
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definition, peaks with RPH < 5 % represent low abundant and peaks with 
RPH > 5 % represent high abundant N-glycan structures. 
2.10.3 Next-generation pyrosequencing for characterizing viral quasispecies 
compositions 
Beside the characterization of attached N-glycans to the major vaccine antigen 
HA, the genomic sequences of virus preparations should be determined during 
virus adaptation to exclude changing potential N-glycosylation sites and 
furthermore, monitor genetic variability/heterogeneity of the virus population [4]. 
Several methods are available for sequencing: 
The oldest method for DNA-sequencing is based on chain termination and was 
developed by Federick Sanger, why it is also referred to as Sanger sequencing. 
Basically, a template DNA is amplified in a polymerase chain reaction (PCR), but 
using additionally to the deoxynucleoside triphosphates (dNTPs) low 
concentrations of fluorescently labeled dideoxynucleoside triphosphates 
(ddNTPs) with a specific label for each of the four bases. Consequently, by 
random ddNTP incorporation chains of all different lengths are amplified. These 
DNA chains are separated by size, e.g. using a capillary DNA sequencer. The 
sequence of the specific label signals corresponds to the base sequence of the 
template DNA. Principally, Sanger sequences the consensus of a population, in 
which low abundant variants disappear. 
In contrast, the more recently developed techniques of next generation 
sequencing sequences variants, from which the consensus is formed. This 
allows characterizing a population consisting of differing genotypes, e.g. the 
composition of a viral quasispecies. All next generation sequencing techniques 
use the principle of sequencing by synthesis. One is called Illumina 
sequencing and uses fluorescently labeled, reversible terminator-bound dNTPs, 
minimizing incorporation bias. During each chain elongation cycle all four 
terminator-bound dNTPs are present. As a dNTP is added to the complementary 
growing DNA-strand and the fluorescently labeled terminator is cleaved off, the 
base-specific fluorescent signal is detected and a next fluorescently labeled, 
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reversible terminator-bound dNTP can be incorporated, and so on. Read length 
of approximately 200 bp can be achieved. Another technique is called next-
generation pyrosequencing using the Roche 454. Here, one dNTP is offered 
for chain elongation after the other. Whenever a dNTP is incorporated into the 
growing DNA chain, pyrophosphate and hydrogen are released. The released 
pyrophosphate is enzymatically converted to ATP, which is used in the 
Luciferin/Luciferase reaction, producing oxyluceferin and light. The latter can be 
detected and signal intensity is proportional to the number of incorporated bases. 
So briefly, whenever a base cycle results in a light signal, this base was 
incorporated. For a detailed scheme of the next-generation pyrosequencing, see 
section 12.10 in the supplementary. A clear advantage of next-generation 
pyrosequencing is that it combines a relatively long read length of approximately 
400 bp with a sequence depth (number of sequences obtained for one position) 
of up to hundreds of reads per base position. Other techniques such as Ion 
Torrent Semiconductor Sequencing have been described, too. As for next-
generation pyrosequencing, one dNTP is offered after the other for 
complementary chain elongation. Here, the released hydrogen ion after chain 
elongation is measured by an ion-sensitive field-effect transistor (ISFET) sensor. 
As for next-generation pyrosequencing a proportionally higher signal (here 
electrical) indicates the presence of homopolymer repeats. Read-lengths of up to 
200 bp have been reported (reviewed in [129, 130]). 
Within this work next-generation pyrosequencing was applied to unravel 
quasispecies composition for the whole coding IVA-PR8 genomes, 
predominantly due to the long read lengths. In this work the limit of detection 
(LOD) of different virus variants is most probably determined by the RT-PCR, 
which is performed prior sequencing to transcribe viral RNA into cDNA for 
sequencing. 
2.11 Immunogenicity and adaptive immune responses 
The combination of different methods such as CGE-LIF-based glycoanalysis and 
pyrosequencing allows a comprehensive characterization of different virus 
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preparations regarding HA N-glycosylation and quasispecies composition. Then, 
questions rise concerning the impact of virus variations on the immunogenicity 
and hence on the efficacy of different virus preparations for vaccine production. 
So what is immunogenicity or better what makes an antigen (Ag) immunogenic? 
To define an Ag such as HA immunogenic, different conditions must be met 
(figure 8): first the Ag needs to be taken up by antigen presenting cells (APC), 
second the Ag needs to be processed within the APC, third processed Ag 
fragments need to be presented by the APC, fourth the presented Ag fragment 
needs to be recognized by a specific T cell expressing a specific T cell receptor 
(TCR) and fifth the specific T cell needs to be activated by the APC to proliferate 
and differentiate [131]. In the following, a brief overview of the immune system, in 
particular of adaptive immunity, will be given, outlining key factors and 
intersections, relevant for the understanding and interpretation of data obtained 
within this study [1]. 
The immune system is divided into two, often closely interacting parts: the innate 
immune system (no memory function; e.g. dendritic cells, DC, CD11c+; 
macrophages, CD19+) and the adaptive immune system (with memory function; 
B and T cells, [132-134]). The adaptive immune system is further divided into a 
cellular arm (T cell-mediated, figure 8A) and a humoral arm (B cell-mediated, 
figure 8B). 
2.11.1 Cellular immunity 
Whenever an Ag, e.g. a viral vaccine after intramuscular application, enters the 
organism, it is taken up by Ag presenting cells (APC) in the peripheral tissues. 
APC are represented either by different cells of the innate immune system such 
as macrophages and DC or by B cells, which belong to the humoral arm of the 
adaptive immune system. Once the Ag is taken up, the APC migrates to 
secondary lymphoid tissues (e.g. spleen, lymph nodes). Meanwhile, the Ag is 
processed into small peptide fragments, which are loaded onto major 
histocompatibility complexes (MHC) of the type I or II. These peptide-MHCI/II-
complexes are transported to the cell surface, where they are presented (figure 
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8A, [135]). In general, with respect to DCs exogenous Ag (e.g. inactivated 
vaccines) is usually presented by MHCII, whereas endogenous Ag is usually 
presented by MHCI (e.g. infected cells). However, the ability of DCs in particular 
to cross-present exogenous Ag results in MHCI-presentation of exogenous Ag 
peptides. Whenever a naive T cell, expressing a specific TCR for the presented 
peptide fragment presented, encounters the Ag presenting DC the TCR binds to 
the peptide-MHC-complex. In general, T helper cells (CD4+) bind to MHCII-
peptide-complexes, whereas cytotoxic T cells (CD8+) bind to MHCI-peptide-
complexes. Additional binding of different cell surface markers triggers 
intracellular signaling series, leading to IL-2 secretion, expression of IL-2 
receptors (IL-2R), T cell activation with CD69 expression (very early T cell 
activation marker, [136]), T cell proliferation and T cell differentiation into effector 
cells ([134, 135, 137, 138], figure 8). However, usually TCR signals are often 
insufficient for complete T cell activation and costimulation by other interactions 
such as CD28/B7.1 (B7.2) are required for full T cell activation and survival [139]. 
The autocrine interaction of IL-2 secretion and IL-2R expression plays an 
essential role for the stimulation of Ag-specific T cells to proliferate, differentiate 
into effector cells and to survive. Different effector cell subtypes have been 
characterized, differing in their secretion of cytokines, their expression of cell 
marker molecules and their function (figure 8A): On the one hand, there are 
CD8+ cytotoxic T lymphocytes (CTL), which kill infected cells and which can 
activate/induce cytotoxic functions in macrophages and granulocytes [135]. On 
the other hand there are CD4+ T helper cells. These are divided into different cell 
types: low abundant cell populations such as T helper cells (Th) 9, Th17 and 
follicular Th (ThFH, [137]) and rather high abundant populations such as Th1, Th2 
and regulatory T cells (Tregs). However, few exceptions (CD4- Th cells) were 
described for special Treg subtypes [137, 138]. Nevertheless, upon activation 
each Th population may be discriminated by specific markers: Th1 cells express 
T-bet and secrete multiple cytokines e.g. IL-2 and IFNγ. Altogether, the Th1 
response activates/induces macrophages, CTL and the production of B cell IgG 
Ab [137]. Th1 responses are generally associated with strong CTL responses,  
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figure 8: Adaptive immune responses. 
Cytokines and cell surface marker proteins quantified in this study are highlighted in red. (A) T 
cell-mediated cellular arm of the adaptive immune response. 1. An antigen (Ag) is taken up by an 
Ag presenting cell (APC), 2. processed and 3. presented on the APC cell surface. 4. When a 
naive, T cell binds with its specific T cell receptor (TCR) to the presented Ag the T cell is 5. 
activated, proliferates and differentiates into different effector cell types such as cytotoxic T 
lymphocytes (CTL, CD8+) or different T helper (Th, mostly CD4+) cells, e.g. Th1, Th2, Th9, Th17. 
So far, it is not known, whether memory cells (TEM: effector memory cells, TCM: central memory 
cells) derive from effector cells or whether they differentiate directly from naive T cells (∙∙∙∙∙►). (B) 
B cell-mediated humoral arm of the adaptive immune response. Once a naive B cell binds with its 
specific B cell receptor (BCR) to the Ag, it is taken up, processed and presented on the B cell 
surface. When a naive, Ag-primed Th cell binds to the Ag-presenting B cell it provides helper 
functions, secretes cytokines and allows cell-cell-contact by CD40-CD154-interactions. Altogether 
this allows B cell proliferation and differentiation into antibody (Ab) producing plasma cells 
(effector cells) or memory cells. 
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predominantly fighting intracellular pathogens [135]. In contrast, Th2 responses 
are associated with Ab-mediated immune responses, predominantly fighting 
extracellular pathogens [135, 140]. Activated Th2 cells express GATA-3 and 
secrete cytokines such as IL 4, IL 5, IL 6, IL 9, IL 10, IL 13 and IL 25 [137, 141-
144]. The Th2 response activates/induces eosinophils, mast cells, basophils and 
the production of B cell IgM, G, A and E Ab [137]. However, most important for 
successful vaccination is the development of memory cells, since most effector 
cells will die once the Ag/pathogen has been cleared. So far, it is not fully 
understood, whether memory cells develop from naive T cells in parallel to the 
effector cells (divergent) or whether they develop from the effector cells (linear, 
[145]). Though, up to date only little research focuses on T cell-mediated vaccine 
function [146]. 
In this study, CD69 expression of CD4+ T-cells and IL-2, IL-4 and IFNγ secretion 
was measured to characterize T cell responses in vitro. The use of TCR-HA 
transgenic mice (i.e. homozygote mice only express a TCR which is specific for 
the HA110-120 peptide) allowed an easy quantification of HA110-120-specific T 
cells. 
2.11.2 Humoral immunity 
So far, most vaccine approaches concentrate on the elucidation of neutralizing 
Ab: Whenever a naive B cell encounters its specific Ag, it binds with its B cell 
receptor (BCR) to the specific epitope (figure 8B). A signaling series leads to the 
transcription of B cell activation-associated genes and the internalization or 
degradation of the BCR. The Ag is processed into small peptide fragments, 
which are loaded onto MHCII molecules and which are transported to the cell 
surface, where they are presented. Whenever a fragment-specific, antigen-
primed T helper cell is encountered, it binds with its specific TCR to the specific 
BCR. Binding induces signaling series leading to complete T cell activation. The 
activated T cell carries out helper functions, such as cytokine secreting and cell-
cell-interaction, finally leading to B cell activation, proliferation and differentiation 
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into effector cells – the Ab-producing plasma cells - and into memory cells (figure 
8B, [135, 140, 141]). 
In this study, B cell responses induced in vivo by differentially glycosylated IVA 
preparations in wild type (wt) BALB/c mice, were characterized by HA-specific Ab 
titers as well as by the ability of induced Ab to inhibit hemagglutination, i.e. the 
ability to block IVA binding to red blood cells. 
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3 Materials and methods 
3.1 Cell lines and cultivation conditions 
An overview of cell lines used during this study is given in table 1 along with 
details including cell growth media and cultivation vessels. Briefly, unless stated 
otherwise, adherently growing MDCK (#84121903, ECACC, Salisbury, UK) and 
adherently growing Vero (#88020401, ECACC) cells were cultivated under 
serum-containing conditions in Glasgow Minimum Essential Medium (GMEM, 
#22100-093, Invitrogen/Gibco, Darmstadt, Germany), supplemented with 5.5 g/L 
glucose (#X997.3, Roth, Karlsruhe, Germany), 2 g/L peptone (#MC33, IDG, 
Lancashire, UK), 10 % fetal calf serum (FCS, #10270-106, Invitrogen/Gibco) and 
4 mg/mL NaHCO3 (#6885.3, Roth) until confluence in T75-flasks (50 mL, 37 °C, 
5 % CO2), T175-flasks (150 mL, 37 °C, 5 % CO2), roller bottles with closed caps 
(250 mL, 37 °C), 1.2 L-stirred tank reactors (STR, cellferm-pro® DasGip, Jülich, 
Germany) with a working volume of 800 mL and parameters set to pO2 40 %, pH 
7.2, 55 rpm, 37 °C as well as 5 L-STR (Biostat C5, B. Braun Biotech International 
GmbH, Melsungen, Germany) with a working volume of 5 L and parameters set 
to pO2 40 %, pH 7.2, 50 rpm, 37 °C (SOP see section 12.9.5). In stirred systems 
the adherently growing cells were cultivated on microcarriers (2 g/L, 
CytodexTM1, #17-0448-03, GE Healthcare, Uppsala, Sweden). For adaptation to 
serum-free growth MDCK cells were cultivated in Episerf medium (#10732-022, 
Invitrogen/Gibco) until at least three consecutive passages of cells were 
successfully propagated using 100 % Episerf medium in total. Suspension 
growth adapted MDCK cells, namely MDCK.SUS1, MDCK.SUS2 and 
MDCK.SUS3 [142] were cultivated in chemically defined, protein- and peptide-
free SMIF8 medium or in SMIF8pgd (both available from Gibco/Invitrogen by 
contact through Prof. Dr. K. Scharfenberg, FH Emden/Leer, Germany) in shaker 
flasks (250 mL with baffles with a working volume of 100 mL, 185 rpm, 37 °C, 
5 % CO2). The new human-derived, suspension cell line CAP was cultivated in 
PEM medium (#12661-013, Invitrogen/Gibco) supplemented with 4 mM 
glutamine (#G3126, Sigma-Aldrich, Steinheim, Germany) and 4 mM pyruvate 
3 Materials and methods 
33 
(#P8574, Sigma-Aldrich) in 1 L-STR (Biostat B-Plus, Sartorius AG, Göttingen, 
Germany) with a working volume of 1 L and parameters set to pO2 40 %, pH 7.1-
7.2, 120 rpm, 37 °C. Duck-derived AGE1.CR.pIX suspension cells (ProBioGen 
AG, Berlin, Germany, [76]) were grown in 250 mL shaker flasks with baffles in a 
total volume of 50 mL in a chemically defined medium (CD-U2, [143]), 
supplemented with 2 mM alanine-glutamine (#G8541, Sigma-Aldrich) and 
10 ng/mL insulin like growth factor (#91590C, Sigma-Aldrich). Flasks were 
shaken at 185 rpm, 37 °C and 5 % CO2 [6, 7]. 
Standard operating procedures (SOPs) for thawing (section 12.9.1) of cells and 
passaging (section 12.9.2) of adherent MDCK cells including the SOP for trypsin 
preparation (1.25 g trypsin Invitrogen/Gibco, #27250018 for 2500 mL 1x trypsin 
solution, section 12.9.7), required for cell passaging are compiled in the 
supplementary section. 
Generally, before infection adherent cells were washed three times with 
phosphate buffered saline (PBS, SOP see section 12.9.3) for complete removal 
of FCS. Cell growth medium of suspension cells was either not changed before 
infection or partly/fully replaced by fresh medium (see table 1 for details). 
 
  
 
table 1: Overview of culture conditions and media used for influenza virus A (IVA) production. 
IVA PR/8/34 (H1N1) from the Robert Koch Institute (RKI, RKI-strain) or the National Institute for Biological Standards and Control (NIBSC, NIBSC-
strain) as well as IVA-California/07//2009-like (H3N2, IVA-California), IVA Uruguay//716/2007-like (H3N2, IVA-Uruguay) and IVA 
Victoria/210/2009-like (H1N1, IVA-Victoria) reassortants were produced in cell culture or embryonated hens’ eggs. 
Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 48 SEC yes 0.1 or 1 mL
Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 SEC yes 0.1 or 1 mL
Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 120 SEC yes 0.1 or 1 mL
Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 360 SEC yes 0.1 or 1 mL
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 SEC yes 1 mL
MDCK IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL 5L-STR 24 SEC yes 0.05
MDCK IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL 5L-STR 72 SEC yes 0.05
Vero Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 HILIC yes 0.08
MDCK MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 HILIC yes 1
Cap Cap RKI-strain PEM° PEM° + trypsin 3x 10-5 units/cell 1L-STR 72 SEC no 0.025
AGE1.CR.pIX AGE1.CR.pIX RKI-strain CD-U2# CD-U2#+ trypsin 1x 10-6 units/cell 250mL shaker w baffles 24 SEC no 1 mL
egg% egg RKI-strain egg egg 0 U/mL egg 96 HILIC % nd
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 SEC yes 1 mL
MDCK RKI-strain Episerf" Episerf" + trypsin 5 U/mL roller bottle 96 SEC no 1 mL
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 HILIC yes 1
MDCK.SUS1 RKI-strain SMIF8-Pgd§ SMIF8-Pgd§ + trypsin 1x 10-5 units/cell 250mL shaker w baffles 72 HILIC yes 188
MDCK.SUS2 RKI-strain SMIF8-Pgd§ SMIF8-Pgd§ + trypsin 1x 10-5 units/cell 250mL shaker w baffles 72 HILIC yes 197.3
MDCK.SUS3 RKI-strain SMIF8-Pgd§ SMIF8-Pgd§ + trypsin 1x 10-5 units/cell 250mL shaker w baffles 72 HILIC yes 192.6
MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.2 mL
MDCK.SUS1 NIBSC-strain SMIF8-Pgd§ SMIF8-Pgd§ + trypsin 12.5 U/mL 250mL shaker w baffles 48 HILIC partly (90 %) 1.41
MDCK.SUS2 NIBSC-strain SMIF8-Pgd§ SMIF8-Pgd§ + trypsin 12.5 U/mL 250mL shaker w baffles 48 HILIC partly (90 %) 1.17
MDCK.SUS3 NIBSC-strain SMIF8-Pgd§ SMIF8-Pgd§ + trypsin 12.5 U/mL 250mL shaker w baffles 48 HILIC partly (90 %) 1.75
MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.2 mL
MDCK IVA-California GMEM* + FCS GMEM* + trypsin 5 U/mL T75 48 HILIC yes 0.2 mL
MDCK IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.05
MDCK IVA-Victoria GMEM* + FCS GMEM* + trypsin 5 U/mL T75 48 HILIC yes 0.2 mL
passage 1 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 0.333333
passage 2 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 3 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 4 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 5 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 6 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 7 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 8 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 9 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
passage 10 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 24 SEC yes 1 mL of previous passage
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 2.33 or 0.2 mL
MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.028 or 0.2 mL
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* GMEM-medium was supplemented with 5.5 g/L glucose, 2 g/L peptone and 4 mg/mL NaHCO3. 
° PEM-medium was supplemented with 4 mM glutamine and 4 mM pyruvate. 
“ Episerf was supplemented with 20 mM glucose, 2 mM glutamine and 2 mM pyruvate. 
#
 CD-U2 [143] was supplemented with 2 mM alanine-glutamine, 10 ng/mL insulin like growth factor. 
$, §
 SMIF8 and SMIF8-Pdg are available from Gibco/Invitrogen by contact through Prof. Dr. K. Scharfenberg (FH Emden/Leer, Germany). 
%
 virus was produced in cooperation with IDT Biologika GmbH, Dessau-Rosslau, Germany 
SEC: size exclusion chromatography, HILIC: hydrophilic interaction chromatography 
  
 
table 1 continued 
passage 1 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 24 SEC yes 2
passage 2 Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 360 SEC yes 1 mL of previous passage
passage 3 Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 120 SEC yes 0.4 mL of previous passage
passage 4 Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 96 SEC yes 0.5 mL of previous passage
passage 5 Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 72 SEC yes 0.5 mL of previous passage
passage 6 Vero RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 48 SEC yes 0.5 mL of previous passage
passage 7 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 96 SEC yes 0.5 mL of previous passage
passage 8 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 72 SEC yes 0.5 mL of previous passage
passage 9 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 96 SEC yes 0.5 mL of previous passage
passage 10 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 72 SEC yes 0.5 mL of previous passage
passage 11 MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 96 SEC yes 0.5 mL of previous passage
passage 1 MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 24 SEC yes 0.0294
passage 2 Vero NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 360 SEC yes 1 mL of previous passage
passage 3 Vero NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 120 SEC yes 0.4 mL of previous passage
passage 4 Vero NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.25 mL of previous passage
passage 5 Vero NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.25 mL of previous passage
passage 6 Vero NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 48 SEC yes 0.25 mL of previous passage
passage 7 MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.25 mL of previous passage
passage 8 MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.25 mL of previous passage
passage 9 MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.25 mL of previous passage
passage 10 MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.25 mL of previous passage
passage 11 MDCK NIBSC-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.25 mL of previous passage
passage 1 MDCK IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 24 SEC yes 0.2 mL virus seed
passage 2 Vero IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 1 mL of previous passage
passage 3 Vero IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 264 SEC yes 0.4 mL of previous passage
passage 4 Vero IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 120 SEC yes 0.25 mL of previous passage
passage 5 Vero IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.25 mL of previous passage
passage 6 Vero IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 SEC yes 0.25 mL of previous passage
seed MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 24 SEC yes 1 mL
passage 1 AGE1.CR.pIX RKI-strain CD-U2# CD-U2#+ trypsin 1x 10-6 units/cell 250mL shaker w baffles 24 SEC no 0.001
passage 2 AGE1.CR.pIX RKI-strain CD-U2# CD-U2#+ trypsin 1x 10-6 units/cell 250mL shaker w baffles 24 SEC no 1 mL of previous passage
passage 3 AGE1.CR.pIX RKI-strain CD-U2# CD-U2#+ trypsin 1x 10-6 units/cell 250mL shaker w baffles 24 SEC no 1 mL of previous passage
passage 4 AGE1.CR.pIX RKI-strain CD-U2# CD-U2#+ trypsin 1x 10-6 units/cell 250mL shaker w baffles 24 SEC no 1 mL of previous passage
passage 1 egg IVA-California egg egg nd nd nd HILIC % nd
passage 2 MDCK IVA-California GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 HILIC yes 0.15 mL from ampulle
passage 3 MDCK IVA-California GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 HILIC yes 0.2 mL of previous passage
passage 4 MDCK IVA-California GMEM* + FCS GMEM* + trypsin 5 U/mL T75 48 HILIC yes 0.2 mL of previous passage
passage 1 egg IVA-Victoria egg egg nd nd nd HILIC % nd
passage 2 MDCK IVA-Victoria GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 HILIC yes 0.15 mL from ampulle
passage 3 MDCK IVA-Victoria GMEM* + FCS GMEM* + trypsin 5 U/mL T75 72 HILIC yes 0.2 mL of previous passage
passage 4 MDCK IVA-Victoria GMEM* + FCS GMEM* + trypsin 5 U/mL T75 48 HILIC yes 0.2 mL of previous passage
passage 1% egg RKI-strain egg egg 0 U/mL egg 96 HILIC % pool of various mois
passage 2% egg RKI-strain egg egg 0 U/mL egg 96 HILIC % pool of various mois
passage 3% egg RKI-strain egg egg 0 U/mL egg 96 HILIC % pool of various mois
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 2.33 or 0.2 mL
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 96 SEC yes 2 or 0.4 mL
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL roller bottle 96 SEC yes 1 mL
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL 1 L-STR 96 SEC yes 0.025
MDCK IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL T75 24 SEC yes 0.25 or 0.25 mL
MDCK IVA-Uruguay GMEM* + FCS GMEM* + trypsin 5 U/mL 5 L-STR 24 SEC yes 0.05
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T175 72 SEC yes 2.8
MDCK RKI-strain GMEM* + FCS Episerf" + trypsin 5 U/mL T175 72 SEC yes 2.8
MDCK RKI-strain GMEM* + FCS SMIF8$ + trypsin 5 U/mL T175 72 SEC yes 2.8
MDCK RKI-strain GMEM* + FCS GMEM* 0 U/mL T75 120 SEC yes 0.025
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL T75 96 SEC yes 0.025
MDCK RKI-strain GMEM* + FCS GMEM* + trypsin 5 U/mL every 24 h T75 96 SEC yes 0.025
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3.2 Viruses and infection conditions 
Depending on the production cell line, either MDCK cell-, Vero cell- or 
AGE1.CR.pIX cell-adapted influenza A virus PR/8/34 (H1N1) - in the following 
referred to as IVA-PR8 - was used for infections. In the scope of this study IVA-
PR8 from two different suppliers was used: one was purchased from the National 
Institute for Biological Standards and Control (NIBSC, #06/114, South Mimms, 
UK), which is also referred to as NIBSC-strain. The other was provided by the 
Robert Koch Institute (RKI, Berlin, Germany, Amp. 3138) and is referred to as 
RKI-strain. Moreover, the reassortant influenza A virus California/07/2009 
(H1N1pandemic, #09/176, NIBSC), IVA-California, the reassortant influenza A 
virus Uruguay/716/2007 (H3N2) x IVA-PR8/34 (H1N1, #07/360, NIBSC), IVA-
Uruguay and the reassortant influenza A virus Victoria/210/2009 (H3N2) x IVA-
PR8/34 (H1N1, #12/112, NIBSC), IVA-Victoria was used as indicated (table 1). 
Details concerning virus production are summarized in table 1. The SOP for virus 
propagation in culture flasks is provided in the supplementary (section 12.9.6). 
Briefly, unless indicated otherwise, virus was produced in non-serum containing 
cell growth medium supplemented with a final activity of 5 U/mL trypsin 
(Invitrogen/Gibco, #27250-18, Darmstadt, Germany). Trypsin was prepared in 
PBS according to the activity given by the supplier (for SOP see section 12.9.8). 
Generally, volume-based infections using 1 mL virus seed for roller bottles and 
shaker flasks, 0.4 mL/0.5 mL for T175- and 0.2 mL/0.25 mL for T-75-flasks were 
applied (for details see table 1). For microcarrier-based cultivations a multiplicity 
of infection (moi) of usually 0.025 was applied. CAP suspension cells were also 
infected with a moi of 0.025. For infection of AGE1.CR.pIX cells 1x 10-6 units 
trypsin (Invitrogen/Gibco) were added per cell and a moi of 0.001 (passage 1) 
was used. During all virus adaptation experiments and all virus passaging 
experiments subsequent passages were infected using an appropriate volume 
(depending on the vessel) of the supernatant of the previous passage (for details 
see table 1). 
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3.3 Virus quantification by hemagglutination- (HA-) assay 
Influenza virus from cell culture supernatant was titrated by hemagglutination 
based on the method from Kalbfuss et al. [144]. Samples were serially diluted 
1:20.5 in PBS resulting in a final volume of 100 μL using round-bottomed 96-well 
plates. 1.9 – 2.1 x 106 red blood chicken cells in a total volume of 100 μL in PBS 
(SOP see section 12.9.11) were added and incubated for 3 h to 4 h at room 
temperature. Light extinction was measured at 700 nm and plotted over the 
logarithm of the inversed dilutions. The end point was defined as the point of 
inflection. The point of inflection represents the last dilution (d) showing complete 
hemagglutination and corresponds to 1 HAU (HAU = HA Units = -log10 d/100 μL). 
A sample’s HA-titer is calculated by considering the dilution factor of the end 
point. Consequently, if e.g. the end point is reached at a dilution of 1/64 (1/101.8), 
this corresponds to an HA-titer of 1.8 HAU for the undiluted sample. The detailed 
SOP can be found in the supplementary (section 12.9.12, [4]). 
3.4 β-propiolactone inactivation 
For immunogenicity studies and prior to native in-solution virus deglycosylation 
MDCK- and Vero cell-derived virus containing culture broths were harvested 
96 hpi and clarified by centrifugation (100 g for 20 min, 4000 g for 35 min and 
10.000 g for 45 min, Avanti J-20XP, Beckman Coulter, Krefeld, Germany). 
Clarified supernatants were stored at -80 °C and were chemically inactivated by 
β-propiolactone (β-PL, #33672.01, Serva Electrophoresis, Heidelberg, Germany) 
as described by Kalbfuss et al. [86, 145]. Briefly, pH of culture broth was 
stabilized by the addition of 25 mM (final) HEPES-buffer (pH 7.5; stock), and β-
PL prediluted in HEPES-buffer was added to the clarified culture broth (final β-PL 
concentration 3 mM). The broth was transferred into a new vessel in order to 
ensure proper mixing and was incubated at 37 °C for 24 h. Inactivation was 
confirmed when two consecutively infected T75-flasks of confluent MDCK cells 
(1 mL inactivated broth + 50 mL medium) exhibited HA-titers according to the 
dilution used during infection, i.e. when latest, the second passage reached a 
titer of 0 HAU. The detailed SOP for β-PL inactivation can be found in the 
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supplementary (section 12.9.13). All steps were carried out under sterile 
conditions. 
3.5 Protein quantification by bicinchoninic acid assay 
A sample’s protein content was determined by bicinchoninic acid assay (BCA 
assay, #23227, Thermo Fisher Scientific Inc., Rockford, Illinois, USA, [146]) 
according to instructions provided by the manufacturer for micro-plate assays. 
3.6 N-glycosylation pattern analysis 
3.6.1 Workflow 
HA N-glycosylation pattern analysis was performed as described earlier using a 
CGE-LIF-based approach ([4, 6, 7, 73, 112, 147, 148], figure 9). According to 
Schwarzer et al. CGE-LIF-based glycoanalysis has a limit of detection (LOD) of 
at least 5 fmol/L and a linear dynamic range from 2 pmol/L up to 2 nmol/L as 
determined by dilution series using the fluorescent marker molecule APTS [112]. 
Furthermore, they determined a SD of 0.3 % to 1.8 % for the reproducibility of 
RPH for bovine IgG-derived N-glycan fingerprints [112]. With respect to migration 
times, long-term reproducibility was described to be below 0.08 min [112], which 
corresponds to roughly 13.9 datapoints (about 2.9 datapoints per second for four 
capillary 3100 ABI PRISM Genetic Analyzer). 
During the time of this work another student improved the purification step of 
labeled N-glycans from excess label and impurity-salts towards high-throughput 
applications within his student’s project (figure 9, step 6). The optimized protocol 
for sample preparation substituted the SEC by HILIC (figure 9, step 6). 
Therefore, in this work both methods (SEC, HILIC) were used as indicated in 
table 1. However, according to [149] the applied purification method - SEC or 
HILIC – does not impact N-glycan structure presence or absence. It may merely 
affect relative N-glycan structure abundances. 
After harvest of the virus-containing supernatant, the culture broth was cleared 
by centrifugation (usually 100 g for 20 min, 4000 g for 35 min, 10.000 g for 
45 min). Virus isolation was performed at 31000 rpm (g force at average 
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diameter 5.24 mm: about 56300 g; Type 70Ti rotor, Beckman Coulter) in 
OptiSeal tubes (32.4 mL, #361625, Beckman Coulter) for 90 min at 4 °C (figure 
9, step 1). Finally, the virus containing pellet was resuspended in 100 mM Tris 
(pH 7) and virus preparations were stored at -80 °C [8]. 
 
figure 9: Workflow of CGE-LIF-based N-glycosylation pattern analysis for IVA-derived HA. 
After virus harvest and isolation by centrifugation (1), viral proteins are separated in a SDS-PAGE 
(2). HA at approximately 70 kDa is cut out and N-glycans are enzymatically cut off the protein 
backbone (3). The protein may as well be analyzed by e.g. LC-MS/MS in order to verify protein 
identity. N-glycans are extracted (4) and labeled with APTS (5). Excess label and impurity-salts 
are removed by SEC or HILIC (6). Finally, the labeled N-glycans are separated by CGE and 
detected by LIF, resulting in capillary electropherograms (7), which are further processed into 
highly reproducible N-glycan fingerprints (workflow according to [112]). 
 
Approximately 10 μg - 25 μg total virus protein (e.g. BCA, section 3.5) was mixed 
in a ratio 3:1 with 4x non-reducing sample buffer (125 mM Tris, 4 % SDS, 20 % 
glycerole, 8 M urea, bromophenol blue) and was applied to a sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE, #161-1158, Bio-Rad 
Laboratories, Inc., Munich, Germany). Subsequently, viral proteins were 
separated according to their size at 15 mA per gel for approximately 95 min 
(figure 9, step 2). Subsequently, the gels were transferred for 1 h into a fixation 
solution (40 % ethanol, 7.5 % acetic acid), washed in ultra pure water (H2OMQ) for 
re-hydration, and stained in a colloidal coomassie solution (0.5 g coomassie 
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brilliant blue, 10 mL H2OMQ, 50 g ammonium sulfate, 6 mL phosphoric acid 
(85 %), filled up to 490 mL with H2OMQ, 125 mL methanol) over night at room 
temperature. Afterwards, the gels were washed multiple times in H2OMQ until 
protein bands were clearly visible. All incubations were performed on a see-saw-
shaker. The stained SDS-PAGEs were stored sealed at 4 °C [8]. 
In a next step, HA-bands were cut out of the gel, divided into pieces and 
transferred into 1.5 mL tubes. During multiple incubation steps the gel pieces 
were washed, reduced and alkylated using different ammonium bicarbonate-, 
acetic acid-, methanol-, acetonitrile-, dithiothreitol- and iodacetamide- solutions 
[112, 147]. Finally, for in-gel-deglycosylation, the gel pieces were incubated with 
6 μL PNGaseF (#7367, Sigma-Aldrich, Taufkirchen, Germany) and 54 μL 50 mM 
ammonium bicarbonate over night at 37 °C (figure 9, step 3). For N-glycan 
extraction (figure 9, step 4), the supernatant was transferred into a new tube and 
remaining N-glycans were extracted by three rounds of sonication (30 min., 
10 °C, level 6, Ultrasonic cleaner, Model USC6000, VWR), each in 200 μL 
H2OMQ, pooling all extracts in the new tube and then desiccated [8]. 
Then, the extracted N-glycans were labeled (figure 9, step 5) with 8-
aminopyrene-1,3,6-trisulfonic acid (APTS) by reductive amination (5 μL 20 mM 
APTS in 15 % acetic acid, 5 μL 1M NaBH3CN in 15 % acetic acid or the non-toxic 
alternative: 2 μL H2OMQ, 2 μL 20 mM APTS in 3,6 M citric acid, 2 μL 0.2 M 
picoline borane in dimethylsulfoxid, DMSO) overnight in the dark at 37 °C whilst 
shaking. Excess label was removed by SEC for NaBH3CN-based labeling or by 
HILIC for picoline borane-based labeling (figure 9, step 6). Briefly, for SEC a 
2 mL toyopearl® (#19808, Tosoh Bioscience, Stuttgart, Germany) column was 
packed and labeled samples were applied. During following step centrifugation 
H2OMQ was continuously added. Finally, labeled N-glycans eluted before excess-
label and impurity-salts [112]. A detailed SOP for glycoanalysis is given in the 
supplementary (NaBH3CN-based: section 12.9.14; picoline borane-based: 
section 12.9.15). For HILIC, Bio-Gel P10 (#150-4144, Bio-Rad) was equilibrated 
by multiple washing steps using different acetonitril/H2OMQ solutions. Sample 
(diluted in 80:20, acetonitril: H2OMQ) addition and incubation (5 min., shaking) 
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was followed by several washing steps with acetonitril/H2OMQ (80 %/20 %) 
solutions with or without 100 mM triethylamine (TEA) supplementation. Finally, 
the labeled N-glycans were eluted using H2OMQ (SOP in section 12.9.16, [8]). 
For glycosylation pattern profiling (figure 9, step 7) labeled N-glycans were 
separated by CGE (see table 2 for settings) and monitored by LIF detection using 
an ABI PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, Foster City, 
California, USA). The resulting electropherograms were normalized to an internal 
bp-standard with respect to migration times (x-axis). The resulting N-glycan 
fingerprints correspond to the actual N-glycosylation pattern of the analyzed 
glycoproteins and are plotted in relative fluorescence units (RFU) over the 
migration time (tmig) in normalized migration time units (MTU’), which are 
equivalent to base pairs (bp; MTU’ = bp). In original electropherograms as well as 
in N-glycan fingerprints one peak corresponds to at least one distinct N-glycan 
structure [6]. 
In general, data processing was performed as published previously [1, 4-7, 73, 
112, 150]. For all other data an additional baseline correction was performed as 
described by Rödig et al. [6]. Therefore, baseline correction was performed by 
asymmetric least squares smoothing according to Eilers et al. [151], using the 
parameters p = 0.01 for asymmetry and λ=109 for smoothness. Blank samples 
were approximately normally distributed and the difference between mean and 
median was always below 0.05 for all signal intensities. Therefore, the noise 
threshold of the signal was set to the signal intensity where the difference 
between mean and median was < 0.05 for all data points below the threshold [6]. 
As published before [4, 7, 73, 112], the range of tmig = 300 MTU’ - 450 MTU’ in 
HA N-glycan fingerprints was defined for MDCK cell-specific peaks. Within this 
range, all N-glycan peaks were generally taken for MDCK cell-derived IVA-PR8 
comparisons, which reached in at least one of the comparable patterns (table 3) 
a peak height of more than 10x the baseline noise threshold (for peak annotation 
see figures of MDCK cell-derived N-glycan fingerprints, e.g. figure 16). Between 
different IVA-PR8 comparisons, the total number of annotated peaks may vary 
slightly (e.g. 15, 16) due to low abundant peaks droping below the 10x the noise 
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threshold. For all further comparisons such as different host cells as well as 
adherence versus suspension growth for MDCK cells, all peaks between 
150 MTU’ and 450 MTU’ exhibiting in at least one of the N-glycan fingerprints 
peak heights of more than 10x the noise threshold were included. However, 
during virus adaptation to AGE1.CR.pIX cells, all peaks were annotated and 
compared, which exhibited at least 20 % of the RFU of the highst peak [7]. 
Whatever comparison stategy was applied (usually as published previously) the 
conclusions are comparable [6]. 
For quantitative comparison, additional normalization of the LIF-signal (y-axis) 
may be performed. Therefore, the set of major N-glycan peaks was defined and 
the total peak height (TPH, summed height of all major peaks) was calculated 
and set to 100 %. Accordingly, N-glycan abundances can be described by 
percentage of relative peak height (RPH, in %), allowing direct qualitative and 
quantitative comparisons of different HA N-glycosylation patterns. In the 
following, peaks were classified as either low- (RPH < 5 %) or high- abundant 
(RPH ≥ 5 %). In general, peaks were numbered as published previously [8]. 
 
table 2: Settings for ABI PRISM 3100- and 3130-Avant Genetic Analyzer for CGE-LIF-based 
glycoanalysis 
Oven Wait Time 1200 Voltage_Numbers_Of_Steps 20 
Poly_Fill_Vol 66 Voltage_Step_Interval 30 
Cap_Fill_Vol 46 DC_Data_Delay 50 
Leak_Threshold 25 Run_Voltage 15.0 
Max_Current 300 DC_Run_Time 6000 or 7200 or 7800 
Current_Tolerance 100 First_Read_Out_Time 160 
Run_Current 100 Second_Read_Out_Time 160 
Voltage_Tolerance 0.6 DC_RS_Plate_Type A 12 8 
PreRun_Voltage 15.0 DC_RS_CSData Cap1 A1 
DC_PreRun_Time 600 DC_Scale_Divisor 8.0 
Injection_Voltage 15.0 DC_Down_Sample 2 
DC_Injection_Time 5 DC_Laser_Power_Setting 15.0 
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3.6.2 Stability of HA N-glycan fingerprint over different harvest time points 
Preliminary experiments showed that virus with a HA-value lower 1.8 may fail 
later glycoanalysis (data not shown). Therefore, if possible only samples with a 
minimum HA-titer of 1.8 were analyzed. With differences in replication dynamics, 
for instance during adaptation to a new cell line, i.e. slow replication dynamics 
 
figure 10: Impact of harvest time point on the HA N-glycosylation pattern of MDCK cell-
derived RKI-strain. 
(A) Shifted overlay of N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the 
migration time (tmig) in normalized migration time units (MTU’). An overall stability of the HA N-
glycosylation pattern is demonstrated for 24 hpi (i) and 96 hpi (ii). HA N-glycan fingerprints from 
both harvest time points exhibited the same 15 numbered main peaks (peak no.: 1-4, 6-16) with 
migration times between 300 MTU’ and 420 MTU’. (B) Relative peak heights (RPH) of the 15 
dominating peaks (no.: 1-4, 6-16; numbering according to virus adaptation from MDCK to Vero 
cells and back, section 4.6.2) are represented by grey (24 hpi) or white (96 hpi) columns. 
Modified and reprinted with permission [4]. 
 
during initial adaptation steps and fast progress of infection towards the end, 
different time points for sampling were required to achieve a minimum of 
1.8 HAU [4]. Hence, the impact of harvest time point on HA N-glycosylation is 
essential for the set-up and later interpretation of experiments investigating the 
impact of virus adaptation (result section). Therefore, as part of materials and 
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methods the stability of HA N-glycosylation patterns over different harvest time 
points was investigated for MDCK cell-adapted IVA-PR8 (sampling 24 hpi and 
96 hpi) and IVA-Uruguay (sampling 24 hpi and 72 hpi) in MDCK cells and for 
Vero cell-adapted IVA-PR8 (sampling 48 hpi, 96 hpi, 120 hpi and 360 hpi) in 
Vero cells. 
For all sampling time points of IVA-PR8 during MDCK cell-based virus 
replication, the HA N-glycan fingerprint was dominated by the same 15 main 
peaks (no. 1 - 4, 6 - 16; figure 10A), exhibiting maximum differences in RPH 
≤ 3.3 % (figure 10B, |ΔRPHmax| for peak15, [4]). 
 
figure 11: Impact of harvest time point on the HA N-glycosylation pattern of MDCK cell-
derived IVA-Uruguay. 
(A) Shifted overlay of N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the 
migration time (tmig) in normalized migration time units (MTU’). Overall stability of HA N-glycan 
fingerprints is demonstrated within the range from 24 hpi (i) to 72 hpi (ii). Both harvest time points 
exhibited the same 21 numbered main peaks with migration times between 150 MTU’ and 
420 MTU’ (also see [5]). (B) Relative peak heights (RPH) of the 21 dominating peaks are 
represented by black (24 hpi) or red (72 hpi) columns. 
 
Similar results were obtained for the impact of harvest time point on the HA N-
glycosylation pattern of MDCK cell-derived IVA-Uruguay (figure 11): Virus 
harvested at either 24 hpi or 72 hpi exhibited 21 MDCK cell-specific peaks above 
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the 10x noise threshold between 160 MTU’ and 400 MTU’. Overall, differences in 
relative structure abundance of all peaks above the 10x noise threshold were 
rather small with a maximal difference of ≤ 0.8 % RPH (figure 11B, |ΔRPHmax| for 
peak 6, table 3). This strongly suggests that HA of virus particles released in the 
supernatant is stable over the time window relevant for influenza virus production 
[5, 152, 153]. 
 
figure 12: Impact of harvest time point on the HA N-glycosylation pattern of Vero cell-
derived RKI-strain. 
(A) Shifted overlay of N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the 
migration time (tmig) in normalized migration time units (MTU’). An overall stability of the HA N-
glycosylation pattern is demonstrated from 48 hpi (i) over 96 hpi (ii) and 192 hpi (iii) to 360 hpi 
(iv). The harvest time point has an impact on the RPH of the 16 numbered main peaks (peak no.: 
5, 7, 8, 11, 15-25; numbering according to virus adaptation from MDCK to Vero cells and back, 
section 4.6.2)), exhibiting normalized migration times between 220 MTU’ and 380 MTU’. (B) For 
each harvest time point, the relative peak heights (RPH) of all 16 dominating peaks (no.: 5, 7, 8, 
11, 15-25) are represented by a column. Modified and reprinted with permission [4].
 
For relative quantification of attached N-glycans to Vero cell-derived RKI-strain 
16 Vero cell-specific peaks (no. 5, 7, 8, 11, 15 - 25, [4] figure 12A) were defined. 
Regarding the complete time span (sampling points 48, 96, 192, 360 hpi), 
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differences of RPH were ≤14.2 % (figure 12B, |ΔRPHmax| for peak 7). 
Considering only the time span until 96 hpi, comparable maximal differences in 
RPH to the time series of the RKI-strain in MDCK cells were observed 
(|ΔRPHmax| ≤ 3.8 %, table 3). In particular, the RPH of peaks 5 and 7 steadily 
increased (almost twofold for peak 7) and the RPH of peaks 16, 20, 22 to 25 
steadily decreased over time. Taking into account the comparatively long 
sampling period of 360 h, the higher maximal differences in RPH may be caused 
by differential N-glycan degradation or synthesis. Another possible reason may 
be slightly changing growth conditions in roller bottles for increasing cultivation 
times with decreasing pH values. This may also explain why the time series for 
IVA-Uruguay, which was performed in a pH-controlled 5 L-STR exhibited the 
lowest differences in RPH. However, even despite those changes of RPH, the 
HA N-glycosylation pattern itself was stable over 360 h [4]. 
Overall, these results demonstrate a highly reproducible HA N-glycosylation 
pattern for MDCK as well as Vero cell-derived HA from the RKI-strain and IVA-
Uruguay with respect to number of present major N-glycan structures. However, 
the bigger the investigated time frame was, the bigger were maximal differences 
of relative N-glycan structure abundances (ΙΔRPHmaxΙ values) of structures 
(peaks) present in the different glycan pools. 
3.6.3 Distribution of attached N-glycan structures over the HA1 and HA2 
subunits in the HA0-molecule 
A part of this work focused on the impact of different process conditions on the 
N-glycosylation pattern of the IVA HA0-molecule. The HA0-molecule comprises 
two subunits, the HA1- and the HA2- subunits, which are connected by disulfide 
bonds. Altogether the HA0 of the RKI-strain comprises seven potential N-
glycosylation sites. Five of these are located within the HA1-molecule and two are 
located within the HA2-molecule. For later data interpretation it is of interest 
whether the different MDCK cell-specific N-glycans are distributed equally over 
all potential N-glycosylation sites or not. An equal distribution would lead to 
matching N-glycan fingerprints of HA0, HA1 and HA2. Therefore, N-glycan 
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fingerprints of HA0, HA1 and HA2 were characterized within the material and 
method section by applying reducing (HA1, HA2) and non-reducing conditions 
during SDS-PAGE sample processing. Resulting N-glycan fingerprints 
 
figure 13: Heterogeneity of HA N-glycosylation of MDCK cell-derived RKI-strain. 
Shifted overlays (A) and direct overlays (B) of N-glycan fingerprints. Relative fluorescence units 
(RFU) are plotted over the migration time (tmig) in normalized migration time units (MTU’). N-
glycosylation fingerprints from HA0- (i), HA1- (ii) and HA2- (iii) molecules. MDCK cell-specific 
peaks between 300 MTU’ and 420 MTU’ are annotated (no. 1 to 15). (C) Relative quantification of 
MDCK cell-specific peaks of a calculated HA0 (summed-up HA1- and HA2-fingerprint), the 
analyzed HA0-, HA1- and HA2-molecule. HA1 shows a tendency towards larger N-glycan 
structures whereas HA2 shows a tendency towards smaller structures. HA0 calculated (sum of 
HA1 and HA2 N-glycan fingerprints) is comparable to the analyzed HA0 with respect to relative N-
glycan structure abundances exhibiting maximum differences of 1.9 % (peak 2). 
 
demonstrated that all MDCK cell-specific peaks (no. 1 to 15, figure 13A, B) 
detected for HA0 were also present on HA1, slightly favoring the larger structures 
with higher migration times indicating that not every N-glycan structure is equally 
distributed over all potential N-glycosylation sites. This is consistent with the 
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fingerprint of HA2 exhibiting a tendency towards smaller structures. Furthermore, 
the low abundant peaks 1 and 8 were not detected for HA2. The maximum 
difference of relative peak abundance for HA0, HA1 and HA2 was 17.8 % for 
peak 14. Summation of HA1 and HA2 fingerprints (HA0 calculated, figure 13C) 
resulted in comparable relative peak abundances as observed for the analyzed 
HA0, showing maximum differences between HA0 and HA0calculated of 1.9 % 
RPH (peak 2). These findings demonstrate that the HA0 N-glycosylation pattern, 
which is investigated throughout this study, results from combining HA1 and HA2 
N-glycosylation patterns. 
3.7 Native influenza virus deglycosylation 
The following section 3.7 contains text, analogous text content and structure 
taken from a paper published together with J. Hütter, D. Höper, P.H. Seeberger, 
E. Rapp and B. Lepenies, January 2013 in J. Immunol. [1]. As described before 
(section 1, last two paragraphs), scentences and/or paragraphs containing 
quotations are not indicated specifically. The reference will only be given after the 
phrase or paragraph by the number of the quoted reference. 
For immunogenicity studies natively deglycosylated virus preparations, i.e. 
natively folded virus proteins in a non-glcosylated state, were required in order to 
investigate the impact of HA N-glycosylation on immunogenicity. Therefore, an 
aliquot of the MDCK and Vero cell-adapted RKI-strain was natively 
deglycosylated in-solution. All buffers and enzymes used for deglycosylation 
were purchased from Sigma-Aldrich (Steinheim, Germany) unless otherwise 
stated. After ultracentrifugation, the virus pellet was resuspended in 160 μL virus 
infection medium and 6.7 μL protease inhibitor (40x, #11777700, Roche, 
Mannheim, Germany), 50 μL reaction buffer (#R9150), 10 μL endoglycosidase 
F2 (#E0639), 10 μL endoglycosidase F3 (#E2264) and 10 μL α-galactosidase 
(#G8507) were added and the mixture was shaken at 450 rpm and 37 °C for 24 h 
in the dark. Then, 10 μL reaction buffer (#R9025) and 10 μL endoglycosidase F1 
(#E9762) were added and shaking was continued at 450 rpm at 37 °C for 24 h in 
the dark. In the following, 10 μL reaction buffer (#R0266), 10 μL α-mannosidase 
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(#M7257), 10 μL α-neuraminidase (#N8271), 10 μL β-N-acetylglucosaminidase 
(#A6805), 20 U β-galactosidase (#G5160), 2 μL α-galactosidase and 2 μL 
endoglycosidase F3 were added and the mixture was again shaken at 450 rpm 
and 37 °C for 24 h in the dark. As before, the virus was isolated by 
ultracentrifugation at 31000 rpm and 4 °C for 90 min. The pelleted virus was 
resuspended in 100 mM Tris, pH 7 and stored at -80 °C. A detailed protocol is 
attached in the supplementary (see section 12.9.17, [1]). 
3.8 Pyrosequencing and sequence evaluation 
Within this study pyrosequencing was performed in cooperation with Dr. D. 
Höper (FLI, Greifswald - Insel Riems, Germany). The Genome Sequencer FLX 
instrument (Roche, Mannheim, Germany) was used for virus genome 
sequencing of IVA-PR8 during three independent virus adaptation series to 
different host cells (principle of next-generation pyrosequencing workflow is 
summarized in section 12.10, http://www.genomicdisorders.nl/downloads/GSFLX 
_Poster1.pdf to http://..._Poster4.pdf): one adaptation was published by Genzel 
et al. [72], demonstrating that at least three virus passages in the new Vero cell 
host are required to achieve high maximum virus titers and faster increase to 
maximum HA-titers (figure 14A). The final passage 4 of this adaptation was 
stored (-80 °C) as in-house Vero-adapted virus seed and was used for 
immunogenicity studies (see sections 3.10, 4.9) performed in cooperation with 
Dr. B. Lepenies and J. Hütter (MPI-KG, Potsdam-Golm, Germany). Two further 
adaptation series – one using the RKI-strain and one using the NIBSC-strain - 
comprised forward-adaptation over five consecutive virus passages from MDCK 
to Vero cells as well as back-adaptation to MDCK cells (five passages; figure 
14B; see also section 4.6). 
Pyrosequencing of the Vero-adapted seed virus [72] for immunogenicity studies 
was performed as follows: The DNA was prepared as described by Höper et al. 
[154] and resulting DNA was fragmented according to manufacturer’s instruction. 
DNA fragments were converted to a GS FLX Titanium library using SPRIworks 
Fragment Library System II (Beckman Coulter, Krefeld, Germany), a SPRIworks 
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Fragment Library Kit II (Beckman Coulter) and a GS FLX Titanium Rapid Library 
MID Adaptor (Roche). The KAPA Library Quant Roche 454 Titanium Universal 
Kitsystem (Kapa Biosystems, Cape Town, South Africa) and the Bio-Rad CFX96 
Real-Time PCR System (Bio-Rad, München, Germany) was used for library 
quantification. Finally emPCR was performed with 0.08 copies per bead. For final 
sequencing of the amplified library Titanium chemistry was used. Raw data 
analysis was performed using the GS FLX software suite (v. 2.5.3; Roche). For 
sequence assembly, primer sequences were cut off the raw data as described 
previously [154]. For quasispecies analysis, the GS FLX reference mapper 
software (version 2.5.3; Roche) and primer-trimmed, raw sequencing reads were 
used. 
 
figure 14: Scheme of IVA-PR8 adaptation and sampling for glycoanalysis and next-
generation pyrosequencing. 
(A) Adaptation of the RKI-strain performed and published by Genzel et al. [72]. The MDCK cell-
derived seed virus (1
st
 passage) is matching the seed virus from B and is therefore indirectly 
sequenced (striped arrow), too. Virus from the 5
th
 passage, which serves as in-house Vero cell-
adapted virus seed was sequenced within this study (white arrow). HA N-glycan fingerprints were 
published by Genzel et al. and are not part of this work (dashed arrows). (B) The MDCK cell-
derived RKI-strain as well as the MDCK cell-derived NIBSC-strain were adapted to Vero cells and 
back (published in [4]). Sampling for HA N-glycosylation pattern analysis and for next-generation 
pyrosequencing is indicated (short and long arrows, respectively). 
 
Pyrosequencing of samples from the forward and backward adaptation (section 
4.6) was performed as published before [4]: Briefly, DNA was prepared according 
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to Höper et al. [155], with slight modifications as specified by Leifer and 
colleagues [156]. Reverse-transcriptase- (RT-) PCR was performed as published 
by Höper et al. [154]. The Transcriptor High Fidelity cDNA Synthesis Kit (Roche, 
Mannheim, Germany) was used for reverse transcription of the viral RNA 
genome segments. cDNA was amplified using iProof High-Fidelity Master Mix 
(Bio-Rad Laboratories GmbH, München, Germany). Pyrosequencing libraries 
were prepared as described by Wiley et al. [157]. Subsequently, DNA was bound 
to library capture beads. Release of the unbound DNA strands resulted in single-
stranded template DNA (sstDNA) library, which was used to estimate DNA 
quality as well as the amount required for following duplicate emulsion PCRs 
(emPCR). Bead-bound DNA amplification by emPCRs was performed using the 
GS emPCR kit I (Roche, Mannheim, Germany), applying two copies per bead. 
Beads were recovered, enriched and finally sequenced using the Genome 
Sequencer FLX instrument and the GS LR70 sequencing kit (Roche, Mannheim, 
Germany). After sequencing, primer sequences were trimmed off the raw read 
data and GS FLX sequence assembly software newbler (version 2.3; Roche, 
Mannheim, Germany) was used for sorting and assembling reads into contigs. 
Such contigs are sets of overlapping reads – finally each set displaying one virus 
genome segment. Quasispecies analysis was performed by aligning primer-
trimmed, raw sequencing reads to the reference sequence using the GS FLX 
reference mapper software (version 2.3; Roche, Mannheim, Germany) applying 
the default parameters [4]. 
High confidence differences (HCD) were defined by a combination of flow signal, 
quality score and difference type information [4]: Required conditions for HCD 
included the existence of more than two non-duplicate reads showing the 
difference and the existence of both forward and reverse reads showing the 
difference, unless there are more than six reads of quality scores over 20 or 30, if 
the difference is at least a 5mer (GS FLX Software Manual 2.17.1.14). In order to 
remove sequences which have resulted from the same microreactor (water drop 
in water-oil emulsion) the software groups reads with matching start sequences 
to one read. 
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HCDs of the forward and backward adaptation series for segment 4 were taken 
from these grouped results as published in 2011 [4]. A disadvantage of this 
grouping is the accumulation of matching reads within the mean read length, 
when prior to pyrosequencing genomic material is transcribed and amplified by 
PCR. Therefore, all other HCDs have been extracted from ungrouped data. The 
trends of grouped HCDs for segment 4 are comparable with the ungrouped 
results, but may differ in their percentage-values. Only one subpopulation (10 %) 
carrying a silent base substitution (A189G = G63G) was not detected by using 
the grouped reads for the RKI-strain in passage 11. 
The limit of detection (LOD) for this method is most probably determined by the 
sensitivity of prior PCRs. Höper et al. demonstrated a minimum sensitivity for 
fragments from segment 1 and segment 3 of roughly 5.6 x 103 copies/µL [155]. 
All sequences of segment 4 were uploaded to the GISAID EpiFlu database. The 
accession numbers are provided in the supplementary (table S 2). All further 
original sequence data can be requested from Dr. D. Höper (FLI, Greifswald – 
Insel Riems, Germany). The consensus DNA- and translated AA-sequences are 
provided in the supplementary (section 12.7 and section 12.8). 
In the following, amino acid substitutions during the adaptation processes will be 
annotated by the one letter amino acid code for the original residue (in 
passage 1), followed by the position number of the residue, followed by the one 
letter code of the substituting amino acid in the later passage. Insertions and 
deletions are indicated by a minus sign (-) at the first or last position, respectively 
[4]. 
3.9 Sequence alignment, cDNA translation and prediction of N-
glycosylation sites 
Sequence alignments were performed using the Universal Protein Resource 
(UniProt, http://www.uniprot.org/align/, [158]). cDNA sequences were translated 
using ExPASy (Expert Protein Analysis System) the Bioinformatics Resource 
Portal from the Swiss Institute of Bioinformatics (SIB) at 
http://web.expasy.org/translate/ [159]. 
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Potential N-glycosylation sites were predicted using the NetNGlyc 1.0 Server 
(http://www.cbs.dtu.dk/services/NetNGlyc/, [160]). Here, all N-glycosylation 
sequons (Asn-Xaa-Ser/Thr) are defined as potential N-glycosylation sites. 
3.10 Immunogenicity studies using TCR-HA-transgenic mice 
TCR-HA transgenic mice and BALB/c wt mice were used for immunogenicity 
studies performed at the group for glycoimmunology at the MPI-KG (Potsdam-
Golm, Germany). In vitro studies included TCR-HA transgenic spleen cell assays 
whereas for monitoring T cell proliferation TCR-HA transgenic T cells were 
adoptively transferred to BALB/c wt mice. HA-specific Ab induction was 
quantified in BALB/c wt mice after prime-boost immunization with different 
glycovariants. For more details see [1] or contact Dr. B. Lepenies (MPI-KG, 
Potsdam-Golm, Germany). 
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4 Results 
The first part of this work investigates the impact of various process conditions on 
the HA N-glycosylation pattern of IVA-PR8 by CGE-LIF-based N-glycan 
fingerprinting. Throughout all tested process conditions the IVA-PR8 was 
replicated in MDCK cells [4, 6]. Moreover, most results were confirmed and 
supplemented by CGE-LIF-based glycoanalysis data from other viruses and/or 
host cells [5, 7]. An overview of all conditions tested and applied process set-ups 
is given in table 1. Tested conditions include varying host cells, host cell 
adaptation stati, virus strains, virus passages, virus suppliers, virus adaptation 
stati, cultivation vessels and varying virus production media. Results during these 
studies suggested that other factors than HA N-glycosylation essentially 
contribute to improved virus titers after virus adaptation. Therefore, in a second 
part, the impact of virus adaptation was investigated in more detail using next-
generation pyrosequencing in cooperation with Dr. D. Höper (FLI, Greifsald – 
Insel Riems, Germany, [4]). Finally, in the last part, the impact of differentially 
glycosylated virus preparations on immunogenicity was investigated in mice 
models (in vitro as well as in vivo; in cooperation with Dr. B. Lepenies and J. 
Hütter, MPI-KG, Potsdam-Golm, Germany; [1]). 
4.1 Host cell 
Up to date manufacturers produce influenza vaccines in different host systems, 
e.g. in embryonated chicken eggs or in mammalian cell lines (e.g. MDCK, Vero). 
Firstly, this raises questions concerning differential HA N-glycosylation caused by 
the selected host system. Secondly, host cell-specific differences in HA N-
glycosylation would lead to the question wether they impact vaccine quality (e.g. 
immunogenic properties) or not. 
To firstly investigate the impact of host cell on HA N-glycosylation, the RKI-strain 
was produced in MDCK, Vero, Cap, AGE1.CR.pIX cells and in embryonated 
chicken’s eggs (in cooperation with Dr. B. Hundt, IDT Biologika GmbH, Dessau-
Rosslau, Germany). CGE-LIF-based glycoanalysis of the HA was performed and 
HA N-glycan fingerprints were compared. The comparison demonstrated strong 
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host cell-specificity of HA N-glycan fingerprints: all fingerprints, i. e. Vero; MDCK, 
Cap and AGE1.CR.pIX cell-derived as well as embryonated chicken egg-derived 
(produced in cooperation with Dr. B. Hundt; IDT Biologika GmbH, Dessau-
Rosslau, Germany), differed significantly with respect to N-glycan structure 
presence and hence to relative N-glycan structure abundance (figure 12). 
Interestingly, MDCK cell-derived HA showed a tendency towards larger N-glycan 
structures in contrast to all other hosts. Small N-glycan structures below 
300 MTU’ were especially favored, when virus was produced in embryonated 
chickens eggs. 
These results confirm previous studies of our group reporting host cell-specificity 
of HA N-glycosylation for MDCK and Vero cell-derived IVA-PR8 [73]. 
Furthermore, these results extend the host cell-specific nature of HA N-
glycosylation for embryonated chicken eggs-, AGE1.CR.pIX and Cap cell-derived 
IVA-PR8. 
 
figure 15: Impact of host cells on the HA N-glycosylation pattern. 
Shifted overlay of N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the 
migration time (tmig) in normalized migration time units (MTU’). IVA-PR8 (RKI-strain) was 
produced in adherent Vero cells (i) of African green monkey origin or in adherent MDCK cells (ii) 
of canine origin. Furthermore, suspension cells such as human-derived Cap cells (iii) or duck-
derived AGE1.CR.pIX cells (iv) were used for virus production. Finally, cell culture-derived virus 
was compared with virus produced in embryonated hen’s eggs (v, produced in cooperation with 
Dr. B. Hundt, IDT Biologika GmbH, Dessau-Rosslau, Germany). 
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4.2 Host cell adaptation 
4.2.1 Cell growth in serum-containing and serum-free medium 
For the production of biologicals the use of animal-derived products is 
problematic due to risks involved with adventitious agents. Therefore, most 
commercial processes avoid the need for animal-derived medium compounds; 
i.e. generally serum, by host cell adaptation to serum-free growth. Here, HA N-
glycosylation of the RKI-strain produced in non-adapted, serum-requiring MDCK 
cells was compared with virus produced in MDCK cells adapted to serum-free 
growth in Episerf medium. In all N-glycan fingerprints, 16 MDCK cell-specific 
peaks were detected between 300 MTU’ and 450 MTU’ (figure 16A), which have 
been described before [4, 7, 73]. Relative quantification of these peaks revealed 
a subset of 10 high abundant N-glycan peaks for non-adapted cells (2 - 5, 7, 9, 
11 – 13 and 15, figure 15B). For serum-free growth adapted cells a slightly 
different subset of 10 high abundant N-glycan peaks (2, 5, 7, 9 – 15) was found 
(figure 16B). The differences of RPH were in the range between 0.3 % and 8.5 % 
(│ΔRPHmax│for peak 14, figure 15B, table 3, [6]).
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figure 16: Impact of host cell adaptation to serum-free growth on the HA N-glycosylation 
pattern of the RKI-strain. 
(A) Shifted overlay of HA N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over 
the migration time (tmig) in normalized migration time units (MTU’). MDCK cell-specific peaks 
between 300 MTU’ and 450 MTU’ exceeding the 10x baseline noise threshold in at least one of 
the direct comparable fingerprints (table 3, +) are annotated. The non-adapted, serum requiring 
MDCK cell line (i) was adapted to growth in serum-free Episerf medium (ii). (B) Relative peak 
abundance (RPH) in % of the total peak height (TPH, sum of all annotated peaks). Peaks are 
defined low abundant if RPH < 5 % (---). Modified and reprinted with permission
 
[6]. 
  
 
table 3: Differences of relative peak height (ΙΔRPHΙ) of all annotated peaks of all performed fingerprint comparisons (numbered 
according to sections in the manuscript). 
In the following, an example is shown for the calculation of ΙΔRPHΙ (section 3.6.2; harvest time point, RKI in MDCK; peak no. 1): the RPH of peak 
1 is 1.4 % at 24 hpi (figure 10, B, grey column), whereas at 96 hpi the RPH of peak 1 is 1.7 % (figure 10B, white column). Hence, ΙΔRPHΙ = Ι1.4 % 
- 1.7 %Ι = 0.3 %. If more than two peaks are compared (e.g. section 3.6.2; harvest time point, RKI in Vero; peak 5), ΙΔRPHΙ is calculated from the 
highest (figure 11, grid column, 360 hpi) and the lowest abundant peak (figure 11, black column, 48 hpi). Maximal difference (ΙΔRPHmaxΙ) of each 
experiment is highlighted in bold. 
section 4.2.1
peak
harvest time point 
RKI in MDCK*
harvest time point 
URU in MDCK#
harvest time point 
RKI in Vero*
harvest time point 
RKI in Vero until 
96 hpi*
serum↔ 
serum-free+
serum↔serum-free 
suspension 
(MDCKadh,SUS1,2,3)'
serum-free 
suspension 
(SUS1,2,3)'
serum-free 
suspension 
(SUS1,2)'
no. |ΔRPH| (%) |ΔRPH| (%) |ΔRPH| (%) |ΔRPH| (%) |ΔRPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%)
1 0.3 0.5 0.2 1.5 0.0 0.0
2 0.8 0.1 5.5 7.3 7.3 0.0
3 0.0 0.2 2.5 1.8 0.9 0.8
4 0.7 0.2 2.6 8.1 2.7 0.2
5 0.2 2.2 0.6 3.7 4.0 1.8 0.7
6 0.8 0.8 1.8 6.6 1.8 0.8
7 0.0 0.4 14.2 3.8 1.3 9.2 0.0 0.0
8 0.0 0.3 1.7 0.3 0.6 9.7 9.7 0.0
9 0.3 0.4 0.3 3.3 2.3 0.3
10 0.1 0.5 4.5 9.5 9.5 1.0
11 0.3 0.2 0.6 0.1 0.4 11.4 3.6 0.0
12 0.1 0.2 0.3 2.7 1.5 0.1
13 0.7 0.2 1.0 7.2 2.9 0.2
14 0.1 0.2 1.2 0.4 8.4 4.3 4.3 1.1
15 3.3 0.3 3.3 0.2 3.1 9.2 9.2 1.1
16 1.2 0.4 2.5 0.4 1.3 2.1 2.1 0.6
17 0.1 1.1 0.3 14.5 10.2 1.9
18 0.3 0.7 0.3 18.1 18.1 0.2
19 0.1 0.3 0.2 3.7 2.3 1.6
20 0.5 4.2 1.0 1.9 0.6 0.3
21 0.8 3.3 1.4 1.6 1.6 0.3
22 2.1 0.5 2.3 0.0 0.0
23 3.1 0.8 6.8 6.8 0.9
24 1.7 0.2 1.9 0.0 0.0
25 2.0 0.1 14.2 3.7 1.7
26 2.0 1.2 1.0
27
28
29
30
3.6.2 4.2.2
 
*, 
#
, 
+
, ‘, °, ^, 
§
 matching tags indicate identical peak annotation. Hence a comparison across different experiments is possible. 
  
 
table 3 continued 
section 4.4 4.5
peak all strains°
H1N1 
strains°
H3N2 
strains°
 diff. virus 
passages 
(no. 1-10)*
RKI↔ NIBSC+
MDCK-derived 
passages      
(no. 1, 7-11)*
Vero-derived 
passages       
(no. 2-6)*
MDCK-derived 
passages        
(no. 1, 7-11)*
Vero-derived 
passages            
(no. 2-6)*
all 
passages 
(no. 1-5)^
AGE1.CR.pIX-
derived passages 
(no. 2-5)^
no. |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%)
1 2.5 1.5 1.0 0.8 0.2 0.5 0.0 0.6 0.0 12.3 0.0
2 2.4 0.9 2.1 2.8 5.0 4.0 0.0 3.7 0.0 3.5 0.0
3 1.5 0.7 0.7 1.4 0.5 1.4 0.0 0.8 0.0 8.6 0.0
4 8.3 0.7 0.6 1.6 3.4 2.9 0.0 2.0 0.0 3.1 2.3
5 2.6 1.9 1.1 2.9 0.0 4.2 0.0 3.9 12.9 0.0
6 1.1 0.2 0.1 1.3 0.4 5.6 0.0 8.5 0.0 8.8 2.8
7 9.4 3.5 0.2 0.9 1.6 1.6 21.0 4.4 14.8 6.2 0.0
8 4.4 2.2 4.4 1.0 1.8 0.7 3.6 0.8 1.1 10.1 0.0
9 9.4 3.7 0.6 1.1 0.8 1.2 0.0 1.3 0.0 2.9 2.2
10 7.8 7.4 0.1 1.8 0.1 2.4 0.0 7.0 0.0 4.1 0.0
11 2.4 0.7 2.3 1.4 0.2 1.6 2.6 2.5 0.7 10.5 0.0
12 15.3 12.4 3.8 1.5 0.4 3.7 0.0 3.4 0.0 3.8 0.0
13 3.5 3.5 0.5 1.9 0.7 3.5 0.0 3.9 0.0 4.9 1.9
14 1.4 1.4 1.0 1.1 1.4 2.9 7.1 4.8 4.0 2.2 1.3
15 3.6 1.0 3.6 3.5 1.5 9.5 5.9 9.9 3.7 2.0 0.8
16 3.5 1.8 3.5 1.5 0.4 3.5 4.1 3.0 2.6 3.0 1.2
17 3.6 0.5 3.1 0.0 2.0 0.0 0.7 2.3 2.3
18 3.9 3.2 0.1 0.0 4.1 0.0 1.0 1.8 1.0
19 3.3 0.9 2.5 0.0 0.6 2.4 2.4 17.0 4.6
20 3.2 0.4 2.5 0.0 5.6 0.9 4.1 3.2 0.0
21 1.2 0.5 1.2 0.0 8.2 5.9 3.2 26.7 13.1
22 25.2 0.7 9.8 0.0 1.0 0.0 1.4 9.3 2.0
23 5.2 5.2 1.5 0.0 5.2 0.0 1.3 5.3 1.4
24 3.7 0.0 0.1 0.0 1.5 0.0 1.5 3.9 2.0
25 2.6 2.0 0.5 0.0 4.9 0.0 2.0 5.7 2.5
26 7.5 2.3 2.5
27 2.0 2.0 0.4
28 4.5 2.5 1.6
29 6.2 0.9 2.8
30 2.5 2.5 0.6
4.3 4.6.1 (RKI-strain) 4.6.1 (NIBSC-strain) 4.6.2 (RKI-strain)
 
*, 
#
, 
+
, ‘, °, ^, 
§
 matching tags indicate identical peak annotation. Hence a comparison across different experiments is possible. 
RKI: RKI-strain 
NIBSC: NIBSC-strain 
SUS1, 2, 3. MDCK.SUS1, MDCK.SUS2, MDCK.SUS3 
IVA-Uru: IVA-Uruguay 
  
 
table 3 continued 
section 4.6.3 (RKI-strain) 4.6.5 (IVA-California) 4.6.5 (IVA- Viktoria) 4.7 (RKI-starin) 4.7 (IVA-Uru) 4.8.1 4.8.2
peak
egg-derived 
passages            
(no. 1-3)
all passages 
(seed, no. 1-
5)§
Vero-derived 
passages   
(no. 1-5)§
MDCK-derived passages                   
(no. 1-3)
MDCK-derived passages               
(no. 1-3)
scales & vessels+ scales & vessels#
virus production 
media 
composition+
trypsin activity of 
virus production 
media+
no. |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%) |Δ RPH| (%)
1 2.3 6.9 4.0 1.3 0.5 2.5 0.7 1.5 1.4
2 2.5 2.2 1.8 0.6 0.7 7.3 1.6 3.5 1.1
3 0.9 3.4 2.0 1.0 0.2 5.3 0.1 1.7 0.9
4 0.8 2.2 0.9 2.5 1.1 2.5 0.6 2.7 1.9
5 1.2 4.0 2.1 1.5 0.8 3.7 0.8 1.7 4.6
6 0.7 1.0 1.0 1.1 1.5 0.4 6.6 1.6 0.7
7 3.2 2.1 0.7 3.1 1.1 1.2 0.9 0.7 0.6
8 1.2 3.5 2.6 1.0 1.3 0.2 0.9 0.3 0.8
9 2.0 3.9 2.2 2.9 1.2 5.5 0.8 3.6 5.2
10 0.5 14.9 5.1 0.6 1.1 0.9 3.7 1.3 1.6
11 8.3 5.5 2.8 3.0 0.6 2.5 2.0 1.3 2.6
12 0.9 6.2 0.0 1.5 0.2 5.4 0.4 5.7 4.0
13 5.5 2.0 0.0 0.9 0.2 2.1 3.2 0.2 6.2
14 2.3 2.6 1.3 0.2 0.5 0.7 3.6 2.6 14.0
15 1.9 2.8 0.9 0.6 0.4 6.8 0.6 5.7 8.5
16 1.0 6.7 1.6 1.2 0.7 2.5 2.9 2.6 1.8
17 1.5 2.7 1.3 0.1 0.7 1.3
18 1.0 1.3 0.0 0.5 0.6 2.6
19 0.5 4.5 0.0 1.9 1.3 3.5
20 0.0 2.0 0.0 1.3 0.5 1.4
21 1.0 2.6 0.0 0.4 1.6 4.5
22 0.2 3.3 0.0 0.3 0.9
23 7.9 3.1 0.6 0.2
24 1.9 0.0 1.1 0.4
25 3.0 1.5 0.6 2.0
26 2.4 0.0 1.8 0.2
27 1.1 0.0 2.5
28 3.1 0.0 0.9
29 1.2
30
4.6.4 (IVA-Uru)
 
*, 
#
, 
+
, ‘, °, ^, 
§
 matching tags indicate identical peak annotation. Hence a comparison across different experiments is possible. 
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4.2.2 Adherent versus suspension growth 
Both, the use of adherent and suspension cells has pros and cons [6, 61]. For 
instance, easier passaging without the need of trypsin treatment and no 
requirement of tissue-culture treated vessels or microcarriers represent clear 
advantages of suspension cell lines. In contrast easier washing of microcarrier-
associated adherent cells during stirred cultivations are among the advantages of 
adherent cell cultivations. Therefore, the impact of an adaptation of adherent 
MDCK cells to serum-free suspension growth on the HA N-glycosylation pattern 
was characterized [6]. Briefly, an adherently growing, serum-dependent MDCK 
cell line was adapted to serum-free suspension growth in two independent 
biological duplicates in cooperation with Prof. Dr. K. Scharfenberg (University of 
Applied Sciences, Emden, Germany, [142]). Two suspension cell lines namely 
MDCK.SUS1 and MDCK.SUS3 resulted. The suspension cell line MDCK.SUS1 
was further adapted to improve growth kinetics in suspension, resulting in the 
MDCK.SUS2 cell line [142]. These four cell lines (MDCK, MDCK.SUS1, 
MDCK.SUS2, MDCK.SUS3) were used for RKI-strain production and HA N-
glycosylation was characterized by CGE-LIF-based glycoanalysis. The 
comparison of all four fingerprints revealed significant differences between 
MDCK, MDCK.SUS1 and MDCK.SUS3 cell lines regarding the types of glycans 
attached as well as their relative abundances (figure 17). MDCK cell-derived 
fingerprints exhibit a higher number of high abundant peaks than all MDCK.SUS 
cells. Furthermore, 100 % of all high abundant peaks of MDCK cells have 
normalized migration times above 320 MTU’, whereas 17 % to 50 % of all high 
abundant peaks (number 25) of any MDCK.SUS cell line have migration times 
below 320 MTU’ (figure 17A). A detailed comparison of fingerprints reveals that 
peaks 1, 7, 22 and 24 were only present in MDCK, peak 15 was only present in 
MDCK.SUS1 and MDCK.SUS2, whereas peaks 2 and 8 were only present in 
MDCK.SUS3 (figure 17B). The maximum difference of RPH was 18.1 % 
(peak 18, figure 17C). The comparison of RPH of MDCK.SUS1 and 
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figure 17: Impact of host cell adaptation to serum-free suspension growth on the HA N-
glycosylation pattern of the RKI-strain. 
(A) HA N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the migration 
time (tmig) in normalized migration time units (MTU’). All peaks exceeding the 10x baseline noise 
threshold in at least one fingerprint are annotated. Serum-requiring adherent MDCK cell line (i), 
MDCK cell line adapted to serum-free suspension growth (ii, MDCK.SUS1) and further adapted 
MDCK.SUS1 cell line to better growth characteristics (iii, MDCK.SUS2) [142]. The first adaptation 
step was performed in biological duplicates (iv, MDCK.SUS3). The number of high abundant 
peaks (RPH > 5 %) with migration times below or above 320 MTU’ is indicated. (B) Overlay of all 
four N-glycosylation fingerprints. (C) Relative N-glycan structure abundance (RPH) in % of the 
total peak height (TPH, sum of all annotated peaks). Peaks < 5 % RPH (---) are defined low 
abundant. 
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MDCK.SUS2-derived fingerprints revealed extensive analogy (max. 
|ΔRPH| = 1.9 %, peak 17; figure 17C). Interestingly, the first adaptation step to 
serum-free suspension growth resulted for both adaptation series (MDCK to 
MDCK.SUS1 and MDCK to MDCK.SUS3) in a totally new cell line, not only with 
respect to their growth characteristics, e.g. reduced doubling times and smaller 
aggregates [142], but also to their HA N-glycosylation characteristics. Therefore, 
figure S 1 (extended figure 15) shows the impact of host system (including 
MDCK.SUS2 and MDCK.SUS3) on the HA N-glycan fingerprint. 
These results were consistent with data obtained from NIBSC-strain production 
in MDCK, MDCK.SUS1, MDCK.SUS2 and MDCK.SUS3 cells (section 12.2, 
figure S 2). 
4.3 Virus strain 
Most manufacturers have their own, approved production cell line, in which 
viruses are propagated for all seasonal or pandemic influenza vaccines. In order 
to investigate the impact of the virus strain on the HA N-glycosylation pattern N-
glycan fingerprints from different MDCK cell-derived IVA were analyzed: two 
strains, namely RKI-strain and IVA-California, belong to the H1N1 subtype and 
two, namely IVA-Uruguay and IVA-Victoria, belong to the H3N2 subtype. The 
comparison of fingerprints demonstrated that most peaks were present for all 
tested viruses (except for low abundant peaks 2, 5, 15, 16, 24 and 30, figure 
18A, B). The relative peak abundance varied with a maximum difference of 
25.2 % (peak 22, figure 18C). Separate consideration of H1N1 and H3N2 strains 
resulted in much smaller maximum differences in RPH of 12.4 % (H1N1-strains) 
and 9.8 % (H3N2-strains), respectively (section 12.3, figure S 4). 
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figure 18: Impact of virus strain on MDCK cell-derived HA N-glycosylation patterns. 
(A) Shifted overlay of HA N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over 
the migration time (tmig) in normalized migration time units (MTU’). IVA-PR8 (i), IVA-California (ii), 
IVA-Uruguay (iii) and IVA-Victoria (iv) were produced in MDCK cell culture. All peaks exceeding 
in at least one of the fingerprints (i-iv) the 10x baseline noise threshold are annotated (no. 1 - 30). 
(B) Direct overlay of HA N-glycan fingerprints. C) Relative N-glycan structure abundances (RPH) 
in % of the total peak height (TPH, sum of all annotated peaks). Peaks are defined high abundant 
if RPH > 5 % (---). 
4.4 Virus passage 
The stability of HA N-glycan fingerprints during multiple virus passages in one 
cell line is one essential condition for the characterization of HA N-glycosylation 
patterns using different cultivation conditions in influenza virus production. 
Therefore, in this study 10 consecutive passages of the RKI-strain were 
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produced in MDCK cells using roller bottles. 24 hpi HA-titers of these 10 virus 
passages ranged between 2 and 2.4 HAU (data not shown). Moreover, 
throughout all passages HA N-glycosylation fingerprints all featured the same 15 
main peaks (no. 1-4, 6-16, figure 19A). Maximum differences of RPH were 3.5 % 
(peak 15, table 3, figure 19B, [4]). Overall, these results demonstrate a high 
stability of the HA N-glycosylation pattern over 10 successive virus passages in 
the same host cell system [4]. 
 
figure 19: Impact of virus passage on the HA N-glycosylation patterns of the RKI-strain. 
(A) Shifted overlays of N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over 
the migration time in normalized migration time units (MTU’). HA N-glycosylation patterns are 
reproducible over 10 successive virus passages in MDCK cells. All 10 patterns exhibit the same 
15 numbered main peaks (no. 1 – 4, 6 – 16, numbering according to virus adaptation from MDCK 
to Vero cells and back, section 4.6.2, table 3 indicated by *) between 300 MTU’ and 420 MTU’. 
(B) Relative peak heights (RPH) of the 15 main peaks. Standard deviations (error bars) for 10 
successive virus passages, range between 0.25 % and 1.14 %. Modified and reprinted with 
permission [4]. 
4.5 Virus supplier 
Next, two IVA-PR8 seed viruses were compared. One was provided from the 
Robert Koch Institute (RKI-strain) and the other was purchased from NIBSC 
(NIBSC-strain). Both strains differ in seven amino acid positions within the HA 
molecule [4]. Both HA N-glycan fingerprints exhibited the set of 16 adherent 
MDCK cell-specific peaks (1-16) between 300 MTU’ and 450 MTU’, (figure 20A). 
For the RKI strain a total number of eight high abundant N-glycan peaks (2, 4, 5, 
7, 9, 12, 15 and 16) was identified (figure 20B). For the NIBSC-strain, the total 
number of high abundant peaks was reduced as peak 7 dropped below 5 % RPH 
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(figure 20B). The minimum and maximum differences of RPH of the two strains 
were calculated with 0.1 % and 5 %, respectively (│ΔRPHmax│: peak 2, table 3, 
[6]). 
Producing the RKI- and the NIBSC-strain in MDCK.SUS2 cells resulted in similar 
findings. Interestingly, the minimal and maximum differences of RPH increased 
to 0.6 % and 11.0 %, respectively (│ΔRPHmax│: peak 9, section 12.3, figure S 3). 
 
figure 20: Comparison of two IVA-PR8 strains from different suppliers with respect to HA 
N-glycosylation patterns. 
(A) Shifted overlay of HA N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over 
the migration time (tmig) in normalized migration time units (MTU’). MDCK cell-specific peaks 
between 300 MTU’ and 450 MTU’ exceeding the 10x baseline noise threshold (---) in at least one 
of the direct comparable fingerprints (table 3, +) are annotated. The virus was purchased from 
either the Robert Koch Institute (i) or NIBSC (ii). (B) Relative peak abundance (RPH) in % of the 
total peak height (TPH, sum of all annotated peaks). Peaks are defined low abundant if 
RPH < 5 % (- - -).Modified and reprinted with permission [6]. 
4.6 Virus adaptation 
4.6.1 Virus replication dynamics 
Usually, viruses require adaptation to new host cells to optimize yields and time 
of harvest [72]. In order to characterize this adaptation process and to investigate 
possible biological mechanisms MDCK cell-adapted virus was propagated for 
24 h in MDCK cells (passage 1). As a result HA-titers of 1.9 HAU and 2.2 HAU 
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figure 21: HA-titers during IVA adaptation to different host cells. 
MDCK cell-adapted RKI-strain (A) or NIBSC-strain (B) served as seed for infection of five 
consecutive passages of Vero cells (no. 2 to 6). Reprinted with permission [4]. (C) MDCK cell-
adapted RKI-strain was adapted to replication in AGE1.CR.pIX cells during 4 consecutive 
passages (no. 1 to 4). (D) MDCK cell-adapted IVA-Uruguay was adapted during 5 consecutive 
passages (no. 1 to 5) to replication in Vero cells. Egg-adapted IVA-Viktoria (E) and IVA-California 
(F) were adapted during 3 consecutive passages (no. 1 to 3) to replication in MDCK cells. * the 
mean value of two measurements is plotted. The 95 % confidence interval of the HA-assay is 
maximum 15 %. All titers at 0 hpi are defined as zero. 
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were obtained for the strains from RKI and NIBSC, respectively (see 
supplementary, table S 1). Supernatant of this passage served as the virus seed 
for a first infection of Vero cells (passage 2). For the RKI-strain virus-release was 
not detected before 288 hpi (0.8 HAU, figure 21A) and the maximal HA-titer of 
1.4 HAU was finally reached 360 hpi. For the NIBSC-strain virus release was first 
detected 216 hpi and virus replication was continued until 360 hpi, exhibiting a 
final HA-titer of 1.95 HAU (figure 21B). An aliquot of these supernatants served 
as virus seeds for the next infections of Vero cells (passage 3) and so on 
(passage 4 to 6). During this virus adaptation to Vero cells, viral fitness of both 
strains, RKI and NIBSC, improved: The time required to achieve specific HAU-
values (≥ 1.4 HAU) decreased, whereas maximum HA-titers increased from 
passage 2 to 4. No significant differences were detected for passage 4 to 6 of the 
RKI-strain, indicating the completion of the adaptation process (figure 21A). For 
the NIBSC-strain, the second passage in Vero cells (passage 3) reached 
2.1 HAU at 120 hpi, and passage 4 reached 2.7 HAU at 96 hpi. For all 
subsequent passages (numbered 5 and 6) the time required to achieve a HA-titer 
of at least 1.8 HAU as well as the maximal titers were more or less the same. 
This indicated the completion of the adaptation process (figure 21B). The 
following five virus passages (7 to 11) were again performed in MDCK cells to 
monitor virus back-adaptation. Here, for the RKI- as well as the NIBSC-strain all 
titers ranged between 2 HAU and 2.5 HAU at 48 hpi and 96 hpi (see 
supplementary, table S 1). In contrast to the adaptation to Vero cells, no impact 
on HA-titer level and virus release dynamics was observed during back-
adaptation [4]. 
Similar results, though less distinct, were obtained for the adaptation of the RKI-
strain from MDCK to duck-derived AGE1.CR.pIX cells (passage 1 to 4, figure 
21C): Virus adaptation to the new avian host cell line allowed an increment of 
virus titers (figure 21C). Accordingly, virus fitness in the new host system has 
improved during the adaptation process. Nevertheless, the virus titer of passage 
1 with 1.9 HAU suggests that the duck-derived AGE1.CR.pIX cell line allowed 
rather efficient virus replication from the beginning [7]. 
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The efficient replication from the beginning in duck cells is consistent with data 
obtained from adaptation of the MDCK cell-derived RKI-strain to replication in 
embryonated chicken eggs, which was performed in cooperation with Dr. B. 
Hundt (IDT Biologika GmbH, Dessau-Rosslau, Germany). For each passage, 
three different virus dilutions (100, 10-1, 10-2) were used to infect three sets of five 
eggs (altogether 15 eggs). The virus was harvested 96 hpi and pooled. The titer 
of the first passage pool already reached 3.0 HAU (two eggs of the 10-2- dilution 
died before harvest at 48 hpi and 72 hpi; data not shown). An aliquot of this first 
passage pool served for the infection of three further sets of embryonated 
chicken eggs. Again, 96 hpi the virus from 13 surviving eggs (two eggs died: 
dilution 10-1/72 hpi and 10-2/72 hpi) was pooled. The titer again reached 3.0 HAU 
(data not shown). The pool of the third passage from altogether 12 eggs (three 
eggs died: dilution 100/72 hpi, 100/96 hpi and 10-1/72 hpi) reached a titer of 
3.3 HAU (96 hpi; data not shown). Interestingly, the titers reached (3.0 HAU to 
3.3 HAU) during the adaptation from MDCK cells to embryonated chicken eggs 
demonstrated that embryonated chicken eggs allowed rather efficient virus 
replication from the very beginning and further increase of virus yield by 
adaptation was not detected. The RKI-strain - as it origins from an egg-adapted 
ancestor - seems to have retained its ability to replicate rather well in avian cells. 
Interestingly, during adaptation of MDCK cell-derived IVA-Uruguay to replication 
in Vero cells the HA-titer of the second passage in Vero cells was even lower 
than the titer of the first passage but in passages 3, 4 and 5 titers increased 
(figure 21D). Taken all data together, the adaptation resulted in a final titer 
increase from 2.1 HAU (passage 1, 96 hpi) to 2.7 HAU (passage 5, 72 hpi). 
Furthermore two egg-derived vaccine strains IVA-Victoria and IVA-California 
were adapted to MDCK cells. Therefore, the egg-adapted virus lyophilisate was 
resuspended in sterile H2OMQ, and was used to infect a first passage of MDCK 
cells. 24 hpi an aliquot of the supernatant was used to infect the second passage 
of MDCK cells and so on. The virus replicated well from the beginning. The 
adaptation resulted in increased maximum virus titers for IVA-Viktoria (2.5 HAU, 
48 hpi, figure 21E). In contrast final titers of IVA-California did not significantly 
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increase by adaptation reaching 1.75 HAU 48 hpi in the third passage (figure 
21F). 
In a next step, it was tested if improved growth characteristics after virus 
adaptation were maintained, even if no selection pressure persisted. Therefore, 
after the adaptation from MDCK to Vero cells (in 5 passages) and back to MDCK 
cells (in another 5 passages) the RKI- as well as the NIBSC-strain were adapted 
again to replication in Vero cells (in 3 passages, numbered passages 12 to 14, 
figure 22). This further adaptation to Vero cells highlighted that the forth- and 
back-adapted virus has somehow acquired and kept (throughout MDCK-
passaging, passages 7-11) the ability to replicate efficiently in Vero cells (figure 
22): HA-titers already increased after one (NIBSC-strain) or two days (RKI-strain) 
in passages 12 and even earlier for the RKI-strain in passages 13 and 14. In 
contrast, a Vero cell-passage (passage 2’) infected with supernatant of non-
adapted virus from passage 1 showed titer increase not before 94 hpi (NIBSC-
strain) and 160 hpi (RKI-strain). This clearly demonstrated an improved viral 
fitness in Vero cells after virus adaptation. 
 
 
figure 22: HA-titers of IVA-PR8 from RKI (blue) and NIBSC (red) during first (▲, ♦) and 
second (Δ, ◊) adaptation to Vero cells. 
MDCK cell-derived virus from passage 1 (no Vero cell contact before) and from passage 11 (Vero 
cell contact during passages 2- 6) was used to infect a passage of Vero cells (passage 2’: filled 
symbol, --- and passage 12: empty symbol, ——), respectively. An aliquot of the supernatant of 
passage 12 was used to infect another passage of Vero cells (passage 13, empty symbol, – – –) 
and so on (passage 14, empty symbol, ----). Viruses, which had Vero cell contact before 
replicated faster in Vero cells than viruses without previous Vero cell contact. Viruses have 
retained the ability to replicate in Vero cells during several passages (7-11) in MDCK cell culture. 
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4.6.2 Host cell-specificity of HA N-glycosylation patterns during virus adaptation 
Next, N-glycan fingerprints were analyzed for all adaptation passages (see also 
section 4.6.1) to investigate the impact of virus adaptation on HA N-glycosylation. 
All HA N-glycosylation patterns of MDCK cell-derived IVA-PR8 samples were 
similar. The same applied to all IVA-PR8 Vero cell-derived virus samples (figure 
23A, B). In agreement with earlier studies the HA N-glycosylation pattern was 
strictly host cell-specific and changed significantly with the switch to the new host 
cells [72, 73]. However, of all Vero cell-derived HA N-glycosylation patterns for 
the RKI- as well as the NIBSC-strain passage 2 revealed the biggest differences 
in RPH (figure 23, figure 24). Here, the RPH of peak 5 and 7 was almost twice as 
high as for all subsequent passages in Vero cells. This is in agreement with the 
time series in Vero cells (also see section 3.6.21.1.1; figure 12) where these RPH 
almost doubled until 360 hpi. Furthermore, the low abundant glycan structure 
represented by peak 11 was missing in passage 2 of both IVA-PR8 strains 
(figure 23, figure 24). This is most likely due to a drop below the detection limit. 
During the adaptation of the RKI-strain the height of peak 16 decreased by a 
factor of two in passage 2 (figure 23A, figure 24A), which was in agreement with 
the steady decrease of peak 16 during time course experiments (also see 
section 1.1.1; figure 12). Besides, peaks 17 and 18 were missing in passage 2 of 
the RKI-strain. In the time series in Vero cells these peaks represented low 
abundant structures with only 0.2 – 2.7 % RPH (also see section 3.6.2; figure 
12). This probably indicates again a drop below the detection limit [4]. 
In table 3 differences of RPH in controls (different virus passages, section 4.4 
and different harvest time points, section 3.6.2) and during adaptation 
experiments are compared for each peak of both host-specific glycosylation 
patterns. The standard deviations (SD) are given in the supplementary (table S 3, 
page 6). A more than 3-fold higher SD compared to the controls was considered 
significant. For the RKI-strain, during adaptation to Vero cells three peaks (11, 14 
and 18) showed a more than 3-fold higher SD of RPH (table S 3; Adaptation 
series H1N1, RKI) compared to the same peaks of the time series experiment 
(also see section 1.1.1; figure 12). Closer examination of the 15 main peaks of all 
  
 
 
figure 23: HA N-glycosylation patterns during IVA-PR8 adaptation from MDCK to Vero cells and back to MDCK cells. 
Shifted overlay of HA N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the migration time (tmig) in normalized migration 
time units (MTU’). Fingerprints represent 11 virus passages during virus adaptation of the RKI- (A) and the NIBSC-strain (B): (1.) MDCK cell-
adapted virus seed, (2.) to (6.) adaptation to replication in Vero cells, (7.) to (11.) back-adaptation to replication in MDCK cells. Modified and 
reprinted with permission [4]. 
 
 
  
 
 
figure 24: Relative peak height of IVA-PR8 HA N-glycosylation patterns during virus adaptation.
 
(A) RKI-strain: In passages (1.) and (7.) to (11.) virus was propagated in MDCK cell culture (■). In passages (2.) to (6.) virus was propagated in 
Vero cell culture (■). Most of the 25 different major peaks are host cell-specific. Only the HA N-glycan structures represented by peak no. 7, 8, 11, 
14 to 16 and 19 to 21 are present in virus samples from both host cells. (B) NIBSC-strain: In passage (1.) and (7.) to (11.) virus was propagated in 
MDCK cell culture (■). In passage (2.) to (6.) virus was propagated in Vero cell culture (■). Most of the 25 different major peaks are host cell-
specific. The HA N-glycan structures represented by peak no. 7, 8, 11, 14 to 16 and 19 to 21 are present in virus samples from both host cells. 
Modified and reprinted with permission [4]. 
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MDCK cell-derived HA N-glycosylation patterns during back-adaptation revealed 
a more than 3-fold higher SD in RPH for peaks 6 and 14 (table S 3; Adaptation 
series H1N1, RKI) compared to the time series in MDCK cells (section 3.6.2; 
figure 12) and biological reproducibility experiments (section 4.4, figure 19). Of 
these peaks, only number 6, with an average RPH of 12.1 %, represents a high 
abundant glycan structure. For the NIBSC-strain, during forward adaptation, a 3-
fold higher SD was found for the high abundant glycan structure represented by 
peak 14, as well as for another low abundant glycan structure represented by 
peak 19. Regarding the back-adaptation to MDCK cells the low abundant glycan 
structures of peaks 7 and 14 as well as the high abundant glycan structures of 
peak 6, 10 and 13 exhibited a more than 3-fold higher SD compared to controls. 
Overall, however, a clear trend during the forward and backward adaptation 
process was not evident (figure 23; figure 24). Furthermore, good reproducibility 
of the host cell-specific HA N-glycosylation pattern during virus adaptation to 
different host cell lines was demonstrated for both IVA-PR8 strains [4]. 
Data from adapting MDCK cell-derived RKI-strain to replication in AGE1.CR.pIX 
cells are consistent with the previous data demonstrating host cell-specificity. 
The HA N-glycan fingerprint of the MDCK cell-derived seed virus (figure 25A) 
was dominated by 14 peaks exhibiting at least 20% of the RFU of the highest 
peak. These peaks are numbered 1–3, 5–8, 10–12, 14, 15, 18, and 20. With the 
first passage in AGE1.CR.pIX cells (passage 1, figure 25A), the HA N-glycan 
fingerprint changed significantly. Now, the fingerprint was dominated by the 14 
peaks (no. 4, 6, 9, 13–17, 19, and 21–25). Peaks 6, 13–15, 17–19, and 23 were 
present in both cell line-derived HA N-glycan fingerprint, whereas peaks 1–3, 5, 
7, 8, 10–12, and 20 were MDCK cell-specific, and peaks 4, 9, 16, 21, 22, 24, and 
25 were AGE1.CR.pIX cell-specific. During all four consecutive virus passages of 
the adaptation process the HA N-glycan fingerprint was more or less stable. 
However, peaks 4, 9, 16–18, and 24 dropped below the 20 % threshold of the 
highest peak in the fingerprints of passages 2 to 4. Peak 13 dropped below this 
threshold only in passages 2 and 3 and peak 25 dropped below this threshold 
only in passage 2 (figure 25). For relative quantification, RPH was calculated and 
  
 
 
 
figure 25: Adaptation of RKI-strain from MDCK (pink) to AGE1.CR.pIX cells (dark grey). 
(A) Shifted overlay of HA N-glycosylation fingerprints, in which relative fluorescence units (RFU) are plotted over the migration time (tmig) in 
normalized migration time units (MTU’). Threshold (- - -) indicates peaks exceeding 20 % of the highest peak. MDCK cell-derived virus seed was 
adapted over four passages (1.) to (4.) to replicate in AGE1.CR.pIX cells. Peaks annotated in grey are only present in MDCK cell-derived HA, 
whereas peaks annotated in black are only present in AGE1.CR.pIX-derived HA. Annotated peaks in black underlined are present in both cell lines 
above the 20 % threshold, whereas peaks annotated in grey underlined are present in both cell lines, though in one only below the 20 °% 
threshold. (B) Relative peak abundance (RPH) in % of the total peak height (TPH, sum of all annotated peaks). Peaks are defined low abundant if 
RPH < 5 % (- - -). The average RPH from all adaptation samples (1.) to (4.) is indicated by black bars (—), and the standard deviations of the RPH 
of each peak of passages (1.) to (4.) are indicated by black error bars. Modified and reprinted with permission [7]. 
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plotted over the peak number (figure 25B). This highlights the low abundance of 
peaks 2, 6, 10, 12, 13, 17, 18, 19, 20, and 23 as well as the high abundance of 
peaks 1, 3, 5, 7, 8, 11, 14, and 15 in the MDCK cell-specific HA N-glycan 
fingerprints. In contrast, in the AGE1.CR.pIX cell-specific fingerprints, peaks 4, 9, 
16–18, and 24 were low abundant in all analyzed passages, whereas peak 13 
dropped to low abundance only in passage 3 and peak 25 dropped to low 
abundance only in passages 2 and 4. During adaptation, all peaks, except peaks 
19 and 21, showed differences in relative N-glycan structure abundances of 
≤ 2.8 %. Peaks 19 and 21 varied stronger with maximum differences for RPH of 
4.6 % and 13.1 %, respectively. The RPH of peak 21 almost doubled from 
passage 1 to passage 2 and decreased again in passages 3 and 4. This 
suggests that the structure represented by peak 21 is not as stable as other 
structures or more susceptible to minor variations in the culture and infection 
process. Either its synthesis or its degradation seems to vary for all consecutive 
AGE1.CR.pIX cell-derived virus passages. For all peaks no clear trend during the 
adaptation process was detected [7]. 
In line with so far observed host cell-specificity during virus adaptations, the data 
from adapting MDCK cell-derived RKI-strain to replication in embryonated 
chicken eggs demonstrated strict host cell-specificity, too (figure 26). The 
fingerprints of the viral HA changed with the switch of host cell completely (figure 
26A, B). Thereafter, the fingerprint remained more or less robust during the 
following three passages in embryonated chicken eggs: relative peak 
abundances differed with maximal 8.2 % (peak 11, figure 26C). 
Furthermore, the data from the adaptation of MDCK cell-derived IVA-Uruguay to 
Vero cells were consistent with the previous results demonstrating that first and 
foremost the host cell determines the HA N-glycan fingerprint. However, also the 
choice of the IVA strain has an impact on the HA N-glycan fingerprint (as shown 
in section 4.3). In contrast to the 16 MDCK cell-specific peaks of IVA-PR8-
derived HA, the fingerprint of MDCK cell-derived IVA-Uruguay seed exhibited 25 
different characteristic peaks in the range of 160 MTU’ to 400 MTU’. Of these, a 
total number of 11 peaks representing large glycans (275 MTU’ - 400 MTU’; 12,
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figure 26: Adaptation of the RKI-strain from MDCK cell- to embryonated chicken egg-based 
replication. 
(A) Shifted overlay of HA N-glycan fingerprints, relative fluorescence units (RFU) are plotted over 
the migration time (tmig) in normalized migration time units (MTU’). Egg-specific peaks between 
150 MTU’ and 450 MTU’ exceeding the 10x baseline noise threshold (---) in at least one of the 
fingerprints are annotated. MDCK cell-derived seed virus (seed) was adapted over three 
passages (1.) to (3.) to replicate in embryonated chicken eggs. (B) Direct overlay of all 
fingerprints. (C) Relative peak abundance (RPH) in % of the total peak height (TPH, sum of all 
annotated peaks). Peaks are defined low abundant, if RPH < 5 % (---). 
 
4 Results 
78 
 
13, 18 - 22, 24, 26 - 28) were unique to MDCK cell-derived virus (figure 27A, 
seed). The HA N-glycosylation pattern changed significantly with the first 
passage in Vero cells. Here, 15 different peaks between 150 MTU’ and 380 MTU’ 
characterized the Vero cell-specific HA N-glycan fingerprint. Four peaks (no. 3, 5, 
23 and 25) were unique to Vero cell-derived virus (figure 27A, first passage). In 
comparison to MDCK cell-derived HA, the Vero cell-derived antigen showed a 
tendency towards smaller glycan structures. This is in agreement with the 
tendency towards smaller glycan structures attached to HA of Vero cell-derived 
viruses from the RKI- and the NIBSC-strain. The relative abundance of each 
peak over all Vero passages only varied marginally with standard deviations (SD) 
≤ 2.1 % and maximal differences in RPH ≤ 5.1 % (|ΔRPHmax|, peak 10, table 3 
and figure 27B, [5]). 
Consistent with all previous results, also for IVA-Viktoria as well as for IVA-
California host cell-specificity of the HA N-glycosylation during virus adaptation 
was demonstrated: with the first passage in MDCK cells, the HA N-glycosylation 
pattern changed completely (figure 28A - D). During further adaptation the 
fingerprint stayed more or less robust. Differences of relative peak abundance 
were ≤ 2.5 % (|ΔRPH|max for peak 27, figure 28E) and ≤ 3.1 % (|ΔRPH|max for 
peak 7, figure 28F), indicating no significant further impact of the adaptation 
process on the HA N-glycan fingerprint of IVA-Viktoria and IVA-California, 
respectively. 
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figure 27: Adaptation of IVA-Uruguay from MDCK to Vero cells. 
(A) HA N-glycan fingerprints. Relative fluorescence units (RFU) are plotted over the migration 
time (tmig) in normalized migration time units (MTU’). (A) MDCK cell-derived virus (seed) was 
consecutively passaged in Vero cells over five passages (1.) to (5.). Peaks annotated in blue are 
present in MDCK as well as Vero cell-derived HA; peaks annotated in black are MDCK cell-
specific, and red annotation indicates Vero cell-specific peaks. Modified and reprinted with 
permission [5]. (B) Relative peak height (RPH) in % of the total peak height (TPH, sum of all 
annotated peaks). Peaks are defined low abundant if RPH < 5 % (- - -, [5]). 
  
 
 
figure 28: Adaptation of IVA-Viktoria (A, C, E) and IVA-California (B, D, F) from embryonated chicken eggs to MDCK cells. 
(A, B) Shifted overlay of HA N-glycan fingerprints, relative fluorescence units (RFU) are plotted over the migration time (tmig) in normalized 
migration time units (MTU’). MDCK cell-specific peaks between 150 MTU’ and 450 MTU’ exceeding the 10x baseline noise threshold in at least 
one of the fingerprints compared are annotated. Egg-derived virus (i) was adapted in three subsequent passages (ii) to (iv) to replicate in MDCK 
cells. (C, D) Direct overlay of all four fingerprints. (E, F) Relative peak abundance (RPH) in % of the total peak height (TPH, sum of all annotated 
peaks) during the adaptation process. Peaks are defined low abundant if RPH < 5 % (---). 
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4.6.3 Changes in quasispecies composition during virus adaptation from MDCK 
to Vero cells and back 
An impact of HA N-glycosylation patterns on virus’ properties, such as virus 
replication, has been described before [104, 161-164]. Interestingly, during all 
analyzed adaptations the N-glycan fingerprint stabilized soon after the first 
passage in the new host. This clearly suggests that further increase in HA-titer, 
e.g. as observed for both IVA-PR8 strains during adaptation from MDCK to Vero 
cells, was not driven by further changes in the HA N-glycosylation pattern. Other 
factors must contribute to higher virus yields. Therefore, changes in the viral 
genome during virus adaptation were investigated in more detail. Each viral gene 
contributes to the virus’ interaction with the host and to resulting infection. 
Understanding the adaptation of each single viral gene to the new host may 
hence provide new insights in the mechanisms of virus adaptation. For this 
purpose, samples of non-adapted (passages 1, section 4.6.1, paragraph 1), Vero 
cell-adapted (passages 6 as well as seed virus for later immunogenicity studies 
[72]) and back-adapted (passages 11) IVA-PR8, either the RKI- or the NIBSC-
strain, were sequenced by massive parallel pyrosequencing. 
All consensus cDNA sequences from passages 1 of the RKI-strain and the 
NIBSC-strain as well as translated and aligned consensus amino acid sequences 
from passages 1 are compiled in the supplementary (sections 12.7 and 12.8). 
The composition of the quasispecies for the RKI- and the NIBSC-strain during 
virus adaptation for all virus segments is presented in table 4 and table 5, 
respectively. 
4 Results 
82 
 
table 4: Overview of changes in quasispecies composition of the RKI-strain during virus 
adaptation to Vero cells. 
Adaptation IVA-PR/8 (RKI)
Passage 1 Passage 6 Passage11 Genzel et al.  2010 (Passage 5)
- 333 A 0 0 0 12
T 343 C Y 115 H 0 13 0 0
- 357 A 0 0 0 11
C 588 G C 196 W 0 7
§
50 0
ACA 670-672 C 0 11 0 0
T 1212 C F 404 F 0 27 0 10§
T 1227 C C 409 C 0 6
§ 1§ 12
T 1338 - 0 16
§
0 21
G 1351 A V 451 I 0 20 0 0
C 1362 T I 454 I 0 15 0 0
ACAAAGA 524-530 CAAG NKE 175-177 TR 0 16 0 0
ACA 1037-1039 C 0 47 0 0
- 1043 A 0 0 0 15
A 1286 - 0 87 0 0
- 1445 A 10 0 0 0
T 2000 CTA 12 1§ 15 2§
TAT 2084-2086 A 0 36 0 0
T 150 C D 50 D 0 4§ 35 0
G 301 T E 101 stop 0 0 0 18
- 303 C 0 0 0 17
G 585 A E 195 E 0 0 38 0
G 954 A K 318 K 0 0 0 23
G 1053 A E 351 E 0 10 0 0
A 1087 - 0 54
§
0 28
ATG 1728 T 0 40 0 0
CAT 1011-1113 - I 338 - 0 2
§ 1§ 46
A 1258 - 0 0 0 37
A 1268 - 0 0 0 18
- 1284 A 0 0 0 19
C 1370 T S 457 L 0 19* 9* 0
A 1378 G K 460 E 0 80* 81* 0
- 1420 A 0 0 0 10
100 few reads# 10 n.d.
- 34 G 0 0 0 15
AA 354-355 - 0 10 0 0
G 359 A W 120 stop 0 10 0 0
G 417 A W 139 stop 11 0 0 0
A 859 C S 287 R 0 17 54 0
G 882 T E 294 D 0 47 9
§ 36
A 926 G N 309 S 0 20 0 0
T 1260 - 0 0 0 12
G 1324 A A 442 T 0 12 0 0
G 1414 C A 472 P 0 42 0 12
G 1418 A S 473 N 0 38 0 9
§
4 AA 4 AA 3 AA 0
A 21 G I 7 M 0 15 85 0
A 607 - 20
§ 24§ 17§ 19
- 610 A 0 0 0 11
A 622 - 12 16
§ 5§ 17
A 1258 - 0 0 0 53
M1 - 730 G 0 0 0 15
M2 1 AA 2 AA 1 AA 0
NS1 T 307 C S 103 P 0 100
+
100 0
NEP C 27 T F 9 F 0 0 0 100
+
Ratio of cDNA / AA Differing from Seed Virus Consensus Sequence 
(%)
Adaptation IVA-PR/8 (RKI)Segment
Coded 
Protein
cDNA / AA Different from Seed Virus Consensus Sequence 
(Consensus Position Substitution) 
Base-Substitution AA-Substitution
1 PB2
frameshift
frameshift
frameshift
frameshift
3
frameshift
2 PB1
frameshift
PA
frameshift
frameshift
frameshift
frameshift
frameshift
frameshift
frameshift
8
frameshift
frameshift
frameshift
frameshift
no AA-substitutions
frameshift
frameshift
frameshift
6 NA
7
last bp missing last AA missing
4 HA
frameshift
frameshift
frameshift
initial seed virus
5 NP
frameshift
frameshift
last bp missing last AA missing
Passage 1 represents the MDCK cell-adapted seed virus. Passage 6 represents the last of five consecutive 
virus passages in Vero cells. Passage 11 represents the last of five subsequent passages in MDCK cells, 
i.e. after final back-adaptation. S457L and K460E in segment 4 are uncoupled in passages 6 and 11. 
Genzel et al. 2010 (Passage 5, [72]) represents the Vero cell-adapted virus seed used for the 
immunogenicity studies. 0% values correspond to below the detection limit. Table content for segment 4 is 
reprinted with permission [4]. 
#
 in Passage 6 only few reads of the original sequence of segment 4 was detected;  
+
 a few reads with the original sequence were detected (difference was detected with a frequency of ≥ 1 %; 
no HCD quality was reached); 
§
 detected frequency of difference was ≥ 1 % and did not reach high confidence quality. 
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table 5: Overview of changes in quasispecies composition of the NIBSC-strain during 
virus adaptation to Vero cells. 
Passage 1 Passage 6 Passage11
1 PB2 T 1287 C N 429 N 0 8§ 15
G 627 A K 209 K 13 1
§ 1§
G 747 A R 249 R 10 1
§ 1§
- 1479 T 0 0 13
T 2000 CTA 8
§
12 9
§
0 5 AA 5 AA
A 399 G E 133 E 0 5
§
11
C 1365 A A 455 A 0 6
§
13
C 1374 T Y 458 Y 2
§ 6§ 12
T 1687 C L 563 L 6
§
28 12
T 70 C Y 24 H 22 0 0
G 1183 A V 395 M 0 41.5 11.3
A 1189 G T 397 A 1.3 0 0
A 1189 T T 397 S 0.6 0 5.4
G 1363 T D 455 Y 21.4 6.1 3.2
G 1363 C D 455 H 0 52 44.1
A 1375 G K 459 E 0 0 44.2
A 1378 G N 460 D 12.2 41.1 10.5
1 AA 0 0
A 59 C Q 20 P 12 0 0
G 684 A G 228 G 0 80 64
A 859 C S 287 R 0 86 77
A 881 T E 294 V 0 11 3
§
T 1191 A N 397 K 0 0 15
G 1323 A R 441 R 0 0 12
4 AA 2 AA 4 AA
T 20 C I 7 T 0 85 65
A 904 G I 302 V 0 0 12
G 940 A E 314 K 0 0 12
- 999 T 0 20 0
A 1032 - 0 11 0
G 1038 A R 346 R 5
§
20 1
§
G 1046 A S 349 N 0 5
§
26
T 1269 C T 423 T 0 0 10
A 1300 G N 434 D 0 0 11
G 1352 C S 451 T 0 0 10
Base-Substitution AA-Substitution
Adaptation IVA-PR/8 (NIBSC)
Segment
Coded 
Protein
cDNA / AA Different from Seed Virus Consensus Sequence 
(Consensus Position Substitution) 
Ratio of cDNA / AA Differing from 
Seed Virus Consensus Sequence (%)
last AA missing
3 PA
4 HA
2 PB1 frameshift
frameshift
last bp missing
last AA missing
6 NA
frameshift
frameshift
5 NP
first bp missing first AA missing
last bp missing
 
Passage 1 represents the MDCK cell-adapted seed virus. Passage 6 represents the last of five consecutive 
virus passages in Vero cells. Passage 11 represents the last of five subsequent passages in MDCK cells, 
i.e. after final back-adaptation. 0% values correspond to below the detection limit. In Passage 1, segment 4 
D455Y and N460D are uncoupled. Incomplete coding sequences are indicated. Table content for segment 4 
is reprinted with permission [4]. 
* if coupled GTC->GCA: V -> A; 
#
 if coupled CGT->CAC: R -> H; °substitutions are coupled; 
“ if coupled: GTT->ACT: V -> T; 
§
 detected frequency of difference was ≥ 1 % and did not reach high 
confidence quality (not defined as HCD). 
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table 5 continued 
Passage 1 Passage 6 Passage11
T 33 A V 11 V 15 30 25
G 75 A A 25 A 13 31 30
A 88 G N 30 D 13 28 27
A 105 G K 35 K 14 28 28
AG 215-216 GA Q 72 R 14 0 0
T 255 C N 85 N 13 6
§
0
G 280 A D 94 N 7
§
36 45
G 289 A V 97 I 1
§
13 6
§
T 309 C L 103 L 10 23 21
T 328 C Y 110 H 10 24 23
T 336 C A 112 A 11 24 22
A 345 C I 115 I 23 25
G 346 T A 116 S 25 27
C 360 T S 120 S 12 27 27
T 376 A C 126 S 11 27 33
A 409 G T 137 A 12 29 34
T 417 C T 139 T 12 27 34
G 418 A A 140 T 12 28 34
T 428* C V 143 A 28 30
G 429* A V 143 V 28 29
G 499 A A 167 T 15 26 24
G 618 T A 206 A 16 33 30
T 620 G I 207 S 16 33 29
G 623 A R 208 Q 16 34 30
G 630 A R 210 R 15 34 29
G 642 A Q 214 Q 15 35 32
A 645 G A 215 A 15 35 32
G 691 A D 231 N 10 27 21
G 767
#
A R 256 H 13 36 22
T 768
#
C R 256 R 13 34 22
T 776 G L 259 R 13 33 21
G 780 A K 260 K 12 28 21
T 804 C D 268 D 12 30 20
T 849 G S 283 S 12 28 20
TT 862-863 AC F 288 T 12 28 21
A 869 G K 290 R 12 28 21
A 918 G S 306 S 13 26 21
G 79" A V 27 I 13 36 22
T 80" C V 27 A 13 34 22
T 88 G S 30 A 13 33 21
G 92 A S 31 N 12 28 21
T 116 C I 39 T 12 30 20
T 161 G L 54 R 12 28 20
TT 174-175 AC GL 58-59 GL 12 28 21
A 181 G R 61 G 12 28 21
A 230 G Q 77 R 13 26 21
0 1 AA 1 AA
C 240 A T 80 T 0 0 13
G 301 A D 101 N 0 0 15
G 306 A W 102 stop 0 49 0
C 320 A P 107 H 1
§
13 2
§
G 547 A G 183 R 0 7
§
25
G 551 A G 184 E 0 4
§
24
G 565 A D 189 N 0 5
§
23
C 778 T L 260 F 1
§ 5§ 29
G 75 A S 25 S 0 0 26
G 79 A D 27 N 0 0 21
G 93 A M 31 I 0 0 24
C 306 T A 102 A 0 0 29
Base-Substitution AA-Substitution
Adaptation IVA-PR/8 (NIBSC)
Segment
Coded 
Protein
cDNA / AA Different from Seed Virus Consensus Sequence 
(Consensus Position Substitution) 
Ratio of cDNA / AA Differing from Seed 
Virus Consensus Sequence (%)
8
NS1
NEP 
(NS2)
7
M1
11°
12°
M2
last bp missing last AA missing
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4.6.3.1 Segment 4 coding for HA 
At first, particular focus was laid on the sequence coding for HA (segment 4) and 
on possible changes in potential HA N-glycosylation sites: Regarding the 
consensus amino acid sequences of HA, the initial virus seeds from RKI and 
NIBSC differed in 7 amino acid positions. The differences comprise K147-, 
A156E, E158K, I208L, R269M, F309Y and S398T (RKI versus NIBSC, figure S 9 
in the supplementary). For the RKI-strain, sequencing analysis clearly indicated 
that the virus population from the first initial MDCK passage 1 was uniform 
concerning RNA segment 4, i.e. only one virus variant was detected above the 
detection limit. In contrast, segment 4 of the initial virus seed from NIBSC 
(passage 1) already comprised several virus variants. The following variants 
different from the consensus were detected with the specified frequencies, (table 
5): Y24H (22 %), T397A (1.3 %), T397S (0.6 %), D455Y (21.4 %) and 
N460D (12.2 %, [4]). 
After complete adaptation to Vero cells (passage 6), 80% of the RKI-strain virus 
population carried amino acid substitution K460E, where a positively charged 
lysine was replaced by the negatively charged glutamic acid. Another population 
of 19 % carried the S457L substitution, where polar serine was replaced by non-
polar leucine, (table 4). These two substitutions were uncoupled. No single read 
was detected, which carried both substitutions. Hence, 99 % of sequenced 
viruses carried either one of these two substitutions, indicating a crucial region of 
the HA for adaptation to efficient virus growth in Vero cells. Only single reads 
were detected that carried the original sequence of the first passage. This 
suggests that on the one hand, the initial virus did replicate in Vero cells, but only 
poorly. Considering the dilutions of the initial virus seed during the five Vero 
passages without any replication, its concentration would have been below 
0.1 virion/mL in passage 6 and would most likely not have been detected at all. 
On the other hand, only a change in very few single amino acids in this HA-
region is necessary to increase virus fitness for sufficient growth in Vero cells. In 
passage 6 of the adaptation of the NIBSC-strain a new variant carrying a V395M 
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substitution was detected with a frequency of 41.5 %, which introduced an 
additional sulfur containing residue into the HA2 peptide chain. Furthermore, the 
D455Y virus seed subpopulation dropped to 6.1 %, but a new variant D455H, in 
which aspartic acid was substituted by the basic amino acid histidine, was 
detected that dominated the virus population with 52 %. In addition, the N460D 
subpopulation increased to 41.1 % (table 5). Sequencing analysis of the Vero-
adapted virus seed [72] for later immunogenicity studies revealed a different set 
of subpopulations within the HA-coding sequence: Except from a few frameshift-
causing and silent mutations, one deletion (I338-: 46 %) as well as one 
substitution (V459M: 11 %) was detected [4]. 
After back-adaptation of the RKI-strain to MDCK cells the dominating virus 
population (81%) still carried the K460E substitution in the HA. The minor 
subpopulation (19 % after Vero-adaptation) carrying the S457L substitution 
decreased to 9 % after back-adaptation. The remaining population of 10 % 
represented the initial virus seed sequence from passage 1, (table 4). This 
demonstrates that the K460E variant allows good virus replication in both cell 
lines. In contrast, the S457L variant seems to be less efficiently replicating in 
MDCK cells. These results, particularly the fitness of the K460E variant in MDCK 
as well as in Vero cells, strongly suggests that a mutation in this region was 
acquired, rather than an already existing virus subpopulation of the initial virus 
seed was selected. This mutation finally allowed sufficient virus replication in 
passage 2 of the adaptation series to reach an HA-titer of 1.4 HAU at 288 hpi. 
After back-adaptation of the NIBSC-strain to MDCK cells the V395M, the D455Y, 
the D455H, and the N460D variants decreased to 11.3 %, 3.2 %, 44.1 %, and 
10.5 %, respectively. In contrast, the T397S variant that was not detected in 
passage 6, came-up again and made up for 5.4 % in passage 11, (table 5). This 
T397S substitution abolished the only difference of the consensus sequences in 
the HA2 chain from the two IVA-PR8 strains (RKI- and NIBSC-strain, figure S 9 in 
the supplementary). Furthermore a new variant carrying the K459E substitution 
was detected with a frequency of 44.2 % [4]. 
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figure 29: Localization of substitutions during adaptation from MDCK to Vero and back to 
MDCK cells within the 3D HA-structure. 
Structures are displayed in a cartoon diagram with potential HA N-glycosylation sites highlighted 
by red space filled residues. (A, B, C, D) RKI-strain, (E, F, G, H) NIBSC-strain . Trimeric (A-C, E-
G) and monomeric (D, H) HA molecules. (A-D) The HA1 chains are colored in pink, green and 
brown; the HA2 chains are colored in blue, grey and orange. The K460E mutation is highlighted in 
yellow, the S457L substitution by white space-filled residues. (A) Bottom (B) side and (C) top 
view. (D) indicates the close proximity within the monomer of these two substitutions, which are 
one helix turn apart from each other. (E-H) For the isolate from NIBSC the HA1 chains are colored 
in pink, purple and green; the HA2 chains are colored in turquoise, yellow and orange. The 
substitutions already present in the virus seed are highlighted by grey (Y24H), yellow (D455Y) 
and pink (N460D) space-filled residues. Substitutions occurring during virus adaptation are 
indicated by white (V395M, T397S) or yellow (D455H) space-filled residues. (E) Top, (F, H) side, 
(G) bottom view. The PDB entry 1RU7 and PyMOL (v0.99, DeLano Scientific LLC, California, 
USA) software was used for structure display. Reprinted with permission [4]. 
 
All substitutions detected during forward and backward adaptation of both IVA-
PR8 strains are located in the HA2 chain, neither inside nor in close proximity of 
any N-glycosylation site. They are, however, located in the inside of the HA 
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trimer within or in close proximity to the fusion peptide pocket: within the 
subunits’ contact site for the RKI-strain (figure 29A-D) and within the subunits’ 
and monomer contact sites for the NIBSC-strain (figure 29E-H). This position 
belongs to the fusion subdomain [165]. Interestingly, the Vero-adapted virus seed 
[72] used for immunogenicity studies revealed beside a few frameshift-causing 
and silent mutations, one deletion (I338-) in the HA1 just before the HA1-HA2 
cleavage site at residues 344-345 as well as one substitution in the HA2 
(V459M), just between the two mutations observed before for the RKI strain 
(S457L and K460E), located in the inside of the HA trimer within or in close 
proximity to the fusion peptide pocket (figure 30, [4]). 
 
figure 30: Localization of substitution/deletion within the 3D HA-structure in the Vero-
adapted seed virus [72] for the immunogenicity studies. 
Trimeric HA molecules are displayed in a cartoon diagram with potential HA N-glycosylation sites 
highlighted by red (HA1) or orange (HA2) space filled residues. (A-C) The HA1 chains are colored 
in pink, green and rosé; the HA2 chains are colored in yellow, turquoise and grey. The I338- 
deletion is highlighted in grey, the V459M substitution by blue space-filled residues. (A) top (B) 
side and (C) top view. The PDB entry 1RU7 and PyMOL (v0.99, DeLano Scientific LLC, 
California, USA) software was used for structure display. 
4.6.3.2 Virus segments 1 - 3, 5 - 8 coding for all other virus proteins 
Sequence analysis of segment 4 coding for HA revealed no differences with 
respect to potential N-glycosylation sites, neither during the adaptation process 
nor between the two tested IVA-PR8 strains RKI and NIBSC. In contrast, the 
comparison of potential N-glycosylation sites in NA (segment 6) between the 
RKI- and the NIBSC-strain seed virus revealed one potential N-glycosylation site 
more in the RKI-sequence at position 131. In NIBSC, N at position 131 is 
replaced by S, disrupting the N-glycosylation sequon NGT (section 12.8, figure S 
11). Altogether, five (positions 44, 58, 73, 131, 220) and four (positions 44, 58, 
73, 220) potential N-glycosylation sites were predicted for the NA of the RKI- and 
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the NIBSC-strain seed virus, respectively. During the adaptation process one 
additional potential N-glycosylation site was formed by the S349N substitution 
detected in passage 11 of the NIBSC-strain (table 5). 
Furthermore, the sequence information of all other segments (1 - 3, 5 – 8) 
confirmed the findings for segment 4 (HA). The RKI-seed virus (passage 1) was 
uniform for all segments: Only one virus variant was detected except from a few 
stop- and frameshift substitutions (W139stop [NP, segment 5], frameshift at 
nucleotides 622 [NA, segment 6], 1445, 2000 [PB1, segment 2], table 4). On the 
basis of the obtained sequencing data it is difficult to decide whether the detected 
stop codon and frameshifts are sequencing artifacts or non-infective virus 
particles. Different sequencing techniques, e.g. Illumina sequencing, are 
recommended to verify this. In contrast to the uniform RKI-seed, the initial 
NIBSC-seed virus (passage 1) comprised multiple virus variants: silent 
substitutions were found in segments 2 (PB1), 3 (PA), 6 (NA) and 8 (NS1, 
NS2/NEP), although the substitutions in segments 3, 6 and 8 did not reach HCD 
quality before later time points of the adaptation processes (table 5). Segment 5 
(NP) of the NIBSC seed virus comprised one base substitution, whereas 
segment 7 (M1, M2) comprised 39 base substitutions, resulting in one amino acid 
substitution for NP and in 22 amino acid substitutions in the M1 and M2 proteins 
(table 5). 
After complete adaptation to Vero cells (passage 6), different subpopulations 
were detected for the RKI-strain in segments 1 (PB2), 2 (PB1), 3 (PA), 5 (NP) 
and 6 (NA, table 4). Populations making up for more than 50 % of the 
quasispecies were detected in segment 2 (PB1, frameshift: 87 %) and in 
segment 8 (NS1, NS2/NEP; S103P: 100 %). For the NIBSC-strain, the initially 
inhomogeneous segments 2 (PB1), 5 (NP) and 7 (M1, M2) remained rather 
inhomogeneous during adaptation to Vero cells. However, the subpopulations of 
the quasispecies often varied in percentages from the initial ones. Additionally, in 
passage 6, also segments 3 (PA), 6 (NA) and 8 (NS1, NS2/NEP) revealed 
various subpopulations. Some newly derived populations in segment 5 (NP; 
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G228G: 80 %, S287R: 86 %) and segment 6 (NA; I7T:85 %) dominated the virus 
population by passage 6 with ratios above 50 %. 
Interestingly, the substitution S287R in segment 5 (NP) was detected for the RKI- 
(17 %) as well as the NIBSC-strain (86 %). Furthermore, in segment 5 (NP) of 
the RKI-strain the substitution E294D (47 %) was detected, whereas 11 % of the 
NIBSC sequences carried the substitution E294V. The Vero-adapted virus seed 
[72], which was later used for immunogenicity studies, also comprised a 
subpopulation of 36 % carrying the E294D substitution in segment 5 (NP). Also in 
segment 6 (NA) the seventh amino acid was partly substituted in the RKI- (I7M: 
15 %) as well as in the NIBSC-strain (I7T: 85 %). The substitution A472P in 
segment 5 (NP) of the RKI-strain was detected in passage 6 of the forward and 
backward adaptation [4] as well as in the Vero cell-adapted seed virus [72] for 
the immunogenicity studies (table 4, table 5). 
After back-adaptation of the RKI-strain (passage 11), most subpopulations 
dropped below the detection limit, some remained (table 4; segment 5, NP, 
S287R: 54 %; segment 6, NA, I7M: 85 %; segment 8, NS1, NS2/NEP, S103P: 
100 %), though with different frequencies. Other substitutions even newly 
emerged (table 4; segment 1, PB2, C196W: 50 %). A similar dynamic was 
observed after back-adaptation of the NIBSC-strain (passage 11): some 
subpopulations dropped below the detection limit, others remained (e.g. 
segment 5, NP, S287R: 77 %; segment 6, NA, I7T: 65 %) though often with 
different frequencies and yet others newly emerged. The drop below the 
detection limit of the E294D- (RKI) and the E294V- (NIBSC) variants suggests 
less efficient replication of these variants in MDCK cells. In contrast, the S287R 
variant of the Vero cell-adapted RKI (17 %) as well as NIBSC strain (86 %) 
persisted well over five passages in MDCK cells (RKI: 46 %; NIBSC: 77 %). In 
agreement with the significantly delayed HA-titer increase for Vero-inexperienced 
viruses (figure 22), these results again, strongly suggest that mutations were 
acquired to allow sufficient replication in the new host rather than already existing 
virus variants in the initial seed virus were selected. 
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4.7 Cultivation scale and vessel 
In a next step the impact of different cultivation scales and vessels on the HA N-
glycan fingerprint was investigated. As reviewed by Genzel et al. [62] a large 
range of influenza vaccine manufacturing processes up to the 6000 L scale have 
been established. In this study, the RKI-strain was produced in MDCK cell culture 
using T75-, T175-flasks, roller bottles and 1 L-STR. Again, all resulting HA N-
glycan fingerprints exhibited the 16 MDCK cell-specific peaks between 300 MTU’ 
and 450 MTU’ (figure 31A). Relative quantification (figure 31B) revealed eight 
high abundant peaks (2, 4, 5, 7, 9, 12, 15 and 16) for both T-flask cultivations. A 
total of nine high abundant peaks were observed when virus was cultivated in 
roller bottles (2, 4, 5, 7, 9, 11 - 13 and 15) and 1 L-STR (2 - 5, 7, 9, 11, 12 and 
15). For all scales and vessels tested, the differences in RPH were in the range 
of 0.2 % (peak 8) - 7.3 % (peak 2, table 3, [6]). 
These results were confirmed for a H3N2 virus subtype, IVA-Uruguay (figure 
31C, D): A comparison of MDCK cell-derived IVA-Uruguay revealed similar 
robust HA N-glycosylation fingerprints (figure 31C) for virus production in a T75-
flask and a 5 L-STR, showing differences in relative N-glycan structure 
abundances between 0.1 % (peak 3) and 6.6 % (peak 6, figure 31D). 
  
 
 
figure 31: Impact of cultivation scale and vessel on the HA N-glycosylation pattern of IVA. 
(A, B) RKI-strain was produced in T75-flask (i), T175-flask (ii), roller bottle (iii) or 1 L-stirred tank reactor (STR, iv) using MDCK cell culture. 
Modified and reprinted with permission [6]. (C, D) IVA-Uruguay was produced in T75-flask (i) and 5 L-STR (ii) using MDCK cell culture. (A, C) 
Shifted overlays of HA N-glycan fingerprints, relative fluorescence units (RFU) are plotted over the migration time (tmig) in normalized migration 
time units (MTU’). Peaks exceeding the 10x baseline noise threshold (---) in at least one of the direct comparable fingerprints are annotated. (B, D) 
Relative peak height (RPH) in % of the total peak height (TPH, sum of all annotated peaks). Peaks are defined high abundant if RPH > 5 % (---). 
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4.8 Virus production media 
4.8.1 Media composition 
To investigate the impact of media composition on the HA N-glycosylation 
pattern of MDCK cell-derived RKI-strain, three different virus production media 
were tested: GMEM, Episerf and the chemically defined, protein- and peptide-
free SMIF8 medium (for details see table 1). Again all N-glycan fingerprints 
exhibited the 16 MDCK cell-specific peaks between 300 MTU’ and 450 MTU’ 
figure 32A). Relative quantification by RPH comparison revealed seven high 
abundant peaks (2, 4, 5, 7, 9, 12 and 15) for all media used and two additional 
high abundant peaks when Episerf was used (10 and 16, figure 32B). Differences 
of RPHs for each peak ranged between 0.2 % and 5.7 % (ΙΔRPHmaxΙ: peak 12, 
table 3, [6]). 
4.8.2 Trypsin activities 
Generally, during virus production trypsin is added for increased virus yields. 
Hence, in a next step the effect of trypsin additions on the HA N-glycosylation 
pattern of MDCK cell-derived RKI-strain was characterized. Therefore, a 
standard trypsin activity of 5 U/mL was added [72] once (at time of infection) or 
every 24 h. As a control, cells were infected without trypsin. Controls reached 
maximum titers of 2.1 - 2.2 HAU (120 hpi), cultivations infected with trypsin at 
time of infection achieved up to 2.5 – 2.7 HAU (96 hpi). Daily addition of trypsin 
resulted in 2.6 – 2.7 HAU (96 hpi, data not shown). As before, the same MDCK 
cell-specific N-glycan fingerprints, consisting of 16 peaks between 300 MTU’ and 
450 MTU’ were obtained for all conditions, (figure 32C). Relative quantification by 
RPH revealed eight high abundant peaks (2, 5, 7, 9, 10, 12, 13 and 15, figure 
32D) for all trypsin containing samples (standard and daily addition) during virus 
production. The control samples showed a slightly different set of eight high 
abundant peaks (7, 9, 10, 11, 12, 13, 14 and 15, figure 32D). For all samples 
differences of relative N-glycan structure abundances ranged from 0.6 % - 
  
 
 
 
figure 32: Impact of virus production media compositions (A, B) and trypsin activities (C, D) on the HA N-glycosylation pattern of IVA-
PR8. 
(A, C) HA N- glycan fingerprints, relative fluorescence units (RFU) are plotted over the migration time (tmig) in normalized migration time units 
(MTU’). MDCK cell-specific peaks between 300 MTU’ and 450 MTU’ exceeding the 10x baseline noise threshold (---) in at least one of the direct 
comparable fingerprints (table 3, +) were annotated. (A) The virus was produced in GMEM (i), Episerf (ii) and SMIF8 (iii) medium. (C) Virus was 
produced without (w/o) trypsin (i), with 5 U/mL trypsin (ii) or with an addition of 5 U/mL trypsin every 24 h (iii). Representatives from duplicate 
samples are displayed (B, D) Relative peak abundance (RPH) in % of the total peak height (TPH, sum of all annotated peaks). Peaks are defined 
low abundant if RPH < 5 % (---). Modified and reprinted with permission [6]. 
 
4 Results 
95 
14.0 % (ΙΔRPHmaxΙ: peak 14, table 3). These results clearly indicate that the 
addition of trypsin has no significant impact on the HA N-glycosylation pattern 
with respect to HA N-glycan structure presence. However, highest impact on 
relative N-glycan structure abundance has trypsin presence or absence since the 
differences of relative N-glycan structure abundances for all trypsin 
supplemented samples is ≤ 1 % (ΙΔRPHmaxΙ: peak 15,data not shown, [6]). 
4.9 Virus N-glycosylation and immunogenicity 
So far, results demonstrated that some cultivation conditions impact HA N-
glycosylation of produced virus significantly (e.g. host cell), while other conditions 
hardly affect HA N-glycosylation (e.g. cultivation scale and vessel). It is known 
that carbohydrates are involved in antigen uptake, processing, presentation, and 
act in an adjuvant manner as described for saponin from Quillaja saponaria [166] 
or phosphatidylinositol mannosides from Mycobacterium tuberculosis [7, 167]. 
Furthermore, few studies have addressed the impact of HA N-glycosylation on 
anti- and immunogenicity [1-3, 88]. Therefore in cooperation with Dr. B. Lepenies 
and J. Hütter (Glycoimmunology, MPI-KG, Potsdam-Golm, Germany)) 
immunogenicity studies were designed in order to directly address the impact of 
differential N-glycosylation on the immunogenicity of IVA preparations. In the 
following the distribution of work is briefly summarized as well as the results are 
presented (sections 4.9.1 to 4.9.2), which were published in 2013 [1]. 
 
Since the influence of HA N-glycosylation on virus immunogenicity and hence on 
vaccine efficiency would make or break the relevance and value of this work, I 
started early during my thesis to think of possible ways to address the impact of 
N-glycosylation on immunogenicity. After discussion with a former colleague, 
Prof. Dr. Th. Schüler, a cooperation with Dr. E. Rapp and myself (MPI for 
Dynamics of Complex Technical Systems, Magdeburg, Germany), Dr. 
B. Lepenies and J. Hütter (MPI-KG, Potsdam-Golm, Germany) as well as Dr. B. 
Hundt (IDT Biologika GmbH, Dessau-Rosslau, Germany), was initiated. Within 
this cooperation the impact of N-glycosylation on immunogenicity of different 
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virus preparations was investigated during immunogenicity studies using a TCR-
HA transgenic mouse model and in addition a BALB/c wildtype (wt) mouse 
model. T cells from these transgenic mice only express a TCR specific for the 
HA110-120 peptide presented by MHC class-II molecules [168, 169]. The great 
advantage of this transgenic model is that it allows the characterization of HA-
specific CD4+ T cell stimulation by differentially N-glycosylated whole virus 
preparations. The work was distributed as followed: 
Multiple differently glycosylated virus preparations were produced by myself. This 
included cell culture-based virus production, β-PL-inactivation of the virus 
containing culture broth, cell culture-based inactivation testing, virus 
quantification by HA-assay, sterility testing, virus isolation and washing. 
Furthermore, I established and performed native enzyme-based deglycosylation 
procedures for the generation of natively folded, non-glycosylated virus 
preparations. Finally, I quantified all virus preparations for their protein content by 
BCA-assay and characterized each sample’s HA N-glycosylation pattern by 
CGE-LIF-based glycoanalysis. Furthermore, seed viruses were sequenced by 
next-generation pyrosequencing in cooperation with Dr. D. Höper (FLI, 
Greifswald - Insel Riems, Germany) to confirm congruence of potential N-
glycosylation sites as well as presence of HA110-120 peptide, for which transgenic 
HA-TCR T cells are specific. Dr. D. Höper and colleagues performed sequencing 
analysis, processed, sorted, assembled and mapped raw data, whereas the 
analysis and interpretation of sequence information was generally conducted by 
myself. 
J. Hütter (PhD-student, MPI-KG, Potsdam-Golm, Germany) established and 
performed in vitro whole spleen cell assays with TCR-HA transgenic mice or 
BALB/c wt mice (controls). She used magnetic assisted cell sorting- (MACS-) 
isolated spleen cell subsets (CD11c+, CD19+) to identify responsible APC 
population. She analyzed T cell activation by flow cytometry (CD69, CD25) as 
well as ELISA (IL-2, IL-4, IFNγ) using the cell culture supernatant. Furthermore, 
she performed in vivo boost immunizations (day 0 and 14) with BALB/c wt mice, 
quantifying HA-specific IgG/IgM Ab-titers of mice sera by ELISA (14 days post 
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immunization, dpi; 28 dpi) and performed an adoptive transfer of labeled TCR-HA 
transgenic T cells, analyzing their proliferation in the spleen (4 dpi) by flow 
cytometry of spleen cells. For in vivo experiments IL-2 and IFNγ production of 
CD4+ spleen T cells was quantified after restimulation by ELISPOT. The results 
of these immunogenicity studies will also be part of J. Hütter’s PhD-thesis. 
HAI assays to determine titers of Ab in immunized mice sera, which are able to 
inhibit hemagglutination, were performed by Dr. B. Hundt (IDT Biologika GmbH, 
Dessau-Rosslau, Germany) and colleagues. 
4.9.1 In vitro studies 
The following section 4.9.1 contains text, analogous text content, structure, 
figures and figure legends or parts of figure legends taken from a paper 
published together with J. Hütter, D. Höper, P.H. Seeberger, E. Rapp and B. 
Lepenies, January 2013 in J. Immunol. [1]. As described before (section 1, last 
two paragraphs), scentences and/or paragraphs containing quotations are not 
indicated specifically. The reference will only be given after the phrase or 
paragraph by the number of the quoted reference. 
MDCK and Vero cell-derived HA N-glycosylation patterns of the RKI-strain differ 
significantly (figure 33A(i), B(i), section 4.1 and [73]). The impact of HA N-
glycosylation on immunogenicity was investigated by stimulating TCR-HA 
transgenic spleen cells with either β-propiolactone inactivated MDCK or Vero 
cell-derived virus preparations [1]. Stimulations with Vero cell-derived virus 
preparations demonstrated significantly increased frequencies of the activation 
marker CD69 for splenic T cells than with MDCK cell-derived preparations (figure 
34A). Consistent with the enhanced CD69 expression, IL-2 levels in splenocyte 
supernatants were significantly higher when incubated with the Vero than with 
the MDCK cell-derived virus preparations (figure 34B). The same tendency, i.e. 
an increased cytokine secretion after stimulation with Vero cell- in comparison to 
MDCK cell-derived virus, was observed for IFN-γ. Whereas IL-4 secretion was 
comparable upon stimulation with the Vero and the MDCK cell-derived virus 
preparations (figure 34C, D). These findings demonstrate that HA N-glycosylation 
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had a marked impact on CD69 expression as well as on IL-2 secretion and to a 
smaller extent on IFN-γ production, suggesting a marked influence of differential 
HA N-glycosylation on the initiated T cell response [1].  
 
figure 33: HA N-glycan fingerprints of glycosylated (i) and deglycosylated (ii) MDCK (A) 
and Vero (B) cell-derived RKI-strain. 
Relative fluorescence units (RFU) are plotted over the migration time (tmig) in normalized 
migration time units (MTU’). Shifted overlays (i, ii) and direct overlays (iii) of fully N-glycosylated 
(i) and native deglycosylated HA (ii) show efficient but not complete deglycosylation (note the 
different scale in i and ii). Glycoanalysis indicated that at least about 90 % of HA N-glycan 
structures were cut off. New glycan structures detected after deglycosylation on the Vero (B (ii)) 
or MDCK (A (ii)) cell-derived HA are marked with an asterisk (*). Reprinted with permission [1]. 
Inactivated virus samples, figure and respective data were generated and analyzed by myself. 
 
Moreover, T cell activation kinetics using the two influenza glycovariants 
indicated that Vero cell- in comparison to MDCK cell-derived virus induces faster 
T cell activation, thus enhancing T cell proliferation: higher CD69 expression 24 h 
post stimulation (hps) but not 72 hps with Vero cell-derived virus and higher IL-2 
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production 72 hps but not 24 hps after stimulation with the Vero cell-derived virus 
preparations (data not shown, [1]). This differential T cell activation by Vero and 
MDCK cell-derived virus preparations was demonstrated to be mediated by 
CD11c+ dendritic cells (data not shown, [1]). 
 
figure 34: Increased T cell activation upon stimulation with Vero cell-derived RKI-strain in 
TCR-HA transgenic whole spleen cell assays. 
Cells were stimulated with a HA peptide (HA110-120, positive control, white), with the MDCK 
(dotted) or Vero cell-derived RKI-strain (striped) or with an ovalbumin peptide (OVA323-339, 
negative control, black). (A) As measured by flow cytometry, a higher frequency of TCR-HA 
transgenic splenic T cells expressed CD69 (very early T cell activation marker) after stimulation 
with Vero than with MDCK cell-derived virus. Background frequency of CD4
+
CD69
+
 cells is 
indicated (•••). (B, C, D) Bar diagrams represent results from three independent experiments. 
Cytokine levels as measured by ELISA in cell culture supernatants. Stimulation with Vero cell-
derived virus induced significantly higher IL-2 secretion by splenocytes, indicating an impact of 
HA N-glycosylation on T cell proliferation. Data are representative of four independent 
experiments. All data are expressed as mean + SEM. The p-values were determined using paired 
Student’s t-test (*p<0.05, **p<0.01) for MDCK vs. Vero. Significance is indicated by asterisks (*), 
ns= no significance. Modified and reprinted with permission [1]. 
Figure and respective data were generated and analyzed by J. Hütter (MPI-KG, Potsdam-Golm, 
Germany). Inactivated virus samples (MDCK, Vero) were generated by myself. 
 
To further investigate the effect of HA N-glycosylation on T cell stimulation, the 
MDCK and Vero cell-derived glycovariants of the RKI-strain were natively 
deglycosylated using a variety of endo- and exoglycosidases (section 3.7). HA 
bands were shifted to lower molecular weights in the SDS-PAGE indicating 
4 Results 
100 
successful deglycosylation (data not shown). Bands of fully glycosylated HA 
monomers were found at about 70 kDa (MDCK cell-derived just above and Vero 
cell-derived just below). In contrast, deglycosylated preparations exhibited a 
more diffuse and broader band pattern just below the fully glycosylated band 
between about 55 kDa and 70 kD (data not shown). N-glycosylation pattern 
analysis confirmed that both variants were deglycosylated for the most part 
(figure 33A(ii-iii), B(ii-iii)). In particular, the significant reduction of signal intensity 
from about 450 RFU - 500 RFU to below 50 RFU indicates efficient protein 
deglycosylation (this conclusion is only possible, if same samples were used, if 
whole sample preparation was performed in the same batch and if same material 
batches were used for N-glycan analysis). Though, no complete deglycosylation 
was achieved, glycan analysis showed a reduction of N-glycosylation by at least 
a factor of 10. Moreover, glycan analysis suggested that Vero cell-derived N-
glycan structures were removed more efficiently (figure 33B(ii)) than MDCK cell-
derived structures (figure 33A(ii)) (max. RFUVero < max. RFUMDCK). Interestingly, 
deglycosylation resulted in multiple truncated glycan structures of lower 
molecular weight on the Vero cell-derived HA (marked with an asterisk (*) in 
figure 33B (ii)). In contrast, on the MDCK cell-derived HA only one shorter glycan 
structure above 300 MTU’ was detected after deglycosylation (marked with an 
asterisk (*) in figure 33A (ii), [1]). 
The impact of HA deglycosylation on immunogenicity was investigated by 
stimulating TCR-HA transgenic splenocytes with MDCK or Vero cell-derived virus 
preparations as well as with the deglycosylated control preparations in a whole 
spleen cell assay (figure 35). Particularly at lower protein concentrations, 
deglycosylation led for both glycovariants to reduced frequencies of CD69 
expression in the CD4+ T cell population as well as to reduced cytokine 
production levels (figure 35A-D). Though, differences between the glycosylated 
and deglycosylated virus preparations were more pronounced for the Vero than 
for the MDCK cell-derived virus (figure 35A-D, [1]). This might be due to the fact 
that deglycosylation of the MDCK cell-derived virus preparation reduced the HA 
N-glycosylation level by about 90% but without modifying most N-glycan 
4 Results 
101 
structures. In contrast, HA N-glycans of the Vero cell-derived virus preparation 
were truncated during deglycosylation leading to multiple new glycan structures 
in addition to the reduced level of glycosylation (figure 33B(ii), [1]). 
 
figure 35: Deglycosylation of the RKI-strain reduces T cell activation significantly in vitro. 
TCR-HA transgenic splenocytes were stimulated for 48 h with glycosylated and natively 
deglycosylated MDCK or Vero cell-derived virus preparations. (A) CD69 (early T cell activation 
marker) frequency of CD4
+
 T cells (duplicates each). Upon deglycosylation frequencies of CD69
+
 
T cells decreased markedly. Also cytokine levels of (B) IL-2, (C) IL-4 and (D) IFN-γ, in particular 
for the Vero cell-derived virus decreased after deglycosylation. Bar diagrams are representatives 
of triplicates and represent mean + SEM. Significance was tested by unpaired student’s t-test 
(ns= no significance, (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) for glycosylated versus 
natively deglycosylated virus preparations. Reprinted with permission [1]. 
Figure and respective data were generated and analyzed by J. Hütter (MPI-KG, Potsdam-Golm, 
Germany). Inactivated virus samples (MDCK, Vero, MDCK deglycosylated, Vero deglycosylated) 
were generated by myself. 
4.9.2 In vivo studies in mice 
The following section 4.9.2 contains analogous text content, structure and 
modified figures taken from a paper published together with J. Hütter, D. Höper, 
P.H. Seeberger, E. Rapp and B. Lepenies, January 2013 in J. Immunol. [1]. As 
described before (section 1, last two paragraphs), scentences and/or paragraphs 
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containing quotations are not indicated specifically. The reference will only be 
given after the phrase or paragraph by the number of the quoted reference. 
To investigate the impact of N-glycosylation on immunogenicity in vivo and in a 
wt background, BALB/c mice were prime-boost immunized intraperitoneal (i.p.) 
on day 1 and 14 with fully glycosylated Vero or MDCK cell-derived virus 
preparations or with the deglycosylated controls. IgG/IgM titers of HA-specific Ab 
in mice sera were determined on day 14 and 28 by ELISA. In agreement with the 
in vitro results, deglycosylation led to dramatically reduced HA-specific Ab levels 
in sera of immunized mice for the MDCK as well as for the Vero cell-derived virus 
14 dpi and 28 dpi (figure 36A). Interestingly, immunization with MDCK cell-
derived virus induced significantly higher levels of HA-specific Ab on day 14 than 
immunization with Vero cell-derived virus (figure 36A, left). This effect was no 
more evident on day 28 (figure 36A, right). Consistent with the ELISA, the ability 
of mice sera of day 28 to inhibit hemagglutination in an HAI assay decreased 
significantly when mice were immunized with the deglycosylated virus 
preparations (figure 36B). Interestingly, on day 28 Ab induced by immunization 
with MDCK cell-derived virus still significantly better inhibited hemagglutination 
than the Ab induced by immunization with Vero cell-derived virus (figure 36B, 
[1]). 
Altogether, these results suggest that the N-glycosylation pattern of the MDCK 
cell-derived virus preparation more promotes the B cell-mediated humoral 
immune response whereas the Vero cell-derived virus preparation slightly more 
stimulates the T cell-mediated cellular immune response [1]. 
Furthermore, T cell proliferation in the spleen of wild-type BALB/c mice of labeled 
and adoptively transferred TCR-HA transgenic T cells was comparable after 
immunization with Vero and MDCK cell-derived virus (figure 36C). But consistent 
with the in vitro findings the frequency of IL-2 producing splenocytes was higher 
after immunization with the Vero than with the MDCK cell-derived virus 
preparations (figure 36D, [1]). 
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figure 36: In-vivo immunogenicity of glycovariants of the RKI-strain. 
(A) HA-specific Ab titers in BALB/c wt mice sera after prime- (day 0) boost- (day 14) immunization 
(i.p.) with 10 µg virus preparation (fully glycosylated or deglycosylated M- or V-variants) as 
measured by ELISA (in triplicates). Data on day 14 and 28 are derived from 5 BALB/c wt mice, 
respectively. Data represent means + SEM. Significance was tested by unpaired student’s t-test 
for glycosylated versus natively deglycosylated virus variants (MDCK cell-derived: *; Vero cell-
derived: °) and for glycosylated MDCK versus Vero cell-derived virus variants (#; ns= no 
significance, */°/
#
p<0.05, **/°°p<0.01, ***p<0.001, ****p<0.0001). (B) Inhibition of 
hemagglutination (HAI) titers of immunized mice sera were measured on day 28. One symbol 
represents one mouse. HAI for Vero-deglycosylated was 0, hence no significance could be 
determined for Vero-glycosylated versus -deglycosylated. (C) MACS-purified TCR-HA transgenic 
T cells were labeled with e670 (cell-proliferation dye) on day 0 were i. v. adoptively transferred 
into BALB/c wt mice. On day 1 mice were immunized with 50 µg of glycovariants (MDCK or Vero) 
or with PBS. Proliferation of TCR-HA transgenic T cells and T cell activation were analyzed on 
day 5. Gating on e670
+
CD4
+
 cells was performed for flow cytometric analysis. Frequency of 
transferred and labeled TCR-HA transgenic T cells, which had proliferated. Each symbol 
represents one mouse, derived from altogether three independent experiments. (D) Frequency of 
IL-2 producing splenocytes as analyzed by ELISpot in triplicates, after re-stimulation of isolated 
splenocytes with HA110-120-peptide. Data are normalized to the number of adoptively transferred 
TCR-HA transgenic T cells based on flow cytometry data. Bar diagram represents mean + SEM. 
Modified and reprinted with permission [1]. 
Figure and respective data were generated (except B; Dr. B. Hundt, IDT Biologika GmbH, 
Dessau-Rosslau, Germany) and analyzed by J. Hütter (MPI-KG, Potsdam-Golm, Germany). 
Inactivated virus samples (MDCK, Vero, deglycosylated MDCK, deglycosylated Vero) were 
generated by myself. 
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In conclusion, these studies indicate that differential N-glycosylation has a 
marked impact on IVA-PR8 immunogenicity in vitro and in vivo, in TCR-HA 
transgenic as well as in wt BALB/c mice [1]. 
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5 Discussion 
5.1 Impact of host cells and host cell adaptation on the HA N-
glycosylation pattern 
This study confirms that host cell choice significantly impacts HA N-glycosylation 
patterns of IVA. Previously, Schwarzer et al. demonstrated strict host cell-
specificity for HA N-glycosylation [73]. They showed by exoglycosidase 
digestions, that all N-glycan structures attached to MDCK cell-derived HA are of 
the complex type with either terminal α- or β-galactose. On the other hand most 
N-glycan structures attached to Vero cell-derived HA are of the complex type 
with terminal β-galactose but some other structures are of the high mannose 
type. Interestingly, AGE1.CR cell-derived HA also carried mostly complex N-
glycans with terminal β-galactose and some high mannose structures, but 
additionally hybrid structures were detected [73]. The present work extends the 
data of Schwarzer et al. [73] for a variety of additional cell lines such as 
AGE1.CR.pIX cells, Cap cells and embryonated hens’ eggs (section 4.1, figure 
15). Strict host cell-specificity was demonstrated and is in agreement with Raju et 
al., who showed significant differences in N-glycosylation for IgG produced in 
host cells from 13 different species [170]. Host cell-specificity of glycosylation is 
caused by species-specific differences, e.g. in the complex glycosylation 
machinery with respect to expressed enzyme repertoires and enzyme activities 
[31]. Also, the hosts’ cellular metabolism associated with glycosylation was 
reported to impact glycosylation outcomes due to differences in the availability of 
intracellular sugar-nucleotide donors [171]. Another factor influencing the N-
glycosylation of proteins is the transit time in the Golgi, which may also differ 
from cell line to cell line [31, 171]. 
Interestingly, taking all different host cell-derived HA N-glycan fingerprints 
obtained in this work into account, MDCK cell-derived fingerprints show the 
largest differences compared to all other hosts in terms of migration times 
(tendency towards bigger structures), number of peaks (tendency towards higher 
variety of different structures), and peak intensities (tendency towards higher 
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numbers of different, more or less high abundant N-glycan structures). MDCK 
cell-derived N-glycan structures are in average bigger. This may be either due to 
longer oligosaccharide chains or due to higher numbers of antennae, which 
remains to be investigated e.g. by MS-based N-glycan structure elucidation. 
The comparison of the AGE1.CR.pIX- with the AGE1.CR-derived HA N-glycan 
fingerprint published by Schwarzer et al. [73] shows no significant differences. 
This suggests that no significant changes to the host cell’s glycosylation 
machinery were induced by the stable integration of the adenoviral pIX gene into 
the AGE1.CR genome. The pIX gene was integrated into the genome to promote 
capsid stabilization of cognate adenovirus in particular and may also alter further 
cell line properties [7, 67, 73, 172]. 
The adaptation of adherent MDCK cells from serum-containing to serum-free cell 
growth in Episerf caused no significant changes in peak presence but resulted in 
differences in relative peak abundance (maximum │ΔRPH│ of 8.4 %, table 3) of 
the HA N-glycan fingerprints (section 4.2.1, figure 16). Therefore, this host cell 
adaptation had no significant impact on the host cell’s glycosylation machinery. 
The differences in relative N-glycan structure abundances may be caused by 
differing nutrient concentrations in the media. In particular, it was shown for 
recombinant protein production processes that glucose and glutamine 
concentrations in the media can affect N-glycosylation [173-175]. Furthermore, 
glucose or glutamine limitations can lead to decreased sialylation and increased 
presence of hybrid and high-mannose glycan types [176], which is possibly due 
to reduced intracellular UDP-N-acetylgalactosamine concentrations [177]. 
Moreover, metabolic by-product accumulation of lactate and ammonia, 
influenced by glucose and glutamine concentrations in the medium [6, 178] have 
been previously described to have an impact on N-glycosylation [179-181] 
influencing antennary-, sialylation- [182] or galactosylation- [183] levels of 
glycoproteins. Finally, adaptation-induced changes of enzyme activities of the 
glycosylation machinery or within the hosts’ cellular metabolism associated with 
intracellular sugar-nucleotide donors may also have contributed to differences in 
relative N-glycan structure abundances [6]. 
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In contrast, adaptation of adherent MDCK cells to serum-free suspension growth 
[142] changed peak presence as well as relative peak abundances in HA N-
glycan fingerprints (maximum │ΔRPH│ of 18.1 %, table 3, section 4.2.2, figure 
17). This emphasizes that every repetition of host cell adaptation - as for 
MDCK.SUS1 and MDCK.SUS3 - may result in a totally new HA N-glycosylation 
pattern, showing a distinct fingerprint. This may be explained by adaptation-
induced, altered presence or absence of oligosaccharide-processing enzymes in 
the host cell’s proteome or by host cell-specific differences in the relative 
activities of competitive enzymes involved. For example, glycoengineering allows 
to modulate, knock out or newly introduce specific glycosyltransferases in 
established producer cells to achieve a more suitable glycosylation pattern for 
therapeutic glycoproteins [184-187]. Concerning the effect of enzyme activities, 
e.g. Kobata described transformational changes of sugar chain moieties of the 
human luteinizing hormone due to an enhancement of the fucosyltransferase 
[188]. Such changes in the glycosylation machinery may occur due to 
spontaneous mutations in the host cell genome as Stanley reported for CHO cell 
mutants, which acquired multiple glycosylation defects leading to altered 
glycosylation of endogenous as well as recombinant glycoproteins [189, 190]. 
The occurrence of such mutations is also suggested by proteomic studies, 
revealing significant changes in the host cell’s proteome, acquired after 
adaptation to suspension growth (manuscript in preparation by Kluge et al., MPI 
for Dynamics of Complex Technical Systems, Magdeburg, Germany). In contrast, 
further adaptation of MDCK.SUS1 to MDCK.SUS2 for better growth 
characteristics did not impact the host cell’s N-glycosylation machinery any 
further as indicated by rather stable HA N-glycosylation fingerprints (maximum 
│ΔRPH│ of 1.9 %, table 3, [6]). 
5.2 Impact of virus strain, virus supplier, virus passage and virus 
adaptation status on the HA N-glycosylation pattern 
First and foremost the host cell determines the HA N-glycosylation pattern. In 
addition, the virus strain may influence the HA N-glycosylation. In this study, 
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CGE-LIF-based glycoanalysis revealed distinct N-glycan fingerprints for two 
H1N1 and two H3N2 strains produced in MDCK cell culture (section 4.3, figure 
18). However, mostly RPH, representing relative N-glycan structure abundances 
(maximum │ΔRPH│ of 25.2 %, table 3), vary between the strains. The 
differences in RPH were smaller, if two strains of the same subtype (IVA-PR8 
and IVA-Victoria, H1N1; or IVA-Uruguay and IVA-California, H3N2) were 
compared (maximum │ΔRPHH1N1│ of 12.4 %, maximum │ΔRPHH3N2│ of 9.8 %, 
table 3). This highlights the closer relation of the H1N1-strains and the H3N2-
strains. A few differences with respect to peak presence were detected, when all 
strains were compared: however, these represented mostly low abundant 
structures (e.g. peak 24, not present in both H1N1 strains, figure 18). These 
differences in N-glycan structure abundance as well as presence are most 
probably due to slightly varying three-dimensional conformations between all four 
analyzed IVA strains. Interestingly, Schwarzer et al. showed for MDCK cell-
specific glycovariants by sequential exoglycosidase digestions that all glycans 
attached to IVA-PR8-derived HA were of the complex type with terminal α- and 
β-galactose, while IVA-WSN/67/2005- (H3N2) derived HA only possessed few 
complex N-glycan structures with terminal α- and β-galactose and the highest 
abundant structures were of the high mannose type [73]. Similar digestion 
patterns were found for influenza virus B/Mal/2506/2004-derived HA: highest 
abundant structures were of the high mannose type, but all detected complex N-
glycan structures were terminated by β-galactose [73]. Already in 1997 Mir-
Shekari et al. highlighted the importance of the three-dimensional structure of HA 
for N-glycosylation. They demonstrated that each of the four N-glycosylation sites 
within the HA1 subunit was occupied by conserved N-glycan structures 
depending on specific N-glycosylation site characteristic: in loop regions bi-, tri- 
and tetra-antennary complex N-glycans were present. In contrast, the 
glycosylation site buried in the α-helix was occupied by high mannose structures, 
indicating that these structures are no more accessible for glycosylation 
modulating enzymes after proper protein folding and trimerization of the HA 
molecule [31, 191]. However, beside the three-dimensional structure of the 
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protein, also specific glycosylation characteristics have been described to 
influence further glycan processing: e.g. Harpaz and Schachter demonstrated 
that the presence of bisecting GlcNAc inhibited GlcNAc transferases, which is 
responsible for further glycan branching [192]. 
In addition to different virus strains, the impact of IVA-PR8 origin with respect to 
suppliers (i.e. RKI- versus NIBSC-strain) on HA N-glycosylation was investigated 
(section 4.5, figure 20). The choice of virus supplier did only slightly effect relative 
peak heights (maximum │ΔRPH│ of 5.0 %, table 3). Overall, this suggests that 
N-glycan fingerprints of strains from different suppliers, which may as well slightly 
vary in their HA genome sequence (as shown for RKI- and NIBSC-strain), can 
also show differences regarding relative peak abundance, i.e. probably with low 
abundance. This was expected as these two closely related IVA-PR8 virus seeds 
do not differ in any potential glycosylation site of the HA molecule [4, 6]. Still, the 
two virus seeds differed significantly concerning maximum virus titers obtained, 
interferon and apoptosis induction as well as the activation of general host cell 
responses [193-196]. These variations may be caused by different ratios of 
defective interfering virus particles in seed viruses [197]. Furthermore, Andersen 
et al. suggested in 2000, that the ratio of cells in G0/G1 phase determines the 
glycosylation efficiency [198]. 20 years before, Hakimi et al. reported that virus 
isolated from rapidly growing fibroblasts exhibited a higher number of larger 
glycans compared to virus replicated in non-growing cells [199]. All this suggests, 
that the cell status can affect N-glycosylation and that the slight differences in 
RPH in the HA N-glycan fingerprints between these two tested virus seeds may 
be due to differing virus-induced physiological statuses of the host cells rather 
than caused by sequential differences in the HA [6]. 
The characterization of HA N-glycan fingerprints derived from multiple virus 
passages demonstrated a good reproducibility and an overall high biological 
stability of HA N-glycosylation (maximum │ΔRPH│ of 3.5 %, table 3, section 4.4, 
figure 19). This stability makes further investigations possible, e.g. during virus 
adaptation. However, HA N-glycosylation pattern stability does not allow any 
conclusions concerning occurred mutation events, since slight differences in 
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virus genome sequences do not necessarily lead to significantly altered HA N-
glycan fingerprints, as observed during the comparison of the RKI- and the 
NIBSC-strain. 
Next, the impact on HA N-glycosylation of seed virus adaptation to various host 
cells was investigated (section 4.6.1/2, figure 21 to figure 24). Virus seed 
adaptation is often necessary to optimize virus yields in production cells. The 
results clearly show that predominantly the host cell line determines the HA N-
glycosylation pattern of a specific virus strain (details in section 5.1). For NIBSC- 
as well as RKI-strain-derived HA N-glycan fingerprints, the variation between the 
first passage in Vero cells (passage 2) and the patterns of all subsequent Vero 
cell adaptation passages (passages 3 – 6) cannot completely be explained by 
applied harvest time point. This indicates that in addition to the harvest time point 
(maximum │ΔRPH│ of 14.2 % for RKI-strain in Vero cells, table 3), the viral 
adaptation status (maximum │ΔRPH│ of 21.0 % for RKI-strain to Vero cells, 
table 3) may impact relative N-glycan structure abundances. Interestingly, for all 
tested virus strains and host cells, the glycan pattern stabilized at the latest after 
the first passage in the new cell line. Moreover, the quicker release of virus 
particles and to begin with the increase in HA-titers - as observed for most seed 
virus adaptations – indicates that other factors are involved in the adaptation 
process resulting in improved fitness of virus subpopulations. Such factors 
include the acquisition of changes in the virus genome sequence [4]. 
Taking together data from all adaptation series, the results clearly indicate that 
the impact of virus adaptation status on HA N-glycan fingerprints and virus 
replication dynamics depends on chosen virus strains as well as on selected cell 
lines for virus replication (section 4.6.2, figure 21 to figure 28). This is caused by 
strain- and/or host cell-specific characteristics: e.g. the passage history of a seed 
virus may have already selected fitter virus variants for the new host system or 
the host cells express favoured receptors. For instance, the expression of both 
α2,3 and α2,6 linked sialic acids on cell surfaces may also support the 
propagation of avian (binding α2,3 sialic acids) as well as human (binding α2,6 
sialic acids) influenza strains, as observed for AGE1.CR.pIX cells [200, 201]. 
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5.3 Impact of virus adaptation on quasispecies composition 
5.3.1 Characterization of virus seeds 
The fact, that cDNA sequences are homogenous in the virus seed of the RKI-
strain (passage 1), clearly suggests the presence of only one virus population 
(table 4). In contrast, the initial virus seed population (passage 1) of the NIBSC-
strain comprises multiple virus variants (table 5) regarding segments 2 (silent), 3 
(silent, non-HCD quality), 4, 5, 6 (silent, non-HCD quality), 7 and 8 (non-HCD 
quality): in segment 4 four substituted AA residues (Y24H, T397A/S, D455Y, 
N460D) were detected, whereas in segment 5 one subpopulation carrying the 
substitution Q20P was detected. Q20P is located within a domain interacting with 
cellular proteins, in particular with the splicing factor BAT1 [202, 203]. In 2011 
Ping et al. characterized this Q20P substitution as a mouse adaptive mutation 
[204]. Its presence may be explained by the NIBSC-strain passage history, which 
is not clear. However, in segment 7 coding for M1 and M2 proteins a total 
number of 22 AA substitutions have been detected in the NIBSC seed virus 
(passage 1). These comprise the substitutions N30D, Q72R, A167 T207S, 
R208Q and D231N, which are located within the domain of M1, interacting with 
the ribonucleocapsid protein (RNP) [204]. The sequence conflict SQ207/208IR 
was characterized before by comparing the sequences published by Winter et al. 
in 1980 and by Ghedin et al. in the course of the National Institute of Allergy and 
Infectious Diseases (NIAD) influenza genome sequencing project [205, 206]. 
Further subpopulations detected for M1 carried the substitutions Y110H, A116S, 
C126S, T137A, A140T and V143A, which are all located within α-helices, 
involved in membrane-binding [158, 207]. Subpopulations detected for M2 
comprised the substitutions V27A/I, S30A, S31N and I39T, which are located 
within the ion channel [204]. Of these V27A and S31N have been associated with 
amantadine resistance [208, 209]. Furthermore, a comparison of available 
sequence information for IVA-PR8 reveals the sequence conflicts A27I, L54R, 
R61G, Q77R as well as characterizes I39T as a natural variant of the IVA-
PR8/Mount Sinai-strain [158, 205, 206, 210]. 
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5.3.2 Comparison of two IVA-PR8 virus seeds, RKI- vs. NIBSC-strain 
The comparison of consensus sequences of both IVA-PR8 seed viruses 
(passages 1) – the RKI- and the NIBSC-strain – reveals four AA substitutions for 
segment 1 coding for PB2 (table 6, figure S 5), six AA substitutions for segment 2 
coding for PB1 (table 6, figure S 6), three AA substitutions for segment 2 coding 
for PB1-F2 (table 6, figure S 7), three AA substitutions for segment 3 coding for 
PA (table 6, figure S 8), six AA substitutions and one deletion for segment 4 
coding for HA (table 6, figure S 9), four AA substitutions for segment 5 coding for 
NP (table 6, figure S 10), nine AA substitutions for segment 6 coding for NA 
(table 6, figure S 11), twelve AA substitutions for segment 7 coding for M1 (table 
6, figure S 12), six AA substitutions for segment 7 coding for M2 (table 6, figure S 
13), two AA substitutions for segment 8 coding for NS1 (table 6, figure S 14) and 
two AA substitutions for segment 8 coding for NS2/NEP (table 6, figure S 15). 
Interestingly, the RKI-sequence for segment 7 matches the subpopulations of the 
NIBSC-sequence (carrying the HCD) perfectly on the AA-level. Even on the 
cDNA-level the 33 differences are reduced to one silent substitution (A438G). 
Similar findings were observed for segment 6, though to a lesser extend: the five 
subpopulations (cDNA/AA: A904G/I302V, G940A/E314K, T1269C/T423T, 
A1300G/N434D, G1352C/S451T) arising during the adaptation processes reduce 
sequential differences between the RKI- and the NIBSC-strain from nine to five 
and from fourteen to nine positions at the AA- and cDNA-level, respectively. 
Hence, these data may indicate a possible contamination and subsequent 
reassortment of segment 7 of the NIBSC-seed with the RKI-strain. Or if the 
original NIBSC-sequence matches the RKI-sequence of segment 7, the NIBSC-
seed may have been contaminated with some other virus strain, which already 
dominates the virus population in passage 1. Since the sequences from other 
NIBSC-strain seed virus variants, also comprised a mixture of RKI-specific (e.g. 
G620/S207) and NIBSC-specific (T620/I207) residues in segment 7 (data not 
shown, data obtained by Dr. T. Frensing and B. Heynisch (MPI for Dynamics of 
Complex Technical Systems, Magdeburg, Germany) in cooperation with Dr. D. 
Höper (FLI, Greifswald - Insel Riems, Germany) a possible contamination of the 
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table 6: Sequence differences of viral genomes between the RKI- and the NIBSC-strain. 
Differing AAs for both strains are indicated by the AA found in the RKI-strain, followed by the AA position, 
followed by the AA in the NIBSC-strain. Consensus suquences were used for the alignment. 
1 2 3 4 5 6 7 8 9 10 11 12
segment 1 PB2 M105I V259L V504I R702K
segment 2 PB1 A155T V195M I205M R208K I336V P394S
segment 2 PB1-F2 P43Q K59R Q60R
segment 3 PA K237E V354I L550I
segment 4 HA K147- A156E E158K I208L R269M F309Y S398T
segment 5 NP V353L V425I T430N A442T
segment 6 NA M15L R128K N131S V302I K314E E371K I403M D434N T451S
segment 7 M1 D30N R72Q H110Y S116A S126C A137T T140A A143V T167A S207I Q208R N231D
segment 7 M2 A27V A30S N31S R54L G61R R77Q
segment 8 NS1 E55K E101D
segment 8 NEP (NS2) R88K V89I
segment protein
number of mutations 
 
NIBSC-strain with the RKI-strain during these studies can be ruled out. Another 
possibility is the accumulation of mutations within segment 7 of the NIBSC-strain. 
Previously, the theoretically identical RKI- and the NIBSC-strain have been 
described to differ significantly in infection characteristics such as IFN response, 
apoptosis induction, final virus yields [194, 195] and the activation of general host 
cell response [193, 196]: The NIBSC-strain was characterized to induce higher 
levels of IFN, to express more Mx proteins, to induce apoptosis earlier, and to 
reach lower final titers than the RKI-strain. Seitz et al. hypothesized that two 
amino acid substitutions in the non-structural protein 1 (NS1) might be related to 
these differences. Another approach correlates higher amounts of defective 
interfering virus particles (DIPS) in seed virus preparations to higher apoptosis 
rates, IFN expression and to decreased final virus titers (personal communication 
Pflugmacher, Frensing, MPI for Dynamics of Complex Technical Systems, 
Magdeburg, Germany). Our present findings suggest that lower average virus 
yields, as well as increased IFN responses and apoptosis rates may at least be 
partly due to a broadened quasispecies of the NIBSC-strain virus seed 
comprising low-yield-virus variants [4]. 
5.3.3 Quasispecies of segments 1 to 3 
During virus adaptation the quasispecies of the RKI-strain broadened in 
dependence of the adaptation pressure. The substitutions within segment 1 
coding for PB2 Y115H (located within PB1-binding site), C196W (located within 
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NP-binding-site) and V451I (located within nuclear localization signal, NLS) are 
all located within regions important for protein-protein contact or protein 
transport, respectively [204]. To the author’s knowledge, these mutations have 
not yet been described before. For the NIBSC strain no AA substitutions were 
detected during the adaptation processes within segments 1, 2 and 3.  
5.3.4 Quasispecies of segment 4 
During all performed IVA-PR8 adaptations from MDCK to Vero cells, additional 
virus variants with mutations in the HA stem region were generated. While the 
quasispecies of the homogenous seed virus of the RKI-strain broadened, the 
heterogeneity of the seed NIBSC-strain persisted during the whole adaptation 
processes: from passages 1 to 11 samples comprised multiple virus 
subpopulations. Thereby, sizes of subpopulations as well as selection and 
extinction of specific virus variants varied in dependence of adaptation pressure, 
i.e. the host. However, no potential HA N-glycosylation sites or AA residue in 
their close neighborhood were affected [4]. 
A comparison of results obtained for both adaptations from MDCK to Vero cells 
and back using the RKI- and NIBSC-strain revealed one interesting similarity: the 
substitution of lysine by glutamic acid at position 459/460 (RKI-/NIBSC-strain). 
The K459E variant of the NIBSC-strain that carries a deletion in the HA1 chain 
(K147-) corresponds to the K460E variant of the RKI-strain. Moreover, all 
substitutions detected during forward and backward adaptation of both IVA-PR8 
strains are located in the HA2 chain, neither inside nor in close proximity of any 
N-glycosylation site. They are, however, located in the inside of the HA trimer 
within or in close proximity to the fusion peptide pocket: within the subunits’ 
contact site for the RKI-strain (figure 29A-D) and within the subunits and 
monomer contact sites for the NIBSC-strain (figure 29E-H). The second 
adaptation of the RKI-strain by Genzel et al. [72] resulted, besides some 
frameshift mutations, in the deletion of AA 338 (I338-). This deletion is located 
within the fusion subdomain [165] of the HA molecule (figure 30). Substitutions in 
the region of HA subunit contacts have been described to be crucial for the 
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stability of the structure of the native protein. Among other factors, the optimal 
stability depends on pH or temperature [22, 211-213]. In this regard lower pH 
environments for instance require higher native structure stability, whereas 
elevated pH-values require less stable structure conformations to mediate 
membrane fusion. In 2010 Reed et al. demonstrated using recombinant H5N1 
influenza viruses that substitutions within the fusion peptide pocket and the α-
helix of HA2 alter the pH of activation of HA, which in term effects influenza virus 
pathogenicity as well as transmissibility in mallards [214]. Furthermore, 
Thoennes et al. showed that different substitutions at HA2 position 111 of a H3N2 
influenza virus strain significantly effected fusion pH, suggesting, a key role of 
this residue for neutral pH structure stability [215]. This is consistent with findings 
of Kawaoka’s group in 2012. They demonstrated, that the N460D (HA2N117D as 
published by Murakami et al.) substitution, we detected after NIBSC-strain 
adaptation to Vero cells, is responsible for improved replication in Vero cells 
without inhibiting growth in MDCK cells [216]. Furthermore, they showed that the 
N460D substitution resulted in an increased or boarded optimal pH range for viral 
membrane fusion in comparison to the wt virus without the N460D substitution. 
Based on two fluorescent dyes – one pH stable, the other pH sensitive – they 
demonstrated a higher intensity ratio for Vero cells then for MDCK cells, 
suggesting higher pH values in the early endosome of Vero cells [216]. Also 
Nakowitsch et al. described mutations in the HA1 and HA2 after passaging a 
H3N2 IVA on Vero cells, which led to impaired virus stability. Interestingly, these 
mutations also led to decreased immunogenicity in ferrets [217]. Other authors 
also reported substitutions within the HA stalk region, altering HA stability and 
hence pH of membrane fusion [22, 214, 218, 219]. Therefore, all substitutions 
within the HA molecule in this study, occurring during virus adaptation from 
MDCK to Vero cell-based replication of the RKI- or NIBSC strain most probably 
modulate the electrostatic balance of the HA molecule and hence alter stability of 
its three-dimensional conformation. Interestingly, Rott et al. [220] described the 
occurrence of virus variants after adaptation to MDCK cells, which exhibited 
elevated fusion pH caused by substitutions within the HA1 chain. However, these 
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experiments indicate a crucial role of the HA stem region for virus adaptation 
from MDCK to Vero cells. Here, inter-monomer or inter-subunit contact is 
mediated, suggesting HA-initiated fusion as a driving factor of adaptation 
pressure. Zaraket et al. reported that altered HA acid stability of a H5N1-strain 
impacts virus growth in the upper respiratory tract and contact transmission in 
ferrets [221]. Furthermore they described an impact on virus replication and 
pathogenesis in mice [4, 222]. 
In this study, all three virus adaptations show a significant change of the HA N-
glycosylation pattern with the change of host cell system as recently published by 
Genzel et al. as well as Roedig et al. [4, 72]. Additionally, all three experiments 
demonstrate that only a small sequence adaptation is required for successful 
infection and fast growth to high titers in new host cell lines. These findings are in 
agreement with results of Wagner et al. and Klenk et al. [163, 164] who reported 
that N-glycans attached to the stem domain of HA efficiently regulate influenza A 
virus replication. The authors showed that a loss of N-glycans in the stem region 
results in increased pH-sensitivity of the virus and that these viruses are also 
temperature sensitive. However, for most detected substitutions (except for 
N460D during NIBSC-strain adaptation), the exact functions remain to be 
investigated, including the question whether these substitutions alter acid stability 
of HA [223], pH of activation, or membrane fusion [224]. Or, whether they simply 
counteract steric hindrance [164] caused by Vero cell-specific changes in HA N-
glycosylation, e.g. on residues 28 and/or 40 in the stem region of HA to achieve 
low-pH conformation required for membrane fusion [4]. 
5.3.5 Quasispecies of segment 5 
In segment 5 coding for NP several substitutions were detected during 
adaptation processes within functional domains of the RKI-strain: the substitution 
S287R is located within the domain for NP-binding, whereas substitutions E294D 
(E294V during NIBSC-strain adaptation), N309S, A442T, A472P and S473N are 
located in a region involved in NP-binding as well as PB2-binding [204]. Although 
mutations occurred in both regions of interaction - in PB2 (C196W) as well as in 
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NP - a correlation between the PB2 and the NP adaptation is not probable due to 
strongly differing mutant population sizes (NP-binding site of PB2: 7 % versus 
NP- and PB2-binding-site of NP: 47 %, 20 %, 12 %, 42 %, 38 %). Furthermore, 
Chen et al. defined the residue 442 as a host-specific genetic signature, where 
avian strains usually carry a T and human strains carry an A [225]. On the one 
hand the A442T subpopulation may have already been present below the 
detection limit in passage 1. The presence of A442T in the virus seed is then 
most likely due to the virus’ passage history: the virus was isolated from humans 
in 1934, passaged in embryonated chicken eggs as all viruses were in former 
times and mostly still are, before the virus was adapted in our laboratory to 
MDCK cell culture-based virus replication. If this was the case, its detection in 
passage 6 is most probably due to selection in Vero cell-based virus replication. 
On the other hand, the fact that a second adaptation of the RKI-strain to Vero 
cells by Genzel et al. did not result in a A442T subpopulation strongly indicates 
that no selection but rather a mutation led to the A442T substitution. However, 
the accumulation of substitutions between AA 294 and 309 (47 % and 20 %) and 
between AA 442 and 473 (12 % - 42 %) suggests that a structural change in this 
region was necessary for successful virus replication in Vero cells. This is 
supported by the data from the second adaptation by Genzel et al. [72] showing 
comparable accumulations of AA substitutions within these two regions. 
Interestingly, all substitutions in these two regions were first detected in 
passage 6 and decreased to under the detection limit in passage 11, which 
strongly indicates a significant advantage of these substitutions for Vero cell-
based, but a significant disadvantage for MDCK cell-based virus replication. In 
contrast the S287R substitution, which was also detected for the NIBSC-strain, 
was first detected in passage 6 (RKI: 17 %, NIBSC: 86 %) and further persisted 
until passage 11 (RKI: 54 %, NIBSC: 77 %) finally representing the major virus 
population in both strains. For segment 5 of the NIBSC strain in passage 11 one 
additional substitution (N397K, region involved in NP-binding as well as PB2-
binding) to the ones also observed for the RKI-strain (S287R and E294V) was 
detected. Naffakh et al. hypothesized a co-evolution of PB2, PA and NP due to 
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strong physical as well as functional interactions [202]. This is in agreement with 
the occurrence of substitutions within the PB2 and NP molecules observed 
during the adaptation processes of the RKI-strain. 
5.3.6 Quasispecies of segment 6 
For segment 6 coding for NA one subpopulation (I7M) was generated during 
virus adaptation processes of the RKI- as well as the NIBSC-strain. This I7M 
subpopulation replicated rather well in Vero as well as in MDCK cells 
(RKI/NIBSC: 0 %/0 % passage 1; 15 %/85 % passage 6; 85 %/65 % 
passage 11). Position 7 is located in the transmembrane domain (7 - 35) of the 
NA molecule and was described as a potential signal-anchor for type-II 
membrane proteins [158, 226]. In contrast to the RKI-strain, further substitutions 
were detected for the NIBSC-strain in passage 11. These comprised the 
substitutions I302K, E314K, S349N, N434D and S451T, which are all located 
within the head of the neuraminidase protein [204]. The comparison of 
sequencing data from Fields et al. with data derived from the NIAID influenza 
genome sequencing project reveals the E314K and S451T sequence conflict 
[205, 227], which may suggest these residue substitutions as frequently 
occurring variants. Interestingly, the substitutions I302V, E314K, N434D and 
S451T result in matching AA sequences at these positions for the RKI- and 
NIBSC-strain. 
5.3.7 Quasispecies of segment 7 
With respect to segment 7 coding for M1 and M2 proteins the RKI-strain stayed 
homogeneous throughout the virus adaptation processes, i.e. no additional 
subpopulation was detected. This is consistent with the persistence of the rather 
broad quasispecies of the NIBSC-strain from passage 1. Only the subpopulation 
Q72R decreased to under the detection limit in passages 6 and 11. These 
findings suggest that the selection pressure during virus adaptation from MDCK 
to Vero cells and vice versa hardly acts on the two matrix proteins M1 and M2. 
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5.3.8 Quasispecies of segment 8 
Differential splicing results in two proteins encoded by segment 8 namely NS1 
and NEP (NS2). During virus adaptations different substitutions within the NS1 
protein have been detected. Interestingly, after virus adaptation from IFN-
competent MDCK to IFN-deficient Vero cells (passage 6) approximately 100 % of 
the viruses of the RKI-strain carried the substitution S103P. Only a few sequence 
reads could be detected carrying the original sequence. This substitution 
persisted and made up for 100 % of the virus population in passage 11 after 
back-adaptation to MDCK cells. This clearly suggests a fitness gain by S103P for 
replication in Vero and definitively no fitness loss for replication in MDCK cells. In 
contrast, after the adaptation of the NIBSC-strain to Vero cells, a subpopulation 
P107H was detected, which decreased again during back-adaptation to MDCK 
cells. Altogether, this suggests a fitness gain for Vero cell-based virus replication 
but a fitness loss for MDCK cell-based replication. Other substitutions, namely 
D101N, G183R, G184E and D189N were detected with high confidence after 
back-adaptation of the NIBSC-strain to MDCK cells. The substitutions S103P 
(RKI-strain), P107H and D101N (NIBSC-strain) are located in the effector domain 
of the NS1 protein within the region involved in interaction with eukaryotic 
initiation factor 4 G1 (elF4G1) as well as the cleavage and polyadenylation 
specificity factor (CPSF), which is involved in the 3’-polyadenylation of cellular 
mRNAs [204]. So far, it is assumed that the ability of an NS1 molecule to interact 
with elF4G1 enhances viral mRNA translation [228, 229], whereas the ability to 
interact with CPSE-30 downregulates host gene expression including IFN 
expression [230, 231]. Recently, Forbes et al. demonstrated that the mutation 
F103L in this region of mouse-adapted IVA-HongKong/1/1968 (H3N2) bound the 
F2F3 domain of CPSF with significantly decreased affinities [232]. Furthermore, it 
was reported that, a hydrophilic S at position 103 of the IVA-PR8 eliminates 
CPSF30 binding affinity, but an unknown viral strategy maintained suppression of 
IFN-β mRNA production [231, 233]. Structural analysis indicated that the 
aromatic side chain of residue 103 interacts with hydrophobic residues of the 
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F2F3 domain of CPSF and contributes to the stability of tetrameric NS1A-F2F3 
complex [233]. Furthermore, the F103L mutation was shown to increase 
significantly virus yields in mouse kidney epithelium cells as well as to increase 
early viral growth (12-24 hpi) in IFN-β primed cells in contrast to wt viruses [232]. 
Interestingly, not only the antagonism to IFN-β was enhanced for the F103L 
mutant but it also induced significantly lower IFN-β expression 1 dpi in the lungs 
of mice [232]. Since MDCK cells are IFN-competent whereas Vero cells are INF-
deficient, it may be assumed that the virus adapted according to IFN competence 
of the host cells. However, this is unlikely since recent studies by Seitz et al. 
demonstrated that IFN expression is no limiting factor for IVA replication in 
MDCK cells [195]. Rather IFN-expression independent functions contribute to 
NS1 mutations during the adaptation processes. The appearance and further 
increase of the G183R, G184E and D189N virus variants during the NIBSC-
strain adaptation may indicate a fitness gain by tuning CPSF interactions. 
Residues 183 and 184 are located in a domain (144 - 188) interacting with 
CPSF, whereas residue 189 is located just outside this domain [204]. Structural 
analysis demonstrated that residues 183/184 belong to the largely hydrophobic 
F2F3 binding pocket within the NS1 molecule interacting with the F3 zinc finger 
of the CPSF complex contributing to CPSF-binding [233]. A strong influence of 
G184 by an unknown mechanism on IVA-PR8 virulence was described, which is 
independent from the IFN system [234]. However, residues F103 and M106 have 
been identified as critical for CPSF binding. Some viruses, e.g. IVA-PR8, vary in 
these positions. As a result, attenuation or even complete loss of CPSF-binding 
was described [231, 235, 236]. 
Altogether, the emergence of NS1 variants with all substitutions located in the 
elF4G1- (AA81 - 113) and/or the CPSF- (AA81 -113, AA147 - 188) binding site or 
nearby (AA189) suggests a fitness gain for all variants in Vero cells and for most 
variants also in MDCK cells, whenever a further increase during back-adaptation 
to MDCK cells was observed. Since Vero cells are IFN-deficient and even in 
MDCK cells IFN is not a limiting factor for virus replication another, IFN-
independent function probably drives NS1 adaptation from MDCK to Vero cells 
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and back. Such a factor may be involved in (i) the suppression of RNAi induction 
[237-240], (ii) the inhibition of host cell mRNA processing by interacting with 
CPSF and the suppression of nuclear export of poly-A-tailed transcripts [233, 
241-244], (iii) suppressing apoptosis in infected cells [245, 246] or (iv) the 
stimulation of the translation of viral transcripts by interacting with elF4G1 [229, 
247]. 
The fact that 100 % of detected viruses of the RKI-strain carried the S103P 
substitution in passages 6 and 11 suggests that either a mutation was essential 
for sufficient virus replication in Vero cells or that this variant had an enormous 
fitness-gain, having outcompeted other virus variants by passage 6. The latter is 
more likely, since after the adaptation by Genzel et al. from MDCK to Vero cells 
no NS1 variants were detected. Consistent with this is the accumulation of some 
substitutions in similar regions during the adaptation of the NIBSC strain. 
Whether the detected substitutions modify CPSF30-, elF4G1-binding or other, so 
far unknown interactions located in this region, remains to be further investigated. 
Regarding the NEP protein, no AA substitutions were detected during both RKI-
strain adaptations, while after back-adaptation of the NIBSC-strain to MDCK cells 
two subpopulations carrying the substitutions D27N and M31I were detected. To 
the author’s knowledge, so far, no specific function was mapped to this region. 
5.3.9 General remarks 
In general, next-generation pyrosequencing was performed to address whether 
sequence changes of the viral genome were required to ensure efficient virus 
replication in the new host system (section 4.6.3). It should be mentioned that on 
the basis of obtained sequencing data, it was difficult to decide whether the 
detected frameshifts are sequencing artifacts or represent non-infectious and/or 
truncated virus particles. Further sequencing by another method e.g. Illumina 
sequencing would be necessary to verify this. Hence, in the previous, only 
sense-mutations were discussed, whereas introduced stop codons and 
nonsense-mutations such as frameshifts were ignored. Moreover, several silent 
substitutions were detected. Some may have occurred by chance, others may 
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have been selected to better match the new host’s codon usage bias, i.e. 
favoured base triplets coding for a specific AA [248]. However, in the previous, 
the focus was laid on substitutions changing the AA sequence. 
5.4 Impact of cultivation scale, vessel and virus production media on the 
HA N-glycosylation pattern 
So far, the host cell line, the host cell line’s adaptation status to adherent or 
serum-free suspension growth and to some extend the virus strain have been 
shown to have an impact on the HA N-glycan fingerprint with respect to N-glycan 
structure presence as well as relative structure abundances. In contrast, different 
harvest time points, different virus passages, different IVA-PR8 virus suppliers as 
well as different virus adaptation statuses only slightly impacted HA N-glycan 
fingerprints, i.e. only affecting N-glycan structure abundances. In a next step, for 
robustness during scale-up, the impact of different cultivation vessels (T75-flasks 
up to microcarrier-based 1L-STR) on the HA N-glycosylation pattern was 
assessed. Again, the use of different cultivation vessels had no significant impact 
on N-glycan structure presence in HA N-glycan fingerprints. Only relative N-
glycan structure abundances were affected, (RKI-strain: maximal ΙΔRPHΙ of 
7.3 % for peak 2; IVA-Uruguay: maximal ΙΔRPHΙ of 6.6 % for peak 6, table 3). 
Nevertheless, one possible cause for such variations can be found in the 
different concentrations of dissolved oxygen (DO) in T-flasks, roller bottles and 
DO-/pH-controlled bioreactors. For example, Kunkel et al. observed different 
galactosylation levels for different DO concentrations for monoclonal antibodies 
[249, 250], and Restelli et al. described DO concentration-dependent fucosylation 
efficiencies for recombinant human erythropoietin [251]. Beside DO 
concentration, also time course of pH differs between pH-controlled STR 
cultivations, T-flasks and roller bottles (both uncontrolled). Variations of the 
extracellular pH in the range of 6.1 to 8.7 have been described, e.g. to influence 
significantly the glycosylation pattern of CHO-derived recombinant mouse 
placental lactogen-I. At low and high pH values a decreased extent of 
glycosylation was found [252]. Furthermore, Zanghi et al. showed that changes in 
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pH as well as partial pressures of CO2 can alter protein glycosylation in CHO 
cells [253]. Other possible causes for variations in RPH are different shear forces 
in T-flasks, roller bottles and STRs. For example, Senger et al. reported shear-
dependent ratios of partially and fully glycosylated recombinant tissue-type 
plasminogen activator protein [254]. Besides, growth in suspension or in 
microcarrier culture can have an impact. Nam et al. observed decreased 
fucosylation and increased sialylation of the recombinant model glycoprotein 
secreted human placental alkaline phosphatase produced in CHO microcarrier in 
contrast to suspension culture [6, 255]. 
The choice of virus production medium only slightly affected relative peak 
abundances (media composition: maximal ΙΔRPHΙ = 5.7 %; trypsin activity: 
maximal ΙΔRPHΙ = 14.0 %, table 3) of the HA N-glycan fingerprints. As 
addressed before, nutrient concentrations in the medium and accumulation of 
metabolic by-products may cause such minor variations of the RPH [6]. 
In summary, except for the choice of host cells, the adaptation of host cells to 
serum-free suspension growth and potentially the selection of virus strain, all 
other investigated process modifications resulted only in minor differences 
regarding relative N-glycan structure abundances. This brings up questions 
concerning the possible impact of such variations on the quality of antigens, i.e. 
immunogenicity or efficacy. Recently, de Vries et al. (2012) investigated the 
impact of N-glycosylation on the immunogenicity of recombinant HA, showing 
that HA antigens carrying terminal mannose residues induced significantly lower 
HAI Ab titers than HA modified by complex glycan structures or single N-
acetylglucosamine side chains. However, using a HA1 antigen microarray they 
demonstrated a comparable breadth of Ab response for all tested recombinant 
HA  glycovariants [3, 6]. 
5.5 Impact of HA N-glycosylation on immunogenicity 
The following section 5.5 contains analogous text content and structure taken 
from a paper published together with J. Hütter, D. Höper, P.H. Seeberger, E. 
Rapp and B. Lepenies, January 2013 in J. Immunol. [1]. As described before 
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(section 1, last two paragraphs), scentences and/or paragraphs containing 
quotations are not indicated specifically. The reference will only be given after the 
phrase or paragraph by the number of the quoted reference. 
To investigate the impact of N-glycosylation on immunogenicity of virus 
preparations in vitro as well as in vivo, mouse studies were performed in 
cooperation with Dr. B. Lepenies and J. Hütter (MPI-KG, Potsdam-Golm, 
Germany). Within these studies it was demonstrated that differences in HA N-
glycosylation have a marked impact on immunogenicity in vitro as well as in vivo 
[1]. Studies were performed with β-propiolactone inactivated MDCK and Vero 
cell-derived as well as natively deglycosylated virus preparations. MDCK and 
Vero cells were selected for virus production due to their industrial relevance [1]. 
Whole spleen cell assays demonstrated higher CD69+ frequencies of CD4+ TCR-
HA transgenic T cells as well as increased secretion of IL-2 after stimulation with 
Vero cell-derived virus. These higher levels of CD69 and IL-2 indicated faster T 
cell activation after stimulation with the Vero than with the MDCK cell-derived 
virus. IL-2 is generally produced very early upon Ag stimulation of Th0 cells, 
promoting division, differentiation and survival of T cells, but may also be 
produced by Th1 cells [1, 256]. Interestingly, secretion levels of IFNγ were less 
affected whereas secretion levels of IL-4 were hardly affected at all. Comparable 
Th1/Th2 effector cytokine levels (IFNγ, IL-4) for both glycovariants and higher 
IL-2 levels for Vero cell-derived virus suggest faster recognition and Ag uptake by 
APC of the Vero cell-derived virus preparation. However, a tendency towards 
higher IFNγ-secretion upon splenocyte stimulation with the Vero cell-derived 
virus was observed, although mostly not significant. IFNγ is predominantly 
produced by stimulated Th1 cells, which are essential for viral clearance [1, 257]. 
The differences observed in T cell activation were predominantly mediated by 
CD11c+ DCs as shown in a DC/T cell co-cultivation assay by Hütter et al. [1]. 
Typically DCs, which are part of the innate immunity, take-up the Ag in the 
periphery, at the site of infection and transport it to the regional lymph node or 
the spleen, where they present specific peptides of the processed Ag, and 
activate specific CD4+ and CD8+ T cells (via cross-presentation) by multiple 
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interactions (see section 2.11 and [258]). Usually CD4+ T cells induce optimal T 
cell activation as well as stimulate Ab-producing B plasma cells [259]. However, 
in this study, DCs were demonstrated being crucial for distinct T cell activation by 
means of CD69+ expression (MDCK vs. Vero cell-derived virus) or IL-2, IL-4 and 
IFNγ secretion (glycosylated vs. deglycosylated virus preparations, [1]). So far, 
different DC subsets have been described, being involved in IVA infections. 
These may cause differential T cell activation induced by MDCK and the Vero 
cell-derived virus preparations. For instance CD103+ CD11blow/neg DCs efficiently 
transport Ag to posterior mediastinal lymph nodes, efficiently load viral peptides 
onto MHCI complexes as well as efficiently present them to CD8+ T cells [260]. In 
contrast, although CD103+ CD11bhigh DCs take up Ag even more efficiently, they 
mainly remain in the lung tissue, where they produce proinflammatory cytokines 
[260]. Another subset is represented by CD8α+ DCs, which play a crucial role for 
CTL priming during various infections including IVA infections [261]. However, 
these data may be mouse-specific and not relevant for human vaccine design. In 
a recent human challenge study preexisting CD4+ T cells, but not CD8+ T cells 
correlated with protection and virus clear before Ab responses were stimulated 
[262], thus, highlighting the need for further experiments in human DC and T cell 
models [1]. 
Furthermore, DCs express pathogen pattern recognition receptors, in particular 
C-type lectin receptors (CLRs), such as the macrophage mannose receptor 
(MMR, [263]). The MMR was recently shown to be involved in macrophage 
infection by IVA [264]. In our study the high mannose N-glycan structures 
attached to the Vero, but not to the MDCK cell-derived virus may be specifically 
recognized by such CLRs on splenic CD11c+ DCs and therefore lead to higher 
immunogenicity in vitro with regard to CD69 expression on CD4+ T cells and IL-2 
secretion. Other receptors identified to interact with glycan moieties of IVA 
include macrophage galactose-type lectin (MGL, [265]) and dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN, [266]), 
allowing sialic acid independent virus entry. Also soluble expressed lectins were 
described to interact with glycan moieties of IVA, such as surfactant protein D 
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(SP-D), which is suggested to contribute to viral clearance via IVA-aggregation 
(reviewed in [267]). Another potential cause of differential immunogenicity of 
differentially glycosylated virus preparations observed in this study may also be 
attributed to masking of antigenic epitopes by N-glycan side chains [1, 268, 269]. 
However, in most studies so far discussed only live influenza viruses were used. 
In order to exclude virus replication in mouse cells and resulting changes in N-
glycosylation of virus preparations, β-propiolactone inactivated virus preparations 
were used in this study. Moreover, β-propiolactone treatment was demonstrated 
an ideal IVA-PR8 inactivation method, hardly affecting HA N-glycosylation at all 
(maximal ΙΔRPHΙ = 0.8, [6]). Thus, solely the impact of HA N-glycosylation on 
immunogenicity could be addressed [1]. 
Furthermore, in this study virus preparations of MDCK as well as Vero cell-
derived virus were natively deglycosylated. T cell activation was dramatically 
reduced after deglycosylation of both glycovariants with respect to CD69 
expression of CD4+ TCR-HA transgenic T cells as well as to IL-2, IL-4 and IFNγ 
secretion. Interestingly, the decrease of T cell activation after deglycosylation 
was more pronounced for the Vero than for the MDCK cell-derived virus. This 
may be explained by differential deglycosylation results: deglycosylation 
efficiency of at least about 90 % was achieved for the MDCK as well as the Vero 
cell-derived virus preparation as indicated by signal intensities of the HA N-
glycan fingerprints. However, while the remaining HA N-glycans on the 
deglycosylated MDCK cell-derived virus still represented predominantly MDCK 
cell-specific structures, the HA N-glycans detected for the deglycosylated Vero 
cell-derived virus also comprised various new, most probably truncated N-glycan 
structures with reduced migration times. Altogether, the marked impact of 
removed glycan moieties, e.g. mannose and β-galactose, on T cell activation, 
confirms the dramatic impact of N-glycosylation on immunogenicity in vitro [1]. 
This is in agreement with obtained in vivo data, demonstrating significantly 
reduced HA-specific Ab levels for the deglycosylated virus variants in contrast to 
the glycosylated ones. Thus, HA N-glycosylation markedly impacts the B cell-
mediated, humoral immunity. Interestingly, 14 days after prime immunization HA-
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specific Ab levels induced by the MDCK cell-derived virus were significantly 
higher than levels induced by the Vero cell-derived virus. HAI-titers in mouse 
sera after prime-boost immunization with the MDCK cell-derived virus were still 
markedly higher at 28 days than HAI-titers induced by the Vero cell-derived virus. 
This is consistent with findings by de Vries et al., demonstrating higher HAI 
activities for HA carrying complex N-glycans or single GlcNAc residues than for 
HA carrying high mannose structures [3]. In agreement with that, Lin et al. 
showed very recently that complex terminally sialated and asialyated-galactose 
type N-glycans induced higher-quality antibodies (i.e. higher neutralizing titers) 
after immunization in mice than pauci-mannose or high-mannose type N-glycans 
did [2]. Interestingly, Lin et al. observed higher total HA-specific Ab titers and 
stronger T cell responses for HA carrying pauci-mannose or high-mannose type 
N-glycans [2]. The second is consistent with our findings of stronger T cell 
activation after immunization with Vero (complex β-galactose and high-mannose 
type N-glycans) than with MDCK cell-derived virus (complex α- and β-galactose 
type N-glycans). Altogether these results indicated differential impact of HA N-
glycosylation on B cell and T cell mediated immune responses [1]. 
Furthermore, TCR-HA splenic T cells were purified, labeled and adoptively 
transferred into wt mice. Although splenic T cell proliferation upon immunization 
was comparable for the MDCK and the Vero cell-derived virus, the frequency of 
IL-2 producing, transferred T cells was higher upon immunization with the Vero 
cell-derived virus. This is consistent with the in vitro data indicating a faster T cell 
activation upon immunization with Vero cell-derived virus. On the other hand the 
MDCK cell-derived virus induced higher HA-specific Ab titers 14 days after prime 
immunization. This clearly indicates that MDCK cell-specific HA N-glycosylation 
triggers a pronounced humoral immune response [1]. 
In summary, these data suggest that Vero cell-specific HA N-glycosylation 
stronger promotes cellular immunity whereas MDCK cell-specific HA N-
glycosylation stronger promotes humoral immunity. Although a dramatic effect of 
HA N-glycosylation on immunogenicity was demonstrated in vitro as well as in 
vivo, further investigations are required to address the impact of HA N-
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glycosylation on vaccine’s efficacy and safety and to finally identify critical quality 
attributes for animal and human vaccines [1]. 
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6 Conclusion and outlook 
6.1 Impact of cultivation conditions on HA N-glycosylation 
In this study, multiple process conditions were investigated for their impact on HA 
N-glycosylation. Thereby, most tested process modifications resulted only in 
minor differences in HA N-glycan fingerprints regarding relative N-glycan 
structure abundances. Hence, HA N-glycosylation seems a rather robust protein 
modification, which is only slightly affected with respect to RPH for most process 
variations tested including variation of virus passages, virus seed suppliers, virus 
adaptation statuses, composition as well as trypsin activity of virus production 
media, virus production vessels and time points of virus harvest. Moreover, 
Rödig et al. demonstrated that also different virus production temperatures 
(33 °C, 37 °C, 39 °C) only slightly impacted relative N-glycan structure 
abundances and interestingly final β-propiolactone inactivation did basically not 
change HA N-glycan fingerprints at all, making it an ideal inactivation method for 
manufacturing influenza vaccines [6]. However, this study identified a few 
cultivation conditions, which affect HA N-glycosylation significantly with respect to 
N-glycan structure presence as well as relative N-glycan structure abundances. 
These included the use of different host cell lines, the adaptation status of the 
host cell line to serum-requiring adherent or serum-free suspension growth and 
potentially the selected virus strain. 
Overall, these results demonstrate that the HA N-glycosylation pattern of IVA is 
remarkably stable, regarding changes in the production process. In particular, 
small variations in a production process are unlikely to change the HA N-
glycosylation dramatically and therefore, it can be assumed that wanted and 
unwanted process variations in influenza vaccine manufacturing have only a 
minor or no impact on product quality. However, the impact of changes in glycan 
profiles, i.e. N-glycan structure presence as well as relative N-glycan structure 
abundance, on properties of live and dead vaccines, e.g. safety and efficacy as 
well as its mechanisms should be further characterized in more detail [4, 6]. 
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However, other factors may impact HA N-glycosylation and remain to be 
investigated. These include the host cell status (cell cycle: G1,G0, etc. as well as 
physiological cell status: virus produced in different time slots: e.g. 0-12 hpi, 12-
24 hpi, 24-48 hpi, …), cell density, multiplicity of infection for the virus production 
phase, other media compositions and media supplements, methods for virus 
harvest (e.g. gradient step centrifugation, filtration), virus inactivation by formalin 
and Triton X-100, methods for virus purification and concentration (e.g. sucrose 
density gradient, affinity and pseudo-affinity chromatography, hydrophobic 
interaction chromatography, SEC, ion-exchange chromatography), detergent 
treatment for HA/NA isolation as used for split and subunit vaccines, benzonase 
treatment for DNA reduction and the dilution in formulation buffer. Moreover, the 
impact of cultivation conditions on NA N-glycosylation should be investigated. 
Furthermore, N-glycan structure elucidation is of special importance for further 
data interpretation and project development and could be achieved by parallel 
MS/MS- and CGE-LIF-based approaches. 
In conclusion, monitoring HA N-glycosylation patterns during vaccine production 
processes allows not only to investigate the impact of process modifications on 
antigen quality, but also offers a sensitive tool to evaluate consequences of 
unwanted process variations or process failures [4]. 
6.2 Fitness gain by virus adaptation and identification of key mutations 
Taken together, this study demonstrated that the adaptation of virus seeds to 
new host cell lines was often necessary for sufficient high virus titers. However, 
the degree of titer enhancement by virus adaptation depends on host cell 
characteristics as well as on viruses. For two IVA-PR8 strains significantly 
increased final titers within shorter cultivation times were achieved by virus 
adaptation from MDCK cells to Vero cells. Interestingly, for all virus strains 
investigated, the HA N-glycan fingerprint stabilized latest with the second 
passage in a new cell line. The faster release of virus particles and the further 
increase in HA-titers, which are mostly observed during the first passages in the 
new host indicate that other factors are as well involved in the adaptation 
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process, i.e. changes in the sequence of the viral genome resulting in improved 
fitness of virus subpopulations [4]. 
Amino acid substitutions within the stem region of HA and/or within the NP- 
and/or PB2-binding domain of NP and/or the transmembrane region of NA and/or 
the CPSF30- and/or elF4G1-binding domain of NS1 rescued the virus population 
and ensured efficient virus replication in the new host [4]. The fitness of these 
adapted virus variants during backward adaptation to MDCK cells varies – some 
variants as the K460E (RKI) replicate well and infect either cell line while others 
grow only poorly in one cell line (e.g. S457L (RKI) in MDCK cells, [4]). This 
fitness gain of adapted viruses was also shown in the direct comparison of non-
adapted virus seeds, Vero cell-adapted viruses as well as Vero cell-adapted and 
back-adapted viruses. The non-adapted viruses hardly replicated during the first 
days after infection, whereas Vero cell-adapted as well as back-adapted viruses 
replicated well from the very beginning. The improved virus fitness of adapted 
viruses is consistent with the sequencing data, since several substitutions 
occurring after adaptation to Vero cells, persisted during back-adaptation to 
MDCK cells. This persistence of substitutions strongly indicates no or only small 
disadvantages for replication in MDCK cells. Moreover, quasispecies analysis 
during virus adaptation of MDCK cell-derived virus seeds identified potential key 
mutations allowing sufficient virus replication in Vero cells. In particular mutations 
within the stem region of the HA molecule, tuning the HA pH-stability, seemed to 
be necessary to adapt to Vero cells’ endosomal pH. Furthermore, substitutions 
within the NP- and PB2-binding sites of the NP molecule may significantly 
contribute to Vero cell adaptation of different IVA-PR8 strains. For the NA 
molecule the N-terminal transmembrane region was identified as potentially 
contributing to successful virus adaptation. Last but not least, substitutions within 
the CPSF30- and/or the elF4G1-binding domains of the NS1 molecule were 
identified as potential key factors for efficient virus replication in the new host cell 
line. In a next step, each substitution’s contribution to successful virus adaptation 
should be characterized in more detail using reverse genetics. In general, due to 
the time frame required for efficient virus replication in the new host (RKI- and 
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NIBSC-strain adaptation from MDCK to Vero cells and back; passage 1; HA-titer 
increase not before 216 hpi and 168 hpi, respectively), we can certainly assume 
that most substitutions detected during virus adaptation were caused by 
mutations which were then selected for, rather than solely selection events. 
6.3 Impact of HA N-glycosylation on immunogenicity 
It was demonstrated that the Vero cell-specific HA N-glycosylation shows a bias 
towards the cellular immune response, whereas MDCK cell-specific HA N-
glycosylation more promotes the humoral immune response. In order to identify 
key characteristics for optimal HA N-glycosylation other IVA-PR8 glycovariants, 
including egg-, AGE1.CR/.pIX-, MDCK.SUS2-derived virus preparations should 
be characterized with respect to their immunogenicity using in vitro and in vivo 
approaches and (transgenic) mouse or other animal models (e.g. ferret, pig). 
Moreover, screening of virus preparations derived from glycosylation-deficient 
cell lines such as HEK293S and CHO 15B cells (both deficient in N-
acetylglucosaminyltransferase I) would complement this approach. However, 
glycosylation-deficient cell lines should be selected with care, since some have 
been described as not very susceptible to IVA infections [270, 271]. Another 
approach is the generation of (conditional) knock-out cell lines as well as knock-
in cell lines. This would allow to directly design optimal product glycosylation, i.e. 
HA N-glycosylation for optimal vaccine efficacy [272-274]. Moreover, the 
mechanisms by which the Vero cell-derived virus shows a bias towards cellular 
immunity and the MDCK cell-derived virus towards humoral immunity should 
further be investigated. Therefore, in vitro studies using TCR-HA transgenic and 
wt mouse models would allow focusing on MHCI- and MHCII-mediated 
responses, whereas in vivo studies using wt models would address the complete 
range of immune responses. Within such studies, CD40 expression would 
identify levels of mature/immature DCs, its expression also indicates cell 
adhesion, cell proliferation and signal transduction in B cells [275]. Investigating 
the expression of the co-stimulatory ligands B7.1 (CD80) and B7.2 (CD86) and 
its interaction with CD28 would further characterize the mechanisms how 
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glycosylation impacts T-, B cell and DC activation, co-stimulation and 
immunoregulation. Monitoring CD74 expression would give more insights 
regarding the regulation of T- and B-cell interactions, their development, 
activation, growth and motility. Furthermore, the expression of MHCI and MHCII 
levels on DCs would give more insights into DC Ag processing and presentation. 
Also, T cells (CD3+) and B cells (CD19+, B220+) from other lymphatic organs than 
the spleen should be characterized for CD4, CD8, CD69 expression and CD22 
(B cell activation marker) respectively. However, especially memory CD8 T cells 
and CD4 T cells have been described to mediate heterosubtypic immunity, i.e. 
protection of severe disease by prior infection with a virus of a different subtype 
[276, 277]. Therefore, the ability of the different virus variants (in particular MDCK 
and Vero cell-derived virus) to cross-protect should be investigated for example 
in challenge studies. The most robust protection may be provided by 
simultaneous induction of multiple immune pathways of the cellular as well as the 
humoral immunity. Thus optimal HA N-glycosylation for B cell-, CD4+ and CD8+ T 
cell-mediated immune responses should be identified with respect to 
heterosubtypic (cross-protection) and homotypic (no cross protection between 
different virus subtypes) immunity. Moreover, the relevance of HA N-
glycosylation in humans should be addressed in more detail, using human DCs 
and peripheral blood mononuclear cell (PBMCs). Finally, the role of N-
glycosylation could be evaluated by specifically designed and synthesized 
glycopeptides (most advisable in cooperation with experts in the field). 
Altogether, this would finally allow the definition of ideal cultivation conditions for 
influenza virus vaccine production, the development of an optimally glyco-
engineered production cell line, improved vaccine formulations substituted with 
specific glycan structures and/or directed chemical N-glycan synthesis onto viral 
peptides. 
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12.1 Impact of different IVA production cells on HA N-glycosylation 
(MDCK.SUS2 and MDCK.SUS3 cells included) 
 
figure S 1: HA N-glycosylation fingerprints derived from viruses produced in different host 
cells. 
The RKI-strain (IVA-PR8) was produced in adherently growing Vero cells (i) of African green 
monkey origin or MDCK (ii) cells of canine origin. Furthermore, the adherently growing MDCK cell 
line was adapted to suspension growth in two biological independent settings generating the in 
suspension growing MDCK.SUS2 (iii) and MDCK.SUS3 (iv) cell line. Additional suspension cells 
such as human-derived Cap cells (v) or duck-derived AGE1.CR.pIX cells (vi) were used for virus 
production. Finally, cell culture-derived virus was compared with virus produced in embryonated 
hen’s eggs (vii). 
12 Supplementary 
S2 
12.2 Host cell adaptation to serum-free suspension growth 
 
figure S 2: Impact of host cell adaptation to serum-free suspension growth on the HA N-
glycosylation pattern of the NIBSC-strain. 
(A) HA N-glycan fingerprints, relative fluorescence units (RFU) are plotted over the migration time 
(tmig) in normalized migration time units (MTU’). [6] All peaks exceeding the 10x baseline noise 
threshold (∙∙∙) in at least one fingerprint are annotated. The non-adapted, serum requiring, 
adherent MDCK cell line (i) was adapted to serum-free suspension growth (ii, MDCK.SUS1) and 
further adapted to better growth characteristics (iii, MDCK.SUS2) [142]. The first adaptation step 
was performed in biological duplicates (iv, MDCK.SUS3). (B) Overlay of all four N-glycosylation 
fingerprints. (C) Relative peak height (RPH) in % of the total peak height (TPH, sum of all 
annotated peaks) displaying relative peak abundance. Peaks are defined high abundant if 
RPH > 5 % (---). 
12 Supplementary 
S3 
12.3 Impact of different virus suppliers in MDCK.SUS2 cells 
 
figure S 3: Comparison of HA N-glycosylation pattern of two IVA-PR8 strains from different 
suppliers. 
(A) HA N-glycan fingerprints, relative fluorescence units (RFU) are plotted over the migration time 
(tmig) in normalized migration time units (MTU’). All peaks exceeding in at least one of the two 
fingerprints the 10x baseline noise threshold are annotated (1 - 15). The virus was purchased 
from the Robert Koch Institute (RKI, i) or from NIBSC (ii). (B) Relative peak height (RPH) in % of 
the total peak height (TPH, sum of all annotated peaks) displays relative peak abundance. 
12.4 Similarity of HA N-glycan fingerprints derived from different viruses 
produced in MDCK cells 
 
figure S 4: Differences of relative peak height (|ΔRPH|) for different viruses produced in 
MDCK cells. 
The differences of RPH between two different H1N1 virus strains (□) and two different H3N2 virus 
strains (■) are smaller than the differences over all tested viruses (■): the variation of relative 
peak abundance within a virus subtype is smaller than over different subtypes. 
 
12 Supplementary 
S4 
12.5 HA-Titers in MDCK cells during virus adaptation 
table S 1: MDCK cell-derived HA-titers during virus adaptation. 
The RKI- and the NIBSC-strain were adapted from MDCK (seed virus, passage 1) to Vero (passages 2-6) 
and back to MDCK cells (passages 7-11). 
passage 
(no.)
hours post infection 
(hpi)
HA-titer 
(HAU)
passage 
(no.)
hours post infection 
(hpi)
HA-titer 
(HAU)
1 24 1.9 1 24 2.2
7 96 2.5 7 96 2.1
8 48 2.0 8 48 2.4
8 72 2.0 8 72 2.4
9 96 2.2 9 96 2.4
10 48 2.3 10 48 2.6
10 72 2.2 10 72 2.5
11 96 2.2 11 96 2.4
RKI-strain NIBSC-strain
 
12 Supplementary 
 
12.6 Supplementary tables 
table S 2: Accession numbers for IVA-PR8 sequences during virus adaptation. 
(1)-(6) Adaptation from MDCK to Vero cells and back or from MDCK to Vero cells (7). The original virus seed was either purchased from the 
National Institute for Biological Standards and Control (NIBSC) or the Robert Koch Institute (RKI). (1, 4) The first virus passages, produced in 
MDCK cell culture (M1), served as virus seed for the first passages in Vero cells. (2, 5) The last of five consecutive Vero cell-derived virus 
passages (V5) served as seed for five consecutive MDCK cell-derived virus passages, of which M6 (3, 6) represents the last [4]. (7) The fourth 
virus passage in Vero cells represents the Vero-adapted seed virus generated by Genzel et al. [72]. This seed was used within the 
immunogenicity studies in cooperation with Dr. B. Lepenies and J. Hütter (MPI-KG, Potsdam-Golm, Germany). All sequences were generated by 
pyrosequencing and are deposited in the GISAID EpiFlu database (www.gisaid.org, [4]). 
no. Segment_Ids Isolate_Name 
Passage 
History 
Seq_Id (HA) 
1 EPI304412 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
RKI-M1 (H1N1) 
P5 
utf_rki-m1-ges_unambig_HA_Segment4_00001 
length=1769 numreads=9121 
2 EPI304420 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
RKI-V5 (H1N1) 
P10 
utf_rki-v5-ges_unambig_HA_Segment4_00001 
length=1763 numreads=3748 
3 EPI304428 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
RKI-M6 (H1N1) 
P15 
mutf_rki-m6-ges_unambig_HA_Segment4_00001, 
1..1761  length=1760   numreads=2824 
4 EPI304436 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
NIBSC-M1 (H1N1) 
P4 
mutf_nibsc-m1-ges_unambig_HA_Segment4_00001 
length=1762 numreads=4279 
5 EPI304444 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
NIBSC-V5 (H1N1) 
P9 
ctf_nibsc-v5-ges_unambig_HA_Segment4_00001 
length=1760 numreads=3493 
6 EPI304452 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
NIBSC-M6 (H1N1) 
P14 
mutf_nibsc-m6-ges_unambig_HA_Segment4_00001, 
1..1759  length=1760   numreads=8589 
7 EF.190974.1 
A/MDCK/Germany/[A/Puerto Rico/8/1934]- 
RKI-V4genzel2010 (H1N1) 
P7 
segment 4 contig00006  gi|145322834|gb|EF190974.1|, 
1..1778  length=1778   numreads=23028 
 
12 Supplementary 
 
table S 3: Overview of relative peak height (RPH) averages and according standard (SD) and relative standard deviations (RSD). 
The average RPH and the respective SD and RSD of each peak (no. 1 - 25) within each experiment (control 1: pattern stability for ten consecutive 
virus passages; control 2: reproducibility in Vero or MDCK time series; adaptation series of H1N1 from RKI and adaptation series of H1N1 from 
NIBSC) are listed. The factors indicate x–fold increase (> 1) or decrease (< 1) of respective deviations observed during adaptation compared to 
the maximal deviation during controls. Factors of > 3 are defined as significantly influenced during adaptation and are highlighted in blue bold 
numbers. Reprinted with permission [4]. 
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12.7 cDNA consensus sequences of the RKI- and the NIBSC-strain from 
passage 1 
12.7.1 >Segment_1_RKI_PB2 
aTGGAAAGAATAAAAGAACTAAGAAATCTAATGTCGCAGTCTCGCACCCGCG
AGATACTCACAAAAACCACCGTGGACCATATGGCCATAATCAAGAAGTACAC
ATCAGGAAGACAGGAGAAGAACCCAGCACTTAGGATGAAATGGATGATGGC
AATGAAATATCCAATTACAGCAGACAAGAGGATAACGGAAATGATTCCTGAG
AGAAATGAGCAAGGACAAACTTTATGGAGTAAAATGAATGATGCCGGATCA
GACCGAGTGATGGTATCACCTCTGGCTGTGACATGGTGGAATAGGAATGGA
CCAATGACAAATACAGTTCATTATCCAAAAATCTACAAAACTTATTTTGAAAG
AGTCGAAAGGCTAAAGCATGGAACCTTTGGCCCTGTCCATTTTAGAAACCAA
GTCAAAATACGTCGGAGAGTTGACATAAATCCTGGTCATGCAGATCTCAGTG
CCAAGGAGGCACAGGATGTAATCATGGAAGTTGTTTTCCCTAACGAAGTGG
GAGCCAGGATACTAACATCGGAATCGCAACTAACGATAACCAAAGAGAAGA
AAGAAGAACTCCAGGATTGCAAAATTTCTCCTTTGATGGTTGCATACATGTT
GGAGAGAGAACTGGTCCGCAAAACGAGATTCCTCCCAGTGGCTGGTGGAA
CAAGCAGTGTGTACATTGAAGTGTTGCATTTGACTCAAGGAACATGCTGGG
AACAGATGTATACTCCAGGAGGGGAAGTGAGGAATGATGATGTTGATCAAA
GCGTGATTATTGCTGCTAGGAACATAGTGAGAAGAGCTGCAGTATCAGCAG
ACCCACTAGCATCTTTATTGGAGATGTGCCACAGCACACAGATTGGTGGAAT
TAGGATGGTAGACATCCTTAGGCAGAACCCAACAGAAGAGCAAGCCGTGGA
TATATGCAAGGCTGCAATGGGACTGAGAATTAGCTCATCCTTCAGTTTTGGT
GGATTTACATTTAAGAGAACAAGCGGATCATCAGTCAAGAGAGAGGAAGAG
GTGCTTACGGGCAATCTTCAAACATTGAAGATAAGAGTGCATGAGGGATAT
GAAGAGTTCACAATGGTtGGGAGAAGAGCAACAGCCATACTCAGAAAAGCA
ACCAGGAGATTGATTCAGCTGATAGTGAGTGGGAGAGACGAACAGTCGATT
GCCGAAGCAATAATTGTGGCCATGGTATTTTCACAAGAGGATTGTATGATAA
AAGCAGTTAGAGGTGATCTGAATTTCGTCAATAGGGCGAATCAGCGACTGA
ATCCTATGCATCAACTTTTAAGACATTTTCAGAAGGATGCGAAAGTGCTTTTT
CAAAATTGGGGAGTTGAACCTATCGACAATGTGATGGGAATGATTGGGATAT
12 Supplementary 
S8 
TGCCCGACATGACTCCAAGCATCGAGATGTCAATGAGAGGAGTGAGAATCA
GCAAAATGGGTGTAGATGAGTACTCCAGCACGGAGAGGGTAGTGGTGAGC
ATTGACCGGTTTTTGAGAGTCCGGGACCAACGAGGAAATGTACTACTGTCT
CCCGAGGAGGTCAGTGAAACACAGGGAACAGAGAAACTGACAATAACTTAC
TCATCGTCAATGATGTGGGAGATTAATGGTCCTGAATCAGTGTTGGTCAATA
CCTATCAATGGATCATCAGAAACTGGGAAACTGTTAAAATTCAGTGGTCCCA
GAACCCTACAATGCTATACAATAAAATGGAATTTGAACCATTTCAGTCTTTAG
TACCTAAGGCCATTAGAGGCCAATACAGTGGGTTTGTAAGAACTCTGTTCCA
ACAAATGAGGGATGTGCTTGGGACATTTGATACCGCACAGATAATAAAACTT
CTTCCCTTCGCAGCCGCTCCACCAAAGCAAAGTAGAATGCAGTTCTCCTCAT
TTACTGTGAATGTGAGGGGATCAGGAATGAGAATACTTGTAAGGGGCAATT
CTCCTGTATTCAACTACAACAAGGCCACGAAGAGACTCACTGTTCTCGGAAA
GGATGCTGGCACTTTAACCGAAGACCCAGATGAAGGCACTGCTGGAGTGG
AGTCCGCTGTTCTGAGGGGATTCCTCATTCTGGGCAAAGAAGACAGGAGAT
ATGGGCCAGCATTAAGCATCAATGAACTGAGCAACCTTGCGAAAGGAGAGA
AGGCTAATGTGCTAATTGGGCAAGGAGACGTGGTGTTGGTAATGAAACGGA
AACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGACCAAAAGAATTC
GGATGGCCATCAATTAGTGTCGAAtaGTT 
12.7.2 >Segment_1_NIBSC_PB2 
CGAAAGACAGGTaCAAATAaTATTCAATATGGAAAGAATAAAAGAACTAAGAA
ATCTAATGTCGCAGTCTCGCACCCGCGAGATACTCACAAAAACCACCGTGG
ACCATATGGCCATAATCAAGAAGTACACATCAGGAAGACAGGAGAAGAACC
CAGCACTTAGGATGAAATGGATGATGGCAATGAAATATCCAATTACAGCAGA
CAAGAGGATAACGGAAATGATTCCTGAGAGAAATGAGCAAGGACAAACTTT
ATGGAGTAAAATGAATGATGCCGGATCAGACCGAGTGATGGTATCACCACT
GGCTGTGACATGGTGGAATAGGAATGGACCAATAACAAATACAGTTCATTAT
CCAAAAATCTACAAAACTTATTTTGAAAGAGTCGAAAGGCTAAAGCATGGAA
CCTTTGGCCCTGTCCATTTTAGAAACCAAGTCAAAATACGTCGGAGAGTTGA
CATAAATCCTGGTCATGCAGATCTCAGTGCCAAGGAGGCACAGGATGTAAT
CATGGAAGTTGTTTTCCCTAACGAAGTGGGAGCCAGGATACTAACATCGGA
12 Supplementary 
S9 
ATCGCAACTAACGATAACCAAAGAGAAGAAAGAAGAACTCCAGGATTGCAA
AATTTCTCCTTTGATGGTTGCATACATGTTGGAGAGAGAACTGGTCCGCAAA
ACGAGATTCCTCCCAGTGGCTGGTGGAACAAGCAGTGTGTACATTGAAGTG
TTGCATTTGACTCAAGGAACATGCTGGGAACAGATGTATACTCCAGGAGGG
GAAGTGAGGAATGATGATGTTGATCAAAGCTTGATTATTGCTGCTAGGAACA
TAGTGAGAAGAGCTGCAGTATCAGCAGATCCACTAGCATCTTTATTGGAGAT
GTGCCACAGCACACAGATTGGTGGAATTAGGATGGTAGACATCCTTAGGCA
GAACCCAACAGAAGAGCAAGCCGTGGATATATGCAAGGCTGCAATGGGACT
GAGAATTAGCTCATCCTTCAGTTTTGGTGGATTCACATTTAAGAGAACAAGC
GGATCATCAGTCAAGAGAGAGGAAGAGGTGCTTACGGGCAATCTTCAAACA
TTGAAGATAAGAGTGCATGAGGGATATGAAGAGTTCACAATGGTtGGGAGAA
GAGCAACAGCCATACTCAGAAAAGCAACCAGGAGATTGATTCAGCTGATAG
TGAGTGGGAGAGACGAACAGTCGATTGCCGAAGCAATAATTGTGGCCATGG
TATTTTCACAAGAGGATTGTATGATAAAAGCAGTCAGAGGTGATCTGAATTT
CGTCAATAGGGCGAATCAGCGATTGAATCCTATGCATCAACTTTTAAGACAT
TTTCAGAAGGATGCGAAAGTGCTTTTTCAAAATTGGGGAGTTGAACCTATCG
ACAATGTGATGGGAATGATTGGGATATTGCCCGACATGACTCCAAGCATCG
AGATGTCAATGAGAGGAGTGAGAATCAGCAAAATGGGTGTAGATGAGTACT
CCAGCACGGAGAGGGTAGTGGTGAGCATTGACCGTTTTTTGAGAATCCGGG
ACCAACGAGGAAATGTACTACTGTCTCCCGAGGAGGTCAGTGAAACACAGG
GAACAGAGAAACTGACAATAACTTACTCATCGTCAATGATGTGGGAGATTAA
TGGTCCTGAATCAGTGTTGGTCAATACCTATCAATGGATCATCAGAAACTGG
GAAACTGTTAAAATTCAGTGGTCCCAGAACCCTACAATGCTATACAATAAAA
TGGAATTTGAACCATTTCAGTCTTTAGTACCTAAGGCCATTAGAGGCCAATA
CAGTGGGTTTGTAAGAACTCTGTTCCAACAAATGAGGGATGTGCTTGGGAC
ATTTGATACCGCACAGATAATAAAACTTCTTCCCTTCGCAGCCGCTCCACCA
AAGCAAAGTAGAATGCAGTTCTCCTCATTTACTGTGAATGTGAGGGGATCAG
GAATGAGAATACTTGTAAGGGGCAATTCTCCTGTATTCAACTATAACAAGGC
CACGAAGAGACTCACAGTTCTCGGAAAGGATGCTGGCACTTTAACTGAAGA
CCCAGATGAAGGCACAGCTGGAGTGGAGTCCGCTGTTCTGAGGGGATTCC
TCATTCTGGGCAAAGAGGACAAGAGATATGGGCCAGCACTAAGCATCAATG
12 Supplementary 
S10 
AACTGAGCAACCTTGCGAAAGGAGAGAAGGCTAATGTGCTAATTGGGCAAG
GAGACGTGGTGTTGGTAATGAAACGGAAACGGGACTCTAGCATACTTACTG
ACAGCCAGACAGCGACCAAAAGAaTTCGGATGGCCATCAATTAGTGTCGAAt
AGTTTAAAacgaCc 
12.7.3 >Segment_2_RKI_PB1_PB1-F2 
AcCAttGaATGGATGTCAATCCGACCtTACTTTTCTTAAAAGTGCCAGCACAAA
ATGCTATAAGCACAACTTTCCCTTATACTGGAGACCCTCCTTACAGCCATGG
GACAGGAACAGGATACACCATGGATACTGTCAACAGGACACATCAGTACTC
AGAAAAGGGAAGATGGACAACAAACACCGAAACTGGAGCACCGCAACTCAA
CCCGATTGATGGGCCACTGCCCGAAGACAATGAACCAAGTGGTTATGCCCA
AACAGATTGTGTATTGGAAGCAATGGCTTTCCTTGAGGAATCCCATCCTGGT
ATTTTTGAAAACTCGTGTATTGAAACGATGGAGGTTGTTCAGCAAACACGAG
TAGACAAGCTGACACAAGGCCGACAGACCTATGACTGGACTCTAAATAGAA
ACCAGCCTGCTGCAACAGCATTGGCCAACACAATAGAAGTGTTCAGATCAA
ATGGCCTCGCGGCCAATGAGTCTGGAAGGCTCATAGACTTCCTTAAGGATG
TAATGGAGTCAATGAACAAAGAAGAAATGGGGATCACAACTCATTTCCAGAG
AAAGAGACGGGTGAGAGACAATGTGACTAAGAAAATGATAACACAGAGAAC
AATAGGTAAAAGGAAGCAGAGATTGAACAAAAGGAGTTATCTAATTAGAGCA
TTGACCCTGAACACAATGACCAAAGATGCTGAGAGAGGGAAGCTAAAACGG
AGAGCAATTGCAACCCCAGGGATGCAAATAAGGGGGTTTGTATACTTTGTT
GAGACACTGGCAAGGAGTATATGTGAGAAACTTGAACAATCAGGGTTGCCA
GTTGGAGGCAATGAGAAGAAAGCAAAGTTGGCAAATGTTGTAAGGAAGATG
ATGACCAATTCTCAGGACACCGAACTTTCTTTCACCATCACTGGAGATAACA
CCAAATGGAACGAAAATCAGAATCCTCGGATGTTTTTGGCCATGATCACATA
TATGACCAGAAATCAGCCCGAATGGTTCAGAAATATTCTAAGTATTGCTCCA
ATAATGTTCTCAAACAAAATGGCGAGACTGGGAAAAGGGTATATGTTTGAGA
GCAAGAGTATGAAACTTAGAACTCAAATACCTGCAGAAATGCTAGCAAGCAT
TGATTTGAAATATTTCAATGATTCAACAAGAAAgaagATTGAAAAAATCCGACC
GCTCTTAATAGAGGGGACTGCATCATTGAGCCCTGGaATGATGATGGGCAT
GTTCAATATGTTAAGCACTGTATTAGGCGTCTCCATCCTGAATCTTGGACAA
12 Supplementary 
S11 
AAGaGATACACCAAGACTACTTACTGGTGGGATGGTCTTCAATCCTCTGACG
ATTTTGCTCTGATTGTGAATGCACCCAATCATGAAGGGATTCAAGCCGGAGT
CGACAGGTTTTATCGAACCTGTAAGCTACTTGGAATCAATATGAGCAAGAAA
AAGTCTTACATAAACAGAACAGGTACATTTGAATTCACAAGTTTTTTCTATCG
TTATGGGTTTGTTGCCAATTTCAGCATGGAGCTTCCCAGTTTTGGGGTGTCT
GGGATCAACGAGTCAGCGGACATGAGTATTGGAGTTACTGTCATCAAAAAC
AATATGATAAACAATGATCTTGGTCCAGCAACAGCTCAAATGGCCCTTCAGT
TGTTCATCAAAGATTACAGGTACACGTACCGATGCCATAGAGGTGACACACA
AATACAAACCCGAAGATCATTTGAAATAAAGAAACTGTGGGAGCAAACCCGT
TCCAAAGCTGGACTGTTGGTCTCCGACGGAGGCCCAAATTTGTACAACATT
AGAAATCTCCACATTCCTGAAGTCTGCCTAAAATGGGAATTGATGGATGAGG
ATTACCAGGGGCGTTTATGCAACCCACTGAACCCATTTGTCAGCCATAAAGA
AATTGAATCAATGAACAATGCAGTGATGATGCCAGCACATGGTCCAGCCAAA
AACATGGAGTATGATGCTGTTGCAACAACACACTCCTGGATCCCCAAAAGAA
ATCGATCCATCTTGAATACAAGTCAAAGAGGAGTACTTGAAGATGAACAAAT
GTACCAAAGGTGCTGCAATTTATTTGAAAAATTCTTCCCCAGCAGTTCATAC
AGAAGACCAGTCGGGATATCCAGTATGGTGGAGGCTATGGTTTCCAGAGCC
CGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGAAAGAAGAGT
TCACTGAGATCATGAAGATCTGTTCCACCATTGAAGAGCTCAGACGGCAAAA
A 
12.7.4 >Segment_2_NIBSC_PB1_PB1-F2 
GGcAaCCATTtGAATGGaTGTCAATCCGACCTTACTTTTCTTAAAaGTGCCAG
CACAAAATGCTATAAGCACAACTTTCCCTTATACTGGAGACCCTCCTTACAG
CCATGGGACAGGAACAGGATACACCATGGATACTGTCAACAGGACACATCA
GTACTCAGAAAAGGGAAGATGGACAACAAACACCGAAACTGGAGCACCGCA
ACTCAACCCGATTGATGGGCCACTGCCAGAAGACAATGAACCAAGTGGTTA
TGCCCAAACAGATTGTGTATTGGAGGCGATGGCTTTCCTTGAGGAATCCCAT
CCTGGTATTTTTGAAAACTCGTGTATTGAAACGATGGAGGTTGTTCAGCAAA
CACGAGTAGACAAGCTGACACAAGGCCGACAGACCTATGACTGGACTCTAA
ATAGAAACCAACCTGCTGCAACAGCATTGGCCAACACAATAGAAGTGTTCA
12 Supplementary 
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GATCAAATGGCCTCACGGCCAATGAGTCTGGAAGGCTCATAGACTTCCTTA
AGGATGTAATGGAGTCAATGAACAAAGAAGAAATGGGGATCACAACTCATTT
TCAGAGAAAGAGACGGGTGAGAGACAATATGACTAAGAAAATGATAACACA
GAGAACAATGGGTAAAAAGAAGCAGAGATTGAACAAAAGGAGTTATCTAATT
AGAGCATTGACCCTGAACACAATGACCAAAGATGCTGAGAGAGGGAAGCTA
AAACGGAGAGCAATTGCAACCCCAGGGATGCAAATAAGGGGGTTTGTATAC
TTTGTTGAGACACTGGCAAGGAGTATATGTGAGAAACTTGAACAATCAGGGT
TGCCAGTTGGAGGCAATGAGAAGAAAGCAAAGTTGGCAAATGTTGTAAGGA
AGATGATGACCAATTCTCAGGACACCGAACTTTCTTTCACCATCACTGGAGA
TAACACCAAATGGAACGAAAATCAGAATCCTCGGATGTTTTTGGCCATGATC
ACATATATGACCAGAAATCAGCCCGAATGGTTCAGAAATGTTCTAAGTATTG
CTCCAATAATGTTCTCAAACAAAATGGCGAGACTGGGAAAAGGGTATATGTT
TGAGAGCAAGAGTATGAAACTTAGAACTCAAATACCTGCAGAAATGCTAGCA
AGCATCGATTTGaaaTATTTCAATGATTCAACAAGAAAGAAGATTGAAAAAAT
CCGATCGCTCTTAATAGAGGGGACTGCATCATTGAGCCCTGGAATGATGAT
GGGCATGTTCAATATGTTAAGCACTGTATTAGGCGTCTCCATCCTGAATCTT
GGACAAAAGaGATACACCAAGACTACTTACTGGTGGGATGGTCTTCAATCCT
CTGACGATTTTGCTCTGATTGTGAATGCACCCAATCATGAAGGGATTCAAGC
CGGAGTCGACAGGTTTTATCGAACCTGTAAGCTACTTGGAATCAATATGAGC
AAGAAAAAGTCTTACATAAACAGAACAGGTACATTTGAATTCACAAGTTTTTT
CTATCGTTATGGGTTTGTTGCCAATTTCAGCATGGAGCTTCCCAGTTTTGGG
GTGTCTGGGATCAACGAGTCAGCGGACATGAGTATTGGAGTTACTGTCATC
AAAAACAATATGATAAACAATGATCTTGGTCCAGCAACAGCTCAAATGGCCC
TTCAGTTGTTCATCAAAGATTACAGGTACACGTACCGATGCCATAGAGGTGA
CACACAAATACAAACCCGAAGATCATTTGAAATAAAGAAACTGTGGGAGCAA
ACCCGTTCCAAAGCTGGACTGCTGGTCTCCGACGGAGGCCCAAATTTATAC
AACATTAGAAATCTCCACATTCCTGAAGTCTGCCTAAAATGGGAATTGATGG
ATGAGGATTACCAGGGGCGTTTATGCAACCCACTGAACCCATTTGTCAGCC
ATAAAGAAATTGAATCAATGAACAATGCAGTGATGATGCCAGCACATGGTCC
AGCCAAAAACATGGAGTATGATGCTGTTGCAACAACACACTCCTGGATCCC
CAAAAGAAATCGATCCATCTTGAATACAAGTCAAAGAGGAGTACTTGAGGAT
12 Supplementary 
S13 
GAACAAATGTACCAAAGGTGCTGCAATTTATTTGAAAAATTCTTCCCCAGCA
GTTCATACAGAAGACCAGTCGGGATATCCAGTATGGTGGAGGCTATGGTTT
CCAGAGCCCGAATTGATGCACGGATTGATTTCGAATCTGGAAGGATAAAGA
AAGAAGAGTTCACTGAGATCATGAAGATCTGTTCCACCATTGAAGAGCTCAG
ACGGCAAAAATGTGAATTTAGCttt 
12.7.5 >Segment_3_RKI_PA 
CAaaaTGGAAGATTTTGTGCGACAATGCTTCAATCCGATGATTGTCGAGCTT
GCGGAAAAAACAATGAAAGAGTATGGGGAGGACCTGAAAATCGAAACAAAC
AAATTTGCAGCAATATGCACTCACTTGGAAGTATGCTTCATGTATTCAGACTT
TCACTTCATCAATGAGCAAGGCGAGTCAATAATCGTGGAACTTGGTGATCCA
AATGCACTTTTGAAGCACAGATTTGAAATAATCGAGGGAAGAGATCGCACAA
TGGCCTGGACAGTAGTAAACAGTATTTGCAACACTACAGGGGCTGAGAAAC
CAAAGTTTCTACCAGATTTGTATGATTACAAGGAGAATAGATTCATCGAAATT
GGAGTAACAAGGAGAGAAGTTCACATATATTATCTGGAAAAGGCCAATAAAA
TTAAATCTGAGAAAACACACATCCACATTTTCTCGTTCACTGGGGAAGAAAT
GGCCACAAAGGCAGACTACACTCTCGATGAAGAAAGCAGGGCTAGGATCAA
AACCAGACTATTCACCATAAGACAAGAAATGGCCAGCAGAGGCCTCTGGGA
TTCCTTTCGTCAGTCCGAAAGAGGGGAAGAGACAATTGAAGAAAGGTTTGA
AATCACAGGAACAATGCGCAAGCTTGCCGACCAAAGTCTCCCGCCGAACTT
CTCCAGCCTTGAAAATTTTAGAGCCTATGTGGATGGATTCAAACCGAACGGC
TACATTGAGGGCAAGCTGTCTCAAATGTCCAAAGAAGTAAATGCTAGAATTG
AACCTTTTTTGAAAACAACACCACGACCACTTAGACTTCCGAATGGGCCTCC
CTGTTCTCAGCGGTCCAAATTCCTGCTGATGGATGCCTTAAAATTAAGCATT
GAGGACCCAAGTCATGAAGGAGAGGGAATACCGCTATATGATGCAATCAAA
TGCATGAGAACATTCTTTGGATGGAAGGAACCCAATGTTGTTAAACCACACG
AAAAGGGAATAAATCCAAATTATCTTCTGTCATGGAAGCAAGTACTGGCAGA
ACTGCAGGACATTGAGAATGAGGAGAAAGTTCCAAAGACTAAAAATATGAAG
AAAACAAGTCAGCTAAAGTGGGCACTTGGTGAGAACATGGCACCAGAAAAG
GTAGACTTTGACGACTGTAAAGATGTAGGTGATTTGAAGCAATATGATAGTG
ATGAACCAGAATTGAGGTCGCTTGCAAGTTGGATTCAGAATGAGTTTAACAA
12 Supplementary 
S14 
GGCATGCGAACTGACAGATTCAAGCTGGATAGAGCTCGATGAGATTGGAGA
AGATGTGGCTCCAATTGAACACATTGCAAGCATGAGAAGGAATTATTTCACA
TCAGAGGTGTCTCACTGCAGAGCCACAGAATACATAATGAAGGGGGTGTAC
ATCAATACTGCCTTGCTTAATGCATCTTGTGCAGCAATGGATGATTTCCAATT
AATTCCAATGATAAGCAAGTGTAGAACTAAGGAGGGAAGGCGAAAGACCAA
CTTGTATGGTTTCATCATAAAAGGAAGATCCCACTTAAGGAATGACACCGAC
GTGGTAAACTTTGTGAGCATGGAGTTTTCTCTCACTGACCCAAGACTTGAAC
CACACAAATGGGAGAAGTACTGTGTTCTTGAGATAGGAGATATGCTTCTAAG
AAGTGCCATAGGCCAGGTTTCAAGGCCCATGTTCTTGTATGTGAGAACAAAT
GGAACCTCAAAAATTAAAATGAAATGGGGAATGGAGATGAGGCGTTGCCTC
CTCCAGTCACTTCAACAAATTGAGAGTATGATTGAAGCTGAGTCCTCTGTCA
AAGAGAAAGACATGACCAAAGAGTTCTTTGAGAACAAATCAGAAACATGGCC
CATTGGAGAGTCCCCCAAAGGAGTGGAGGAAAGTTCCATTGGGAAGGTCTG
CAGGACTTTATTAGCAAAGTCGGTATTCAACAGCTTGTATGCATCTCCACAA
CTAGAAGGATTTTCAGCTGAATCAAGAAAACTGCTTCTTATCGTTCAGGCTC
TTAGGGACAACCTGGAACCTGGGACCTTTGATCTTGGGGGGCTATATGAAG
CAATTGAGGAGTGCCTGATTAATGATCCCTGGGTTTTGCTTAATGCTTCTTG
GTTCAACTCCTTCCTTACACATGCATTGAGTTAGTTGTGGCAGTGCTACTATT
TGCTATCCATACTGT 
12.7.6 >Segment_3_NIBSC_PA 
CTAaaaTGGAAGATTTTGTGCGACAATGCTTCAATCCGATGATTGTCGAGCTT
GCGGAAAAAACAATGAAAGAGTATGGGGAGGACCTGAAAATCGAAACAAAC
AAATTTGCAGCAATATGCACTCACTTGGAAGTATGCTTCATGTATTCAGATTT
TCACTTCATCAATGAGCAAGGCGAGTCAATAATCGTAGAACTTGGTGATCCA
AATGCACTTTTGAAGCACAGATTTGAAATAATCGAGGGAAGAGATCGCACAA
TGGCCTGGACAGTAGTAAACAGTATTTGCAACACTACAGGGGCTGAGAAAC
CAAAGTTTCTACCAGATTTGTATGATTACAAGGAGAATAGATTCATCGAAATT
GGAGTAACAAGGAGAGAAGTTCACATATACTATCTGGAAAAGGCCAATAAAA
TTAAATCTGAGAAAACACACATCCACATTTTCTCGTTCACTGGGGAAGAAAT
GGCCACAAAGGCAGACTACACTCTCGATGAAGAAAGCAGGGCTAGGATCAA
12 Supplementary 
S15 
AACCAGACTATTCACCATAAGACAAGAAATGGCCAGCAGAGGCCTCTGGGA
TTCCTTTCGTCAGTCCGAGAGAGGAGAAGAGACAATTGAAGAAAGGTTTGA
AATCACAGGAACAATGCGCAAGCTTGCCGACCAAAGTCTCCCGCCGAACTT
CTCCAGCCTTGAAAATTTTAGAGCCTATGTGGATGGATTCGAACCGAACGG
CTACATTGAGGGCAAGCTGTCTCAAATGTCCAAAGAAGTAAATGCTAGAATT
GAACCTTTTTTGAAAACAACACCACGACCACTTAGACTTCCGAATGGGCCTC
CCTGTTCTCAGCGGTCCAAATTCCTGCTGATGGATGCCTTAAAATTAAGCAT
TGAGGACCCAAGTCATGAAGGAGAGGGAATACCGCTATATGATGCAATCAA
ATGCATGAGAACATTCTTTGGATGGAAGGAACCCAATGTTGTTAAACCACAC
GAAAAGGGAATAAATCCAAATTATCTTCTGTCATGGAAGCAAGTACTGGCAG
AACTGCAGGACATTGAGAATGAGGAGAAAATTCCAAAGACTAAAAATATGAA
GAAAACAAGTCAGCTAAAGTGGGCACTTGGTGAGAACATGGCACCAGAAAA
GGTAGACTTTGACGACTGTAAAGATGTAGGTGATTTGAAGCAATATGATAGT
GATGAACCAGAATTGAGGTCGCTTGCAAGTTGGATTCAGAATGAGTTTAACA
AGGCATGCGAACTGACAGATTCAAGCTGGATAGAGCTCGATGAGATTGGAG
AAGATGTGGCTCCAATTGAACACATTGCAAGCATGAGAAGGAATTATTTCAC
ATCAGAGGTGTCTCACTGCAGAGCCACAGAATACATAATGAAGGGGGTGTA
CATCAATACTGCCTTGCTTAATGCATCTTGTGCAGCAATGGATGATTTCCAAT
TAATTCCAATGATAAGCAAGTGTAGAACTAAGGAGGGAAGGCGAAAGACCA
ACTTGTATGGTTTCATCATAAAAGGAAGATCCCACTTAAGGAATGACACCGA
CGTGGTAAACTTTGTGAGCATGGAGTTTTCTCTCACTGACCCAAGACTTGAA
CCACATAAATGGGAGAAGTACTGTGTTCTTGAGATAGGAGATATGCTTATAA
GAAGTGCCATAGGCCAGGTTTCAAGGCCCATGTTCTTGTATGTGAGAACAA
ATGGAACCTCAAAAATTAAAATGAAATGGGGAATGGAGATGAGGCGTTGCC
TCCTCCAGTCACTTCAACAAATTGAGAGTATGATTGAAGCTGAGTCCTCTGT
CAAAGAGAAAGACATGACCAAAGAGTTCTTTGAGAACAAATCAGAAACATGG
CCCATTGGAGAGTCCCCCAAAGGAGTGGAGGAAAGTTCCATTGGGAAGGT
CTGCAGGACTTTATTAGCAAAGTCGGTATTCAACAGCTTGTATGCATCTCCA
CAACTAGAAGGATTTTCAGCTGAATCAAGAAAACTGCTTCTTATCGTTCAGG
CTCTTAGGGACAACCTTGAACCTGGGACCTTTGATCTTGGGGGGCTATATG
AAGCAATTGAGGAGTGCCTGATTAATGATCCCTGGGTTTTGCTTAATGCTTC
12 Supplementary 
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TTGGTTCAACTCCTTCCTTACACATGCATTGAGTTAGTTGTGGCAGTGCTAC
TATTTGCTATCCATACTGtaCCAAAAAAaG 
12.7.7 >Segment_4_RKI_HA 
cGTAGCGAAAGCAGGggAAAaTAAAAACAACCAAAATGAAGGCAAACCTACT
GGTCCTGTTATGTGCACTTGCAGCTGCAGATGCAGACACAATATGTATAGG
CTACCATGCGAACAATTCAACCGACACTGTTGACACAGTGCTCGAGAAGAA
TGTGACAGTGACACACTCTGTTAACCTGCTCGAAGACAGCCACAACGGAAA
ACTaTGTAGATTAAAAGGAaTAGCCCCACTACAATTGGGGAAATGTAACATC
GCCGGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAG
ATCATGGTCCTACATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTAT
CCAGGAGATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAGCTCAGTG
TCATCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCCAACC
ACAACACAAACAAAGGAGTAACGGCAGCATGCTCCCATGCGGGGgAAAGCA
GTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCATACCCAA
AGCTGAAAAATTCTTATGTGAACAAGAAAGGGAAAGAAGTCCTTGTACTGTG
GGGTATTCATCACCCGTCTAACAGTAAGGAGCAACAGAATATCTATCAGAAT
GAAAATGCTTATGTCTCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCC
GGAAATAGCAGAAAGACCCAAAGTAAGAGATCAAGCTGGGAGGATGAACTA
TTACTGGACCTTGCTAAAACCCGGAGACACAATAATATTTGAGGCAAATGGA
AATCTAATAGCACCAAGGTATGCTTTCGCACTGAGTAGAGGCTTTGGGTCC
GGCATCATCACCTCAAACGCATCAATGCATGAGTGTAACACGAAGTGTCAAA
CACCCCTGGGAGCTATAAACAGCAGTCTCCCTTTCCAGAATATACACCCAGT
CACAATAGGAGAGTGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGT
TACAGGACTAAGGAACATTCCGTCCATTCAATCCAGAGGTCTATTTGGAGCC
ATTGCCGGTTTTATtGAAGGGGGATGGACTGGAATGATAGATGGaTGGTACG
GTTATCATCATCAGAATGAACAGGGATCAGGCTATGCAGCGGATCAAAAAA
GCACACAAAATGCCATTAACGGGATTACAAACAAGGTGAACTCTGTTATCGA
GAAAATGAACATTCAATTCACAGCTGTGGGTAAAGAATTCAACAAATTAGAA
AAAAGGATGGAAAATTTAAATAAAAAAGTTGATGATGGATTTCTGGACATTTG
GACATATAATGCAGAATTGTTAGTTCTACTGGAAAATGAAAGGACTCTGGAT
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TTCCATGACTCAAATGTGAAAAATCTGTATGAGAAAGTAAAAAGCCAATTAAA
GAATAATGCCAAAGAAATCGGAAATGGATGTTTTGAGTTCTACCACAAGTGT
GACAATGAATGCATGGAAAGTGTAAGAAATGGGACTTATGATTATCCCAAAT
ATTCAGAAGAGTCAAAGTTGAACAGGGAAAAGGTAGATGGAGTGAAATTGG
AATCAATGGGGATCTATCAGATTCTGGCGATCTACTCAACTGTCGCCAGTTC
ACTGGTGCTTTTGGTCTCCCTGGGGGCAATCAGTTTCTGGATGTGTTCTAAT
GGATCTTTGCAGTGCAGAATATGCATCTGAGATTAGAATTTCAGAAATATGA
GGAAAAACACC 
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GTaGCgAAAGCAGGGgAAAATAAAAACAACCAAAATGAAGGCAAACCTACTG
GTCCTGTTATGTGCACTTGCAGCTGCAGATGCAGACACAATATGTATAGGCt
ACCATGCGAACAATTCAACCGACACTGTTGACACAGTACTCGAGAAGAATGT
GACAGTGACACACTCTGTTAACCTGCTCGAAGACAGCCACAACGGAAAACT
aTGTAGATTAAAAGGAaTAGCCCCACTACAATTGGGGAAATGTAACATCGCC
GGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAGTGAGATCA
TGGTCCTACATTGTAGAAACACCAAACTCTGAGAATGGAATATGTTATCCAG
GAGATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAGCTCAGTGTCAT
CATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCATGGCCCAACCACAA
CACAAACGGAGTAACGGCAGCATGCTCCCATGAGGGGAAAAGCAGTTTTTA
CAGAAATTTGCTATGGCTGACGGAGAAGGAGGGCTCATACCCAAAGCTGAA
AAATTCTTATGTGAACAAAAAaGGGAAAGAAGTCCTTGTACTGTGGGGTATT
CATCACCCGTCTAACAGTAAGGAACAACAGAATCTCTATCAGAATGAAAATG
CTTATGTCTCTGTAGTGACTTCAAATTATAACAGGAGATTTACCCCGGAAATA
GCAGAAAGACCCAAAGTAAGAGATCAAGCTGGGAGGATGAACTATTACTGG
ACCTTGCTAAAACCCGGAGACACAATAATATTTGAGGCAAATGGAAATCTAA
TAGCACCAATGTATGCTTTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCA
TCACCTCAAACGCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCT
GGGAGCTATAAACAGCAGTCTCCCTTACCAGAATATACACCCAGTCACAATA
GGAGAGTGCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTACAGGA
CTAAGGAACATTCCGTCCATTCAATCCAGAGGTCTATTtGGAGCCATTGCCG
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GTTTTATtGAAGGGGGatGGACTGGAATGATAGATGGATGGTATGGTTATCAT
CATCAGAATGAACAGGGATCAGGCTATGCAGCGGATCAAAAAAGCACACAA
AATGCCATTAACGGGATTACAAACAAGGTGAACACTGTTATCGAGAAAATGA
ACATTCAATTCACAGCTGTGGGTAAAGAATTCAACAAATTAGAAAAAAGGAT
GGAAAATTTAAATAAAAAaGTTGATGATGGATTTCTGGACATTTGGACATATA
ATGCAGAATTGTTAGTTCTACTGGAAAATGAAAGGACTCTGGATTTCCATGA
CTCAAATGTGAAGAATCTGTATGAGAAAGTAAAAAGCCAATTAAAGAATAAT
GCCAAAGAAaTCGGAAATGGATGTTTTGAGTTCTACCACAAGTGTGACAATG
AATGCATGGAAAGTGTAAGAAATGGGACTTATGATTATCCCAAATATTCAGA
AGAGTCAAAGTTGAACAGGgAAAaGGTAGATGGAGTGAAATTGGAATCAATG
GGGATCTATCAGATTCTGGCGATCTACTCAACTGTCGCCAGTTCACTGGTG
CTTTTGGTCTCCCTGGGGGCAATCAGTTTCTGGATGTGTTCTAATGGATCTT
TGCAGTGCAGAATATGCATCTGAGATTAGAATTTCAGAGATATGAGGAAAAA
Cn 
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CAACATCATGGCGTCCCAAGGCACCAAACGGTCTTACGAACAGATGGAGAC
TGATGGAGAACGCCAGAATGCCACTGAAATCAGAGCATCCGTCGGAAAAAT
GATTGGTGGAATTGGACGATTCTACATCCAAATGTGCACAGAACTTAAACTC
AGTGATTATGAGGGACGGTTGATCCAAAACAGCTTAACAATAGAGAGAATG
GTGCTCTCTGCTTTTGACGAAAGGAGAAATAAATACCTGGAAGAACATCCCA
GTGCGGGGAAAGATCCTAAGAAAACTGGAGGACCTATATACAGAAGAGTAA
ACGGAAAGTGGATGAGAGAACTCATCCTTTATGACAAAGAAGAAATAAGGC
GAATCTGGCGCCAAGCTAATAATGGTGACGATGCAACGGCTGGTCTGACTC
ACATGATGATCTGGCATTCCAATTTGAATGATGCAACTTATCAGAGGACAAG
AGCTCTTGTTCGCACTGGAATGGATCCCAGGATGTGCTCTCTGATGCAAGG
TTCAACTCTCCCTAGGAGGTCTGGAGCCGCAGGTGCTGCAGTCAAAGGAGT
TGGAACAATGGTGATGGAATTGGTCAGGATGATCAAACGTGGGATCAATGA
TCGGAACTTCTGGAGGGGTGAGAATGGACGAAAAACAAGAATTGCTTATGA
AAGAATGTGCAACATTCTCAAAGGGAAATTTCAAACTGCTGCACAAAAAGCA
ATGATGGATCAAGTGAGAGAGAGCCGGAACCCAGGGAATGCTGAGTTCGA
12 Supplementary 
S19 
AGATCTCACTTTTCTAGCACGGTCTGCACTCATATTGAGAGGGTCGGTTGCT
CACAAGTCCTGCCTGCCTGCCTGTGTGTATGGACCTGCCGTAGCCAGTGGG
TACGACTTTGAAAGAGAGGGATACTCTCTAGTCGGAATAGACCCTTTCAGAC
TGCTTCAAAACAGCCAAGTGTACAGCCTAATCAGACCAAATGAGAATCCAGC
ACACAAGAGTCAACTGGTGTGGATGGCATGCCATTCTGCCGCATTTGAAGA
TCTAAGAGTATTGAGCTTCATCAAAGGGACGAAGGTGGTCCCAAGAGGGAA
GCTTTCCACTAGAGGAGTTCAAATTGCTTCCAATGAAAATATGGAGACTATG
GAATCAAGTACACTTGAACTGAGAAGCAGGTACTGGGCCATAAGGACCAGA
AGTGGAGGAAACACCAATCAACAGAGGGCATCTGCGGGCCAAATCAGCATA
CAACCTACGTTCTCAGTACAGAGAAATCTCCCTTTTGACAGAACAACCGTTA
TGGCAGCATTCACTGGGAATACAGAGGGGAGAACATCTGACATGAGGGCC
GAAATCATAAGGATGATGGAAAGTGCAAGACCAGAAGATGTGTCTTTCCAG
GGGCgGGGAGTCTTCGAGCTCTCGGACGAAAAGGCAGCGAGCCCGATCGT
GCCTTCCTTTGACATGAGTAAtGAAGGATCTTATTTCTTCGGAGACAATGCAG
AGGA 
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TGGCGTCTCAAGGCACCAAACGATCTTACGAACAGATGGAGACTGATGGAG
AACGCCAGAATGCCACTGAAATCAGAGCATCCGTCGGAAAAATGATTGGTG
GAATTGGACGATTCTACATCCAAATGTGCACCGAACTCAAACTCAGTGATTA
TGAGGGACGGTTGATCCAAAACAGCTTAACAATAGAGAGAATGGTGCTCTC
TGCTTTTGACGAAAGGAGAAATAAATACCTTGAAGAACATCCCAGTGCGGG
GAAAGATCCTAAGAAAACTGGAGGACCTATATACAGGAGAGTAAACGGAAA
GTGGATGAGAGAACTCATCCTTTATGACAAAGAAGAAATAAGGCGAATCTG
GCGCCAAGCTAATAATGGTGACGATGCAACGGCTGGTCTGACTCACATGAT
GATCTGGCATTCCAATTTGAATGATGCAACTTATCAGAGGACAAGAGCTCTT
GTTCGCACCGGAATGGATCCCAGGATGTGCTCTCTGATGCAAGGTTCAACT
CTCCCTAGGAGGTCTGGAGCCGCAGGTGCTGCAGTCAAAGGAGTTGGAAC
AATGGTGATGGAATTGGTCAGAATGATCAAACGTGGGATCAATGATCGGAA
CTTCTGGAGGGGTGAGAATGGACGAAAAACAAGAATTGCTTATGAAAGAAT
GTGCAACATTCTCAAAGGGAAATTTCAAACTGCTGCACAAAAAGCAATGATG
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GATCAAGTGAGAGAGAGCCGGAACCCAGGGAATGCTGAGTTCGAAGATCT
CACTTTTCTAGCACGGTCTGCACTCATATTGAGAGGGTCGGTTGCTCACAAG
TCCTGCCTGCCTGCCTGTGTGTATGGACCTGCCGTAGCCAGTGGGTACGAC
TTTGAAAGGGAGGGATACTCTCTAGTCGGAATAGACCCTTTCAGACTGCTTC
AAAACAGCCAAGTGTACAGCCTAATCAGACCAAATGAGAATCCAGCACACA
AGAGTCAACTGGTGTGGATGGCATGCCATTCTGCCGCATTTGAAGATCTAA
GAGTATTAAGCTTCATCAAAGGGACGAAGGTGCTCCCAAGAGGGAAGCTTT
CCACTAGAGGAGTTCAAATTGCTTCCAATGAAAATATGGAGACTATGGAATC
AAGTACACTTGAACTGAGAAGCAGGTACTGGGCCATAAGGACCAGAAGTGG
AGGAAACACCAATCAACAGAGGGCATCTGCGGGCCAAATCAGCATACAACC
TACGTTCTCAGTACAGAGAAATCTCCCTTTTGACAGAACAACCATTATGGCA
GCATTCAATGGGAATACAGAGGGGAGAACATCTGACATGAGGACCGAAATC
ATAAGGATGATGGAAAGTGCAAGaCCAGAAGATGTGTCTTTCCAGGGGCgG
GGAGTCTTCGAGCTCTCGGACGAAAAGGCAGCGAGCCCGATCGTGCCTTC
CtTTGACATGAGTAATGAAGGATCTTATTTCTTCGGAGACAATGCAGAGGA 
12.7.11 >Segment_6_RKI_NA 
CGTAGCGaaAgcagGGGTTTaAAATGAATCCAAACCAGaAAATAATAACCATTG
GATCAATCTGTATGGTAGTCGGACTAATTAGCCTAATATTGCAAATAGGGAA
TATAATCTCAATATGGATTAGCCATTCAATTCAAACTGGAAGTCAAAACCATA
CTGGAATATGCAACCAAAACATCATTACCTATAAAAATAGCACCTGGGTAAA
GGACACAACTTCAGTGATATTAACCGGCAATTCATCTCTTTGTCCCATCCGT
GGGTGGGCTATATACAGCAAAGACAATAGCATAAGAATTGGTTCCAAAGGA
GACGTTTTTGTCATAAGAGAGCCCTTTATTTCATGTTCTCACTTGGAATGCAG
GACCtTTTTTCTGACCCAAGGTGCCTTACTGAATGACAGGCATTCAAATGGG
ACTGTTAAGGACAGAAGCCCTTATAGGGCCTTAATGAGCTGCCCTGTCGGT
GAAGCTCCGTCCCCGTACAATTCAAGATTTGAATCGGTTGCTTGGTCAGCAA
GTGCATGTCATGATGGCATGGGCTGGCTAACAATCGGAATTTCAGGTCCAG
ATAATGGAGCAGTGGCTGTATTAAAATACAACGGCATAATAACTGAAACCAT
AAAAAGTTGGAGGAAGAAAATATTGAGGACACAAGAGTCTGAATGTGCCTG
TGTAAATGGTTCATGTTTTACTATAATGACTGATGGCCCGAGTGATGGGCTG
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GCCTCGTACAAAATTTTCAAGATCGAAAAGGGGAAGGTTACTAAATCAATAG
AATTGAATGCACCTAATTCTCACTATGAGGAATGTTCCTGTTACCCTGATACC
GGCAAAGTGATGTGTGTGTGCAGAGACAATTGGCATGGTTCGAACCGGCCA
TGGGTGTCTTTCGATCAAAACCTGGATTATCAAATAGGATACGTCTGCAGTG
GGGTTTTCGGTGACAACCCGCGTCCCAAAGATGGAACAGGCAGCTGTGGT
CCAGTGTATGTTGATGGAGCAAACGGAGTAAAGGGATTTTCATATAGGTATG
GTAATGGTGTtTGGATAGGAAGGACCAAAAGTCACAGTTCCAGGCATGGGTT
TGAGATGATTTGGGATCCTAATGGATGGACAGAGACTGATAGTGAGTTCTCT
GTGAGGCAAGATGTTGTGGCAATGACTGATTGGTCAGGGTATAGCGGAAGT
TTCGTTCAACATCCTGAGCTAACAGGGCTAGACTGTATAAGGCCGTGCTTCT
GGGTTGAATTAATCAGGGGACGACCTAAAGaAAAAACAATCTGGACCAGTG
CGAGCAGCATTTCtTTTTGTGGCGTGGATAGTGATACTGTAGATTGGTCTTG
GCCAGACGGTGCTGAGTTGCCATTCACCATTGACAAGTAGTCTGTTCAAAAA
AACtT 
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GGGGtTTaAAATGAATCCAAATCAGAAAATAATAACCATTGGATCAATCTGTC
TGGTAGTCGGACTAATTAGCCTAATATTGCAAATAGGGAATATAATCTCAATA
TGGATTAGCCATTCAATTCAAACTGGAAGTCAAAACCATACTGGAATATGCA
ACCAAAACATCATTACCTATAAAAATAGCACCTGGGTAAAGGACACAACTTC
AGTGATATTAACCGGCAATTCATCTCTTTGTCCCATCCGTGGGTGGGCTATA
TACAGCAAAGACAATAGCATAAGAATTGGTTCCAAAGGAGACGTTTTTGTCA
TAAGAGAGCCCTTTATTTCATGTTCTCACTTGGAATGCAGGACCtTTTTTCTG
ACCCAAGGTGCCTTACTGAATGACAAGCATTCAAGTGGGACTGTTAAGGAC
AGAAGCCCTTATAGGGCCTTAATGAGCTGCCCTGTCGGTGAAGCTCCGTCC
CCGTACAATTCAAGATTTGAATCGGTTGCTTGGTCAGCAAGTGCATGTCATG
ATGGCATGGGCTGGCTAACAATCGGAATTTCAGGTCCAGATAATGGAGCAG
TGGCTGTATTAAAATACAACGGCATAATAACTGAAACCATAAAAAGTTGGAG
GAAGAAAATATTGAGGACACAAGAGTCTGAATGTGCCTGTGTAAATGGTTCA
TGTTTTACTATAATGACTGATGGCCCGAGTGATGGGCTGGCCTCGTACAAAA
TTTTCAAGATCGAAAAGGGGAAGGTTACTAAATCAATAGAGTTGAATGCACC
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TAATTCTCACTATGAGGAATGTTCCTGTTACCCTGATACCGGCAAAGTGATG
TGTGTGTGCAGAGACAATTGGCATGGTTCGAACCGGCCATGGGTGTCTTTC
GATCAAAACCTGGATTATCAAATAGGATACATCTGCAGTGGGGTTTTCGGTG
ACAACCCGCGTCCCGAAGATGGAACAGGCAGCTGTGGTCCAGTGTATGTTG
ATGGAGCAAACGGAGTAAAGGGAtTTTCATATAGGTATGGTAATGGTGtTTGG
ATAGGAAGGACCAAAAGTCACAGTTCCAGACATGGGTTTGAGATGATTTGG
GATCCTAATGGATGGACAGAGACTGATAGTAAGTTCTCTGTGAGGCAAGAT
GTTGTGGCAATGACTGATTGGTCAGGGTATAGCGGAAGtTTCGTTCAACATC
CTGAGCTGACAGGGCTAGACTGTATGAGGCCGTGCTTCTGGGTTGAATTAA
TCAGGGGACGACCTAAAGAAAAAACAATCTGGACTAGTGCGAGCAGCATTT
CtTTTTGTGGCGTGAATAGTGATACTGTAGATTGGTCTTGGCCAGACGGTGC
TGAGTTGCCATTCAGCATTGACAAGTAGTC 
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GTTGAAAGATGAGTCTTCTAACCGAGGTCGAAACGTACGTTCTCTCTATCAT
CCCGTCAGGCCCCCTCAAAGCCGAGATCGCACAGAGACTTGAAGATGTCTT
TGCAGGGAAGAACACCGATCTTGAGGTTCTCATGGAATGGCTAAAGACAAG
ACCAATCCTGTCACCTCTGACTAAGGGGATTTTAGGATTTGTGTTCACGCTC
ACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGTCCAAAATGC
CCTTAATGGGAACGGGGATCCAAATAACATGGACAAAGCAGTTAAACTGTAT
AGGAAGCTCAAGAGGGAGATAACATTCCATGGGGCCAAAGAAATCTCACTC
AGTTATTCTGCTGGTGCACTTGCCAGTTGTATGGGCCTCATATACAACAGGA
TGGGGGCTGTGACCACTGAAGTGGCATTTGGCCTAGTATGTGCAACCTGTG
AACAGATTGCTGACTCCCAGCATCGGTCTCATAGGCAAATGGTGACAACAA
CCAATCCACTAATCAGACATGAGAACAGAATGGTTTTAGCCAGCACTACAGC
TAAGGCTATGGAGCAAATGGCTGGATCGAGTGAGCAAGCAGCAGAGGCCA
TGGAGGTTGCTAGTCAGGCTAGGCAAATGGTGCAAGCGATGAGAACCATTG
GGACTCATCCTAGCTCCAGTGCTGGTCTGaAAAATGATCTTCTTGAAAATTT
GCAGGCCTATCAGAAACGAATgGGGGTGCAGATGCAACGGTTCAAGTGATC
CTCTCGCTATTGCCGCAAATATCATTGGGATCTTGCACTTGATATTGTGGAT
TCTTGATCGTCTTTTTTTCAAATGCATTTACCGTCGCTTTAAATACGGACTGA
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AAGGAGGGCCTTCTACGGAAGGAGTGCCAAAGTCTATGAGGGAAGAATATC
GAAAGGAACAGCAGAGTGCTGTGGATGCTGACGATGGTCATTTTGtCAGCAT
AGAGCT 
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gtTGaAAGaTGAGTCTTCTAACCGAGGTCGAAACGTACGTTCTCTCTATCATC
CCGTCAGGCCCCCTCAAAGCCGAGATCGCGCAGAGACTTGAAAATGTCTTT
GCAGGGaAAAACACCGATCTTGAGGTTCTCATGGAATGGCTAAAGACAAGA
CCAATCCTGTCACCTCTGACTAAGGGGATTTTAGGATTTGTGTTCACGCTCA
CCGTGCCCAGTGAGCAGGGACTGCAGCGTAGACGCTTTGTCCAAAATGCC
CTTAATGGGAACGGGGATCCAAATAACATGGACAAAGCAGTTAAACTGTATA
GGAAGCTTAAGAGGGAGATAACATTCTATGGGGCTAAAGAAATAGCACTCA
GTTATTCCGCTGGTGCACTTGCCTGTTGTATGGGCCTCATATACAACAGGAT
GGGGACTGTGACTGCTGAAGTGGTGTTTGGCCTGGTATGTGCAACCTGTGA
ACAGATTGCTGACTCCCAGCATCGGTCTCATAGGCAAATGGTGGCAACAAC
CAATCCACTAATCAGACATGAGAACAGAATGGTTTTAGCCAGCACTACAGCT
AAGGCTATGGAGCAAATGGCTGGATCGAGTGAGCAAGCAGCAGAGGCCAT
GGAGGTTGCGATTCGGGCTAGGCAAATGGTGCAGGCAATGAGAACCATTG
GGACTCATCCTAGCTCCAGTGCTGGTCTGAAAGATGATCTTCTTGAAAATTT
GCAGGCCTATCAGAAACGAATGGGGGTGCAGATGCAACGGTTCAAGTGATC
CTCTCGTTATTGCCTCAAGTATCATTGGGATCTTGCACTTGATATTGTGGATT
CTTGATCGTCTTTTTTTCAAATGCATTTACCGTCTCTTTAAATACGGTTTGAAA
AGAGGGCCTTCTACGGAAGGAGTGCCAAAGTCTATGAGGGAAGAATATCAA
AAGGAACAGCAGAGTGCTGTGGATGCTGACGATGGTCATTTTGTCAGCATA
GAGCTGGAGTAAAA 
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GTGACAAAGACATAATGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTG
CTTTCTTTGGCATGTCCGCAAACGAGTTGCAGACCAAGAACTAGGTGATGC
CCCATTCCTTGATCGGCTTCGCCGAGATCAGAAATCCCTAAGAGGAAGGGG
CAGCACTCTCGGTCTGGACATCGAGACAGCCACACGTGCTGGAAAGCAGAT
AGTGGAGCGGATTCTGAAAGAAGAATCCGATGAGGCACTTAAAATGACCAT
12 Supplementary 
S24 
GGCCTCTGTACCTGCGTCGCGTTACCTAACTGACATGACTCTTGAGGAAAT
GTCAAGGGAATGGTCCATGCTCATACCCAAGCAGAAAGTGGCAGGCCCTCT
TTGTATCAGAATGGACCAGGCGATCATGGATAAGAACATCATACTGAAAGC
GAACTTCAGTGTGATTTTTGACCGGCTGGAGACTCTAATATTGCTAAGGGCT
TTCACCGAAGAGGGAGCAATTGTTGGCGAAATTTCACCATTGCCTTCTCTTC
CAGGACATACTGCTGAGGATGTCAAAAATGCAGTTGGAGTCCTCATCGGAG
GACTTGAATGGAATGATAACACAGTTCGAGTCTCTGAAACTCTACAGAGATT
CGCTTGGAGAAGCAGTAATGAGAATGGGAGACCTCCACTCACTCCAAAACA
GAAACGAGAAATGGCGGGAACAATTAGGTCAGAAGTTTGAAGAAATAAGAT
GGTTGATTGAAGAAGTGAGACACAAACTGAGGGTAACAGAGAATAGTTTTG
AGCAAATAACATTTATGCAAGCCTTACATCTATTGCTTGAAGTGGAGCAAGA
GATAAGAACTTTCTCATTTCAGCTTATTTAATAA 
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GGgtGaCaGAcaTAaTGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGC
TTTCTTTGGCATGTCCGCAAACGAGTTGCAGACCAAGAACTAGGTGATGCC
CCATTCCTTGATCGGCTTCGCCGAGATCAGAAATCCCTAAGAGGAAGGGGC
AGTACTCTCGGTCTGGACATCAAGACAGCCACACGTGCTGGAAAGCAGATA
GTGGAGCGGATTCTGAAAGAAGAATCCGATGAGGCACTTAAAATGACCATG
GCCTCTGTACCTGCGTCGCGTTACCTAACTGACATGACTCTTGAGGAAATGT
CAAGGGACTGGTCCATGCTCATACCCAAGCAGAAAGTGGCAGGCCCTCTTT
GTATCAGAATGGACCAGGCGATCATGGATAAGAACATCATACTGAAAGCGA
ACTTCAGTGTGATTTTTGACCGGCTGGAGACTCTAATATTGCTAAGGGCTTT
CACCGAAGAGGGAGCAATTGTTGGCGAAATTTCACCATTGCCTTCTCTTCCA
GGACATACTGCTGAGGATGTCAAAAATGCAGTTGGAGTCCTCATCGGAGGA
CTTGAATGGAATGATAACACAGTTCGAGTCTCTGAAACTCTACAGAGATTCG
CTTGGAGAAGCAGTAATGAGAATGGGAGACCTCCACTCACTCCAAAACAGA
AACGAGAAATGGCGGGAACAATTAGGTCAGAAGTTTGAAGAAATAAGATGG
TTGATTGAAGAAGTGAGACACAAACTGAAGATAACAGAGAATAGTTTTGAGC
AAATAACATTTATGCAAGCCTTACATCTATTGCTTGAAGTGGAGCAAGAGAT
AAGAACTTTCTCGTTTCAGCTTATTTAGTACTAA 
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12.8 Alignment of amino acid consensus sequences of the RKI- and the 
NIBSC-strain from passage 1 
 
figure S 5: Alignment of AA consensus sequences of segment 1 coding for PB2 of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
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figure S 6: Alignment of AA consensus sequences of segment 2 coding for PB1 of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
 
 
figure S 7: Alignment of AA consensus sequences of segment 2 coding for PB1-F2 of the 
RKI- and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
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figure S 8: Alignment of AA consensus sequences of segment 3 coding for PA of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
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figure S 9: Alignment of AA consensus sequences of segment 4 coding for HA of the RKI- 
and the NIBSC-strain. 
The virus seed of RKI (Amp. 3138) corresponds to a homogeneous population. Substitutions in 
the sequence during the virus adaptation processes are indicated in red. In contrast, the virus 
seed from NIBSC (#06/114) comprises various virus variants; substitutions in the sequence are 
indicated in green. The positions of substitutions, acquired during the adaptation processes are 
indicated in blue. The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
Reprinted with permission [4]. 
12 Supplementary 
S29 
 
figure S 10: Alignment of AA consensus sequences of segment 5 coding for NP of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
 
 
figure S 11: Alignment of AA consensus sequences of segment 6 coding for NA of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
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figure S 12: Alignment of AA consensus sequences of segment 7 coding for M1 of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
 
 
figure S 13: Alignment of AA consensus sequences of segment 7 coding for M2 of the RKI- 
and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
 
 
figure S 14: Alignment of AA consensus sequences of segment 8 coding for NS1 of the 
RKI- and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
 
 
figure S 15: Alignment of AA consensus sequences of segment 8 coding for NS2 (NEP) of 
the RKI- and the NIBSC-strain. 
The amino acid assembly was performed at http://services.uniprot.org/clustalw. 
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12.9 SOPs and protocols 
12.9.1 Thawing of cells 
Internal SOP (file Z_02_Auftauenzellen_250603_IB.doc). Please ask Dr. habil. Y 
Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex Technical 
Systems, Magdeburg, Germany) for access. 
12.9.2 Passaging MDCK cells 
12.9.2.1 Serum-containing 
Internal SOP (Z_04_Passagieren_MDCK_200606_SK.doc). Please ask Dr. habil. 
Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex Technical 
Systems, Magdeburg, Germany) for access. 
12.9.2.2 Serum-free 
Internal SOP (Z_05_Passagieren_MDCK_serumfrei_211105_SK.doc). Please 
ask Dr. habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex 
Technical Systems, Magdeburg, Germany) for access. 
12.9.3 Preparation of isotonic phosphate-buffered saline (PBS) 
Internal SOP (file M_01_Herstellung_PBS_260907_CB.doc). Please ask Dr. 
habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex 
Technical Systems, Magdeburg, Germany) for access. 
12.9.4 Preparation of caso-bouillon for sterility testing 
Internal SOP (file M_05_Herstellung_Von_CASO_Bouillon_290606_CB.doc). 
Please ask Dr. habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of 
Complex Technical Systems, Magdeburg, Germany) for access. 
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12.9.5 Preparation of cell culture and virus production media 
12.9.5.1 Glasgow-MEM-medium from powder 
Internal SOP (M_03_Herst_von_GMEM_aus_Pulvermedium_231105_SK.doc). 
Please ask Dr. habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of 
Complex Technical Systems, Magdeburg, Germany) for access. 
12.9.5.2 Glasgow-MEM-medium from prepared solutions 
Internal SOP (file M_04_Herst.von Glasgow-MEM-Vollmed._Z-
Med._200606_SK.doc). Please ask Dr. habil. Y Genzel or Prof. Dr.-Ing. U. Reichl 
(MPI for Dynamics of Complex Technical Systems, Magdeburg, Germany) for 
access. 
12.9.5.3 Smif 8 PGd-medium from powder 
H2OMQ      fill up to 10 L 
Smif 8-PGd powdermedium (FH Emden) 30.6 g 
NaCl (Roth)      62.4 g 
NaHCO3 (Roth)     20.0 g 
Ethanolamine (98%, Sigma)   1.6 g 
L-glutaminic acid (Merck)    10 μL 
D- (+)-glucose (H2O-free, Roth)   36.5 g 
Pluronic F68 10% (GIBCO Invitrogen)  100 mL 
pH       7.3 
osmolarity      300 mOs/kg 
12.9.6 Virus propagation 
Internal SOP (file V_03_Virenvermehrung_Kulturgefaesse_260907_CB.doc). 
Please ask Dr. habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of 
Complex Technical Systems, Magdeburg, Germany) for access. 
12 Supplementary 
S33 
12.9.7 Preparation of trypsin-EDTA-stock solution (10x) for cell detaching 
Internal SOP (file M_07_Trypsinherstellung_200607_CB.doc). Please ask Dr. 
habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex 
Technical Systems, Magdeburg, Germany) for access. 
12.9.8 Preparation of trypsin for virus propagation 
Internal SOP (file V_02_Trypsin_fuer_Virus_170107_CB.doc). Please ask Dr. 
habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex 
Technical Systems, Magdeburg, Germany) for access. 
12.9.9 Preparation of peptone solution (20%) 
Herstellungsmenge LAB-M-Peptone Milli-Q-Wasser 
200ml 40g 160g 
500ml 100g 400g 
Peptonpulver in 80°C warmen dest. H2O lösen, in kleine Schottflaschen verteilen 
und bei 120°C 20 min autoklavieren 
12.9.10 Preparation of Alsevers solution 
Internal SOP (file M_13_Alseversloesung_040107_CB.doc).Please ask Dr. habil. 
Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex Technical 
Systems, Magdeburg, Germany) for access. 
Solution should be sterile for stabilizing chicken erythrocytes 
12.9.11 Preparation of chicken erythrocytes 
Internal SOP (file V_07_Erythrocytenloesung_07.06.07_CB.doc). Please ask Dr. 
habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of Complex 
Technical Systems, Magdeburg, Germany) for access. 
12.9.12 Hemagglutination-assay 
Internal SOP, Version: 2.1 and 2.2 (04.12.2006 and 20.01.2011, respectively). 
Please ask Dr. habil. Y Genzel or Prof. Dr.-Ing. U. Reichl (MPI for Dynamics of 
Complex Technical Systems, Magdeburg, Germany) for access. 
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12.9.13 β-propiolactone inactivation 
Internal SOP, Version: 1.1 (26.10.06). Please ask Dr. M. Wolff or Prof. Dr.-Ing. U. 
Reichl (MPI for Dynamics of Complex Technical Systems, Magdeburg, Germany) 
for access. 
12.9.14 N-glycosylation pattern analysis (NaBH3CN-based, V1.2) 
Internal SOP, please ask Dr. E. Rapp or Prof. Dr.-Ing. U. Reichl (MPI for 
Dynamics of Complex Technical Systems, Magdeburg, Germany) for access. 
12.9.15 N-glycosylation pattern analysis (picoline borane-based, V1.5) 
Internal SOP, please ask Dr. E. Rapp or Prof. Dr.-Ing. U. Reichl (MPI for 
Dynamics of Complex Technical Systems, Magdeburg, Germany) for access. 
12.9.16 Purification of labeled N-glycans by HILIC 
Internal SOP, please ask Dr. E. Rapp or Prof. Dr.-Ing. U. Reichl (MPI for 
Dynamics of Complex Technical Systems, Magdeburg, Germany) for access. 
12.9.17 Native influenza virus deglycosylation 
12.9.17.1 Virus concentration 
o isolate virus from virus-containing, cleared supernatant by ultra-
centrifugation (90 min, 4 °C, 31.000 rpm, 70Ti rotor, UZ-tubes) => from 
approx. 240 mL virus-containing supernatant 
o resuspend virus pellets in 20 – 25 L V-medium each making a final 
volume of 160 -200 L 
12.9.17.2 Deglycosylation procedure 
add 190 L of the concentrated, recovered sample from step (1) 
add 6:7 L protease inhibitor (40x in sterile H2OMQ; this corresponds to 1 tablet in 
250 L; #11777700, Roche) 
add 50 L reaction buffer (R9150, Sigma-Aldrich) 
add 10 L endoglycosidase F2 
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add 10 L endoglycosidase F3 
add 10 L -galactosidase (G7163, Sigma-Aldrich) 
incubate at 37 °C, 450 rpm over night 
 
add 10 L reaction buffer (R9025, Sigma-Aldrich) 
add 10 L endoglycosidase F1 
incubate at 37 °C, 450 rpm over night 
 
add 10 L reaction buffer (R0266, Sigma-Aldrich) 
add 10 L -mannosidase (M7257, Sigma-Aldrich) 
add 10 L -neuramidase (N8271, Sigma-Aldrich) 
add 10 L -N-acetylglucosaminidase (A6805, Sigma-Aldrich) 
add 10 L -galactosidase (G0413, Sigma-Aldrich) 
add 2 L -galactosidase (G7163, Sigma-Aldrich) 
add 2 L endoglycosidase F3 
incubate at 37 °C, 450 rpm over night 
 
Isolate virus by ultra-centrifugation at 31.000 rpm (Beckman Coulter, Rotor 70Ti, 
31000 rpm, Ø65.7 mm 70714 g) for 90 min at 4 °C in 100 mM Tris (pH7) 
transfer the supernatant into a labeled falcon tube for later APTS-labelling 
resuspend the virus pellet in 20 - 30 L 100 mM Tris-HCl (pH7) and store 2 
aliquots 1x 7 – 10 L: for later N-glycoanalysis (could be diluted by a factor of 5) 
and 1x 13 – 20 L for immunogenicity studies, pellet should later be washed 
once again in 100 mM Tris pH7) 
Store samples at -80 °C 
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12.10 Principles of next-generation pyrosequencing 
12.10.1 DNA library preparation 
 
 
 
 
 
 
See / from http://www.genomicsdisorders.nl/GSFLX_Poster1.pdf 
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12.10.2 emPCR – emulsion PCR set up 
 
 
 
 
 
 
 
 
See / from http://www.genomicsdisorders.nl/GSFLX_Poster2.pdf 
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12.10.3 emPCR – emulsion PCR breaking and enrichment 
 
 
 
 
 
 
 
See / from http://www.genomicsdisorders.nl/GSFLX_Poster3.pdf 
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12.10.4 Sequencing 
 
 
 
 
 
 
 
 
See / from http://www.genomicsdisorders.nl/GSFLX_Poster3.pdf 
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13.1 Reviewed journal articles, book sections and statement on 
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13.2 Conference proceedings and statement on authorship 
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author elsewhere. In the following a detailed overview of proceedings is given in 
the order of their publication date using numbers according to the reference list 
(section 7). 
 
[5] Roedig JV, Rapp E, Genzel Y, Reichl U: Impact of different influenza 
cultivation conditions on HA N-Glycosylation. BMC proceedings 2011, 5 
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Full Biomed Central Open Access license, identical to Creative Commons 
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